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ABSTRACT
Studies of the Transcriptional Control of the Human c-fos 
Proto-oncogene.
The c-fos gene is the cellular counterpart of the transforming 
genes of several retroviruses. Its transcription and expression 
is increased in many types of different cells following 
extra-cellular stimuli, and this increase is both rapid and 
transient in most cases. Many studies have focussed on the 
transcriptional control of the c-fos proto-oncogene. These 
studies have characterised an element (the serum response 
element - SRE) that was initially found to increase 
transcription from the c-fos promoter following serum 
stimulation of quiescent cells and subsequently has been shown 
to activate transcription from the c-fos promoter following a 
variety of extra-cellular stimuli in a variety of different cell 
types.
A computer-aided search of the human c-fos sequence revealed a 
sequence directly 3' of the SRE that shows similarity to the DNA 
binding sites for the transcription factors AP-1 and ATF. These 
proteins bind to their sequences and confer phorbol ester and 
cyclic AMP responsiveness upon adjacent promoters. The purpose 
of this project was to re-examine the role of the SRE in 
stimulating transcription from the c-fos promoter, to 
characterise the transcriptional properties of the fosATF/AP-1 
binding site that lies adjacent to the SRE, and to investigate 
any interaction that may take place between these two sequences 
in controlling transcription from the c-fos promoter.
Results obtained confirm that the SRE confers serum and phorbol 
ester responsiveness upon the c-fos promoter. They also show 
that the fosATF/AP-1 sequence forms a weaker complex with an 
AP-l/ATF protein than previously characterised AP-l/ATF binding 
sites, and that this sequence activates transcription from the 
c-fos promoter in growing cells. The fosATF/AP-1 binding site 
also confers serum and phorbol ester responsiveness upon the 
c-fos promoter. In quiescent cells the juxtaposed SRE and 
fosATF/AP-1 sequences contribute to a lower level of 
transcription from the c-fos promoter than does the SRE itself. 
This suggests an interaction between the proteins binding to 
these two sequences. Separating the SRE and fosATF/AP-1 
sequences resulted in elevated levels of expression in quiescent 
cells and also resulted in higher levels of transcription from 
the c-fos promoter following stimulation of quiescent cells with 
serum or phorbol esters. It is concluded that there is a complex 
mechanism of interaction between the proteins that bind to the 
adjacent SRE and fosATF/AP-1 sequences and that there may be 
several proteins involved in this interaction.
xi
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1.1 Isolation and Structure of Viral and Cellular Fos Genes
1.1.1 A fos sequence is the transforming gene of FBJ-MSV
In 1966 a viral complex was isolated from a spontaneous
osteosarcoma in a 260-day-old CFI mouse (1). This complex consisted
of two viruses, FBJ-MLV (Finkel, Biskis, Jinkins murine leukaemia
virus) which is a replication-competent helper virus and FBJ-MSV (FBJ
murine osteosarcoma virus) which is replication-defective (2,3).
When the FBJ viral complex was injected into neo-natal mice neoplasms
developed at several sites and displayed bone-like properties (4) .
To identify the transforming sequence of the FBJ viral complex,
presumably present in FBJ-MSV since this virus is
replication-defective, the two viruses present in the complex were
isolated separately in tissue culture (5,6). FBJ-MLV was isolated by
3 4diluting our the FBJ-MSV (it is present in a 10 to 10 -fold excess 
over FBJ-MSV), and FBJ-MSV by the establishment of non-virus 
producing rat cells. These non-producer rat cells were injected into 
rats and serum was taken from those that developed tumours. This 
tumour-bearing-rat-serum (TBRS) identified, in immunoprecipitation 
reactions, two proteins present in FBJ-MSV transformed cells that 
were virus specific. These were a 55kD phosphoprotein (p55) which 
was the product of the transforming gene of FBJ-MSV, and a 39kD 
cellular protein (p39) which forms a complex with the viral 
transforming product (7) .
The genome of FBJ-MSV was isolated from the non-producer rat cells 
used to raise the serum which identified the gene product (8) . When
5
the plasmid containing the FBJ-MSV DNA sequence, pFBJ2, was 
transfected into rat 208F cells it induced morphological 
transformation. The transforming gene of FBJ-MSV was called v-fos 
(FBJ murine osteosarcoma virus) and a probe specific for this gene 
was taken from pFBJ-2 and used to probe Southern blots of cellular 
DNA from chicken, mink, mouse and human. All four species displayed 
a band when probed with v-fos suggesting that the transforming gene 
of FBJ-MSV has a cellular counterpart that is reasonably conserved, 
as would be expected if FBJ-MSV had transduced a cellular gene as its 
oncogenic sequence.
There have been two modes of viral oncogene egression discerned in 
cells infected with acutely oncogenic retrovisuses such as FBJ-MSV. 
The acquired cellular sequence, fos in this case, may be expressed as 
an independent viral gene product (9) or, alternatively, as a fusion 
protein containing peptides derived from the viral structural 
sequences (10) . To determine which of these two possibilities was 
true for FBJ-MSV the DNA complimentary to the RNA of its helper 
virus, FBJ-MLV, was also cloned (11) as well as murine and human 
cellular fos genes, and comparisons were made between these sequences 
(and that of FBJ-MSV (12-14)). Heteroduplex analysis between FBJ-MSV 
and FBJ-MLV revealed that the FBJ-MSV genome had 6.8kb of the helper 
virus RNA deleted and replaced with 1.7kb cellular sequence thus 
creating v-fos. Heteroduplex analysis between FBJ-MSV and the mouse 
c-fos gene revealed five regions of homology separated by four 
regions of non-homology. The first three regions of discontinuity 
were due to introns in the mouse DNA while the fourth corresponds to 
a 104bp deletion from the v-fos gene (see Figure 1) . The human and
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Figure 1. From c-fos to v-fos.
Molecular architecture of FBJ-MSV proviral DNA and mouse v-fos gene. 
FBJ-MSV is shown at the top. The large open box indicates the 
acquired cellular sequences; solid bars, initiation and termination 
coldons of v-Fos proteins; the hatched box, the C-terminal 49 amino 
acids of v-Fos protein encoded in a different reading frame because 
of deletion of 104bp of c-fos sequence; bold lines, 5' and 3' 
recombination junctions. In the c-fos gene below, the stippled boxes 
are the exons. The 104bp sequence that has been deleted in v-fos is 
indicated by a triangle. Unlike the v-Fos protein, the c-Fos protein 
terminates at a TGA codon. The position of the TAG codon which acts 
as a chain terminator for v-fos protein is shown by an arrow. This 
diagram is taken from I. M. Verma, Nature, 308, p317, 1984.
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mouse c-fos genes have an almost identical structure with 
approximately 90% nucleotide sequence homology and this is why one 
can assume that the 104bp have been deleted from the v-fos sequence 
and not added to that of the c-fos. The results of the heteroduplex 
analysis showed that the v-fos gene present in FBJ-MSV was expressed 
as a single protein and not as a viral hybrid (e.g. gag-fos) . This 
confirms earlier work which showed that the candidate product of 
FBJ-MSV, p55, could not be irrmumqprecipated with any virus-specific 
antibodies (6) .
1.1.2. Two other retroviruses contain fos sequences responsible for 
transformation.
90A viral complex was isolated from a Sr-radiation-induced bone 
tumour in an X/Gf mouse (15) which contained two viruses, FBR-MSV 
(Finkil, Biskis, Reilly osteosarcoma virus) which is 
replication-defective • and therefore presumably codes for the 
transforming gene, and FBR-MLV (FBR-murine leukaemia virus) which is 
the replication-component helper virus (16) . FBR-MSV induced tumours 
are similar in pathology and histological appearance to those induced 
by FBJ-MSV and indeed FBR-MSV was shown to encode fos sequences which 
were presumably involved in the transformation properties of this 
retrovirus (17) . The FBR-MSV genome was isolated from non-viral 
producing rat cells in a similar manner to FBJ-MSV (8) and sequenced 
which allowed comparison between the two fos-containing retroviruses 
and the mouse c-fos gene (18,19). TBRS used to identify p55, the 
product of FBJ-MSV, immunoprecipitated a 75kD protein that was also
immunoprecipitated using anti-gag serum. This suggested that the 
product of FBR-MSV was a gag-fos fusion product and this was 
confirmed upon the sequencing of FBR-MSV which was shown to contain 
an open reading frame that encoded the gag-fos fusion protein. 
Interestingly, the sequence also showed an additional cellular 
sequence, termed fox, that was present as the carboxy-terminal 
portion of the FBR-MSV transforming protein and thus this protein was 
called p75^a<^  ^os ^ox. On comparison with the mouse c-fos sequence 
it was shown that FBR-MSV lacks the sequence that codes for the first 
24 amino acids and the last 98 amino acids of the 380 amino acid 
mouse c-Fos product. In addition the coding sequence for 
p75^a^ ^os ^OX has sustained three internal deletions, one within the 
gag sequence and the other two within the fos sequence.
The third, and so far the last, transforming retrovirus found to code 
for a Fos-related protein was isolated from a spontaneous 
nephroblastoma in an adult chicken (20) . This retrovirus was called 
NK24 and, like FBJ-MSV and FBR-MSV, was replication-defective and so 
was isolated along with a replication-conpetent retrovirus. Upon 
re-injection of this virus into chickens tumours developed consisting 
of fibrobasts and osteoblasts with a degree of calcification, and in 
one particular chicken a nephroblastoma developed. A non-virus 
producing quail cell line was established and from these cells a 
lOOkD protein was immunoprecipitated using anti-gag serum, suggesting 
that the transforming protein of this virus is a gag-fusion product. 
Upon isolation and sequencing of the NK24 genome this was confirmed 
as the virus contains an open reading frame that encodes a gag-Fos 
fusion protein of lOOkD. On comparison of the fos sequence present
9
in NK24 with the chicken c-fos gene (21) it was observed that the 
oncogene product of NK24 contained a truncated version of the chicken 
c-fos gene as it lacks the nucleotides coding for the first 45 amino 
acids of the c-Fos protein.
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1.2. Fos Proteins and Their Transforming Properties
1.2.1. Size and distribution of cellular and viral Fos proteins 
within the cell.
Iimrunqprecipitation and immunoblotting techniques using Fos-specific 
antibodies have been employed to identify the intracellular location 
of viral and cellular Fos proteins. These techniques detected the 
presence of Fos proteins (both cellular and viral) exclusively within 
the nucleus and immunoprecipitation of the Fos proteins 
co-precipitated a cellular protein, p39 (7, 18, 22, 23) . p39 is
complexed with the viral and cellular Fos proteins and is not 
antigenically related to them since denaturation of cell lysates 
completely abolishes the immunoprecipitation of p39 whereas the 
precipitation of the Fos proteins is unaffected.
The v-fos gene of FBJ-MSV has a 104bp deletion near the 3'-terminus 
when compared to the mouse c-fos gene and this deletion is out of 
frame resulting in p55v Fos protein being 381 amino acid residues in 
length whereas c-Fos is 380 amino acids. The out-of-frame deletion 
means that the carboxy-terminal 48 amino acids of the c-Fos protein 
is completely different to the carbox-terminal 49 amino acids of the 
v-Fos protein (13) . The preceding 332 amino acids, prior to the 
104bp deletion region, show only 5 amino acid differences between the 
v-Fos and c-Fos proteins. To determine whether the different 
carboxy-terminals present in the v-Fos and c-Fos proteins leads to 
different protein populations, a pulse-labelling experiment was 
carried out with cells expressing either the c-Fos or v-Fos proteins
11
(22) . After 15 minutes of labelling both cell lines, 
immunoprecipitation studies detected identically sized proteins of 
54kD which were shown to smear up to around 55kD (p55) . However, 
thereafter the pattern produced by the two cell-lines became very 
different. After 2 hours of labelling, in the cells expressing c-Fos 
protein, products of 57, 60 and 62kD could be detected by
immunoprecipitation studies. The cells expressing v-Fos contained a 
product of 55kD that is presumably derived from the 54kD protein by 
some slight modification. At this point it is necessary to define a 
general rule for the nomenclature of viral and cellular Fos proteins. 
v-Fos will be used when describing p55v ^os (or in relation to any of 
the other transforming viral proteins) and c-Fos protein will be used 
to describe the heterogeneous populaton of modified forms of c-Fos 
(57, 60 and 62kD).
Because the c-Fos and v-Fos proteins have different carboxy termini 
it was suspected tha the differences in the protein populations were 
due to differential phosphorylation of the respective proteins on 
their carboxy-terminal regions. There have been conflicting reports 
regarding this possibility. The first report suggested that the 
differential modification of v-Fos and c-Fos was not due to their 
different carboxy-termini (24). This study involved the analysis of 
the protein products of transfected plasmids encoding the v-Fos 
protein, the c-Fos protein and c-Fos carboxy-terminal truncated 
proteins. These studies were carried out in E.coli and S.cerevisiae 
cells and in the prokaryotic cells the c-Fos protein was not modified 
suggesting that the modification process is eukaryotic-specific. In 
S.cerevisiae cells the modification of the c-Fos protein took place
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with both the intact gene and also with the deletion mutants that had
the carboxy-terminal sequences removed, suggesting that these
sequences were not responsible for the modifications of the c-Fos
protein in these cells. Another report provided a conflicting set of
results (25) . Treatment of cell extracts containing c-Fos or v-Fos
proteins with alkaline phosphatase showed that most of the c-Fos
protein modifications were due to phosphorylation. The c-Fos protein
was 4- to 5-fold more highly phosphorylated than the v-Fos protein
32and comparison of tryptic peptide fragments from P-labelled 
proteins indicated that, although the two proteins have several 
tryptic phosphopeptides in common, the c-Fos protein contains unique 
major phosphopeptides. These were tentatively localised to the 
carboxy-terminal 20 amino acids of the c-Fos protein.
1.2.2. The c-Fos protein is a transforming protein.
Not surprisingly it was originally thought that the altered carboxy 
terminus of the v-Fos protein was responsible for the transformation 
properties of FBJ-MSV. Indeed, the introduction of the c-fos gene 
into fibroblasts failed to induce the morphological transformation of 
these fibroblasts. However, when chimaeric plasmids were made 
containing viral (FBJ-MSV) and cellular (mouse) fos sequences, the 
c-Fos protein was shown to be capable of transforming fibroblasts 
(26). Two manipulations of the c-fos gene were required to activate 
its transformation properties.
i) The transcription of the gene had to be driven by a viral 
LTR.
ii) Sequences in the 3' translated and 3' untranslated regions
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had to be disturbed.
These two manipultaions presumably lead to a greater level of 
transcription of the c-fos gene and a stabilisation of the mRNA, both 
of which would lead to increased levels of c-fos mRNA and therefore 
increased levels of c-Fos protein. A sequence in the 3' untranslated 
region downstream from the translation stop codon and upstream from 
the polyadeylation site has been identified as being important in 
suppressing the oncogenic potenital of the c-fos gene (27) . Removal 
of this sequence leads to the activation of the transforming 
potential of the c-fos gene (providing transcription is driven by a 
strong promoter such as a viral LTR) . Similar alterations in the 
human c-fos gene are required to activate its transforming potential, 
and it was also shown with the human gene that the removal of the 3' 
untranslated sequence from c-fos did indeed result in greater levels 
of c-fos RNA due to increased mRNA stability (28) .
Upon analysis of the c-Fos protein present in rat 208F fibroblasts 
transformed with c-fos (both human and mouse) it was noted that the 
protein was less modified than its normal cellular counterpart and 
also that its half-life was reduced to 30 minutes (instead of 2 
hours). The c-Fos protein that is responsible for transformation in 
these cells is similar in size to that found in v-fos transformed 
cells (22) . One explanation for this could be that in the cells 
ejqpressing endogenous c-Fos protein phosphorylation cascades which 
modified the c-Fos protein could be operating, and these cascades may 
not be operating in the c-fos transformed fibroblasts leading to a 
slowing down in the modification process.
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To date, there have been no reports of c-fos sequences being the 
transforming gene in tumours isolated from any species. However, the 
human c-fos gene maps to chromosome 14, band q24.3-q31 (29) and this 
region has a high frequency of aberrations in connection with various 
types of human neoplasia (30) . The activation of the c-fos 
transforming potential would require the deletion of the 3' sequences 
responsible for mRNA destablisation and the addition of a strong 
transcriptional activator in the vicinity of the gene and these two
criteria would most easily be met by a chromosomal translocation. 
Such translocations have been implicated in activating the 
transforming potential of the c-myc and bcr-abl genes (31, 32) . 
However it has not yet been shown that these altered sequences can 
cause cellular transformation and their precise role in the 
transformation process is not yet clear. It will be of interest to 
see if any such translocations can be identified involving the c-fos 
gene resulting in the activation of its transforming potenetial.
To determine whether c-fos sequences can induce malignant
transformation in animals, transgenic mice populations were
established. These mice had the mouse c-fos sequences under the
transcriptional control of the metallothionein promoter (33) or the
c.
H2-K (the murine major histocompatibility complex) promoter (34) . 
Interestingly, the c-fos 3' untranslated sequence which destabilises 
the c-fos mRNA had to be removed from the c-fos sequences to obtain 
elevated levels of expression of the exogenous c-fos sequences in the 
transgenic mice. None of the c-fos transgenic mice established 
developed malignancies similar to those developed with FBJ-MSV 
although the c-Fos protein did interfere with normal bone development
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when expressed in bone tissue. Visible swelling on the tibia of both 
hind legs could be detected in certain transgenic mice, although all 
of them displayed an aberrant bone formation upon histological 
examination and the phenotype of the bone aberrations was generally 
inherited. However, as mentioned above, these lesions were not 
malignant and failed to progress to tumours even after ten months.
The H2-k^ promoter allowed for a wider spectrum of tissue expression 
for the exogenous c-fos sequences (although they did not cause 
expression of c-fos sequences in bone tissue), including 
haematopoietic cells which did not express the exogenous c-fos 
sequences under the transcriptional controls of the metallothionein 
promoter. These mice displayed aberrant thymus development due to 
increased levels of epithelial cells which resulted in altered T-cell 
development (possibly due to abnormal levels of hormones coming from 
the epithelial cells), resulting in immune deficiency. However, once 
again these mice showed no sign of malignancies due to the exogenous 
c-fos sequences.
Many reasons can be thought of for the failure of the exogenous c-fos 
sequences to cause malignancy. Conclusions can only be drawn from 
these transgenic experiments when the viral sequences and chimaeric 
v-fos/c-fos sequences are also used to establish transgenic mice and 
the effects of these sequences upon for example, bone structure and 
development, are determined.
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1.2.3. FBJ-MSV and FBR-MSV have different biological properties.
The two acutely transforming murine retroviruses encoding fos 
sequences are FBJ-MSV and FBR-MSV which code for two different 
proteins : p55v_fos and p75gag-fos-fox, respectively. The FBJ-MSV
fos gene consists entirely of cellular fos sequences, the only 
difference between the viral and cellular genes being a deletion at 
the 3' terminus of the c-fos gene resulting in different carboxy 
terminals for the v-Fos and c-Fos proteins (13) (see 1.2.1.) . The 
FBR-MSV transforming fos sequence is very different from that of 
FBJ-MSV as it has truncated 5' and 3' ends (which have been replaced 
by other viral and cellular sequences) and contains several deletions 
and point mutations. These different protein structures lead to 
different biological properties for the two proteins with FBR-MSV 
possessing a more potent transforming activity in rat fibroblasts 
than FBJ-MSV (18), even although both viruses can induce tumours when 
injected into newborn mice. This observation was confirmed in a 
subsequent report (35) which also established that the gag sequences 
present in p75gag ^0S ^OX were not responsible for the increased 
transforming ability of this protein. It was also observed that 
FBR-MSV could establish low-passage mouse connective tissue cells as 
well as cause their transformation (36) . This showed that the 
transforming protein of FBR-MSV also had immortalising properties. 
Although FBJ-MSV could also transform these low-passage mouse 
connective tissue cells the resultant transformed cells did not 
become established. This shows that FBJ-MSV does not possess 
iirmortalising properties and it was also observed that this virus 
induced smaller foci after a longer latency period than did FBR-MSV.
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The different biological properties of the FBR-MSV gene product 
compared with that of FBJ-MSV appear to be directly related to 
structural alterations, since similar expression levels and turnover 
rates are observed with both proteins (22, 37) . A comprehensive
panel of FBJ/FBR/c-fos chimeric genes was used to characterise those 
structural alteration in Fos protein that are responsible for 
enhancing its transforming potential (37) . This analysis yielded 
three major results:
1. An FBR-MSV specific amino acid exchange (glu to val at amino acid 
position 138) introduced into FBJ protein activates the immortalising 
potential of the resultant protein.
2. Replacement of glu-175 with lys in FBR-MSV (representing an 
FBJ-MSV specific amino acid exchange) leads to an approximately 80% 
decrease in the number of foci induced.
3. Replacement of the two small in-frame deletions in the C-terminal 
half of the FBR-MSV protein by the corresponding fos sequences 
reduces the transforming efficiency to approximatley 25% of that of 
the wild type protein.
So, it was possible to dissociate the enhanced transforming potential 
of FBR-MSV from its immortalising properties as any alterations which 
decrease its transforming efficiency do not affect i£s immortalising 
properties, and the point mutation which abolishes its immortalising 
properties has very little effect upon its enhanced transformation 
properties.
Although FBR-MSV and FBJ-MSV have different transforming properties 
there is evidence to suggest that both oncogenic proteins of these
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retroviruses induce transformation through similar mechansism (38) . 
This evidence has come from the study of revertants of FBJ-MSV 
transformed rat cells. Revertants of these cells, isolated by 
mutagenesis, are refractory to re-transformation with either FBJ-MSV 
or FBR-MSV (as well as other oncogenes) . Results from this study 
suggest that the revertants carry mutations in cellular effector 
genes (those genes that are the target for oncogenic proteins) and 
therefore any failure to re-transform these cells suggests that the 
potential transforming proteins act through simialr cellular 
sequences.
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1.3. c-fos Expression During Development and Differentiation.
1.3.1. Expression of c-fos during mouse and human development.
To determine whether c-fos is expressed in a tissue-type or 
stage-specific manner the level of c-fos transcripts were analysed in 
the embryo and extra-embryonal tissues of mouse and humans (39-42). 
In 10 day-old mouse foetuses there are higher levels of c-fos 
transcripts present in the placenta than in either the embryo proper 
or extra-embryonal tissues and these high levels persist until day 
18, remaining both relatively high and constant throughout gestation. 
The level of c-fos transcripts is > 15-fold higher in the separated 
outer portion of the midgestation placenta (relatively 
undifferentiated) than in the inner moiety (predominantly 
differentiated) . Both foetal (trophoblast) and maternal (decidua) 
moieties of the placenta are rapidly proliferating tissues and the 
mouse trophoblast has been considered a "pseudo-malignant" tissue as 
it grows invasively into the uterine epithelium or any other 
surrounding tissue. In the amniotic tissue the level of c-fos 
transcripts increases during gestation and in 18-day conceptuses the 
abundance of the c-fos transcripts in the amnion (which increases 
2-fold from 12 to 18 days) approaches the levels of v-fos transcripts 
present in virus-transformed cells. These levels of c-fos expression 
were similar in human amniotic and chorionic tissues, and the rest of 
the human tissues also followed a similar pattern of c-fos expression 
to that of the mouse.
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When a peptide antibody was raised against a c-fos sequence and used 
to determine the levels of c-Fos protein in the embryonic and 
extra-embryonic tissues the antibody reacted with the nuclei of cells 
approximately in proportion to the level of c-fos transcipts detected 
in the cells (43) . It was also possible to detect imrnunoreactive 
material in the nuclei of most foetal and adult tissues using 
relatively high concentrations of antibodies, even though c-fos 
transcript levels were present at very low levels in most of these 
tissues. In all cases where the antibody reacted, representing the 
c-Fos protein, the reaction occurred in the nucleus and the 
previously identified cellular protein p39 could be co-precipitated 
from cells expressing the c-Fos protein which is similar to previous 
findings (7) .
In a further study it was observed that there were high levels of 
c-fos transcripts and protein present in the parietal endoderm of 
13.5 day-old mouse foetuses and these levels were higher than those 
observed in the amnion or placenta at this stage of development (44) . 
In a bid to mimic the in vivo situation, F9 teratocarcinoma cells (a 
murine embryonal-carcinoma cell line) were induced to differentiate 
to parietal endoderm-like cells by reti noic acid and dibutyryl cAMP 
treatment. However, no elevated levels of c-fos transcripts could be 
detected in these terminally differentiated cells although a rapid 
and transient increase (about 3-fold) was observed within the first 2 
hours after treatment. It was suggested that the failure to observe 
elevated levels of c-fos transcripts in the terminally differentiated 
F9 cells was possibly due to the cells not receiving certain growth 
factors or hormones that may be responsible for the elevated levels
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of c-fos transcripts observed in the parietal endoderm cells. This 
possibility gained further credence when it was observed that in 
mouse primary amniotic cells grown in normal growth medium the levels 
of c-Fos protein and c-fos transcripts decreased to undetectable 
levels after a short time (45). However, in these cells c-fos 
expression is inducible by, and maintained at high levels in the 
presence of, dialysed placenta or embryo conditioned medium (dialysis 
removes elevated ion concentrations which may have an effect on c-fos 
egression) . This strongly suggested a growth factor presence in the 
placenta or embryo-conditioned medium that was responsible for the 
increased levels of c-fos expression.
In post-natal mice (1 to 3 days) low levels of c-fos transcripts 
could be detected in all tissues (39) although RNA extracted from 
'bone' tissue (sternum, ribs and vertebrae including bone marrow, 
muscles and part of the placenta) and 'skin' tissue (including 
sub-cutaneous tissue, muscles and part of the peritoneum) showed 5 to 
20-fold greater levels of c-fos transcripts than other tissues. 
Analysis of a 17 day-old mouse embryo by in situ hybridisation 
demonstrated that c-fos expression is restricted to the perichondrial 
growth regions of the cartilaginous skeleton and to the web forming 
mesodermal cells which are characterised by a stage-specific high 
growth capacity (46) . No c-fos transcripts could be detected in 
either of these tissues in day 10 or 13 embryos suggesting that c-fos 
transcripts are restricted to those parts of the foetal bone having 
the highest growth potential at about day 17 of development. This 
result was confirmed by a subsequent study (47) using fos-specific 
antibodies which also showed c-Fos protein present in the bone tissue
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of day 17 embryos.
Thus, although here is a definite stage- and tissue-specific 
expression of both the c-fos transcript and protein the role that 
c-fos expression plays in the development of mouse and human embryos 
remains unclear. The elevated levels do appear to coincide with 
tissues that are rapidly proliferating (such as the amnion and 
placenta) but when amniotic primary cells are plated out in normal 
growth medium the levels of c-fos expression become undetectable but 
the cells retain the potential to proliferate, suggesting that 
elevated levels of c-fos are not crucial to the proliferation of 
these cells. Perhaps c-fos expression is required for an initial 
burst of proliferation and the degree and timing to which it is then 
turned off is less relevant to particular cells. However, it is very 
difficult on the basis of these studies to assign a definite role to 
the c-fos expression in the embryo and extra-embryonal tissues. 
Interestingly, in certain tissues (e.g. the amnion in both mouse and 
humans) the levels of c-Fos protein detected are similar to those 
found in v-fos transformed fibroblasts. Obviously the amniotic 
tissue is not transformed, and amniotic cells fail to induce tumours 
when injected sub-cutaneously into mice. This suggests that the 
c-Fos protein, as it can transform fibroblasts, requires to be 
elevated in inappropriate cell types in order to cause 
transformation. Other reasons for this failure to observe 
transformation in the amniotic cells can be suggested such as 
different post-translational modifications of the c-Fos protein 
occurring in the amniotic cells resulting in a different c-Fos 
protein population, perhaps preventing the accumulation of c-Fos
protein that is capable of transformation. One fact that would argue 
for the latter possibility is that elevated levels of c-fos 
expression are observed in bone tissue which is the target for the 
transforming FBJ-MSV and FBR-MSV retroviruses. However, it is 
possible that the virus infects different cells to those expressing 
the c-Fos protein, and it is also possible tha the v-Fos proteins 
transform simply because of their elevated expression levels.
1.3.2 Role of c-fos expression in haematopoietic cell 
differentiation.
Cellular proto-oncogenes were suspected of playing a pivotal role in 
crucial biological functions such as differentiation because of their 
ability, or that of their viral counterparts, of causing cellular 
transformation when expressed in an aberrant fashion. To examine the 
role of c-fos in haematopoietic cell differentiation the levels of 
c-fos expression were examined in several haematopoietic cell-lines 
(many of which can be induced to differentiate by chemical inducers) 
and in isolated populations of normal and leukaemic blood cells. 
These studies provided confusing and sometimes contradictory results 
with several reports arguing for and against a crucial role for c-fos 
egression in the differentiation of haematopoietic cells.
Most of the evidence indicating that c-fos expression does play a 
crucial role in haematopoietic cell differention has come from 
studies of leukaemic cell-lines and leukaemic blood cell populations. 
These were studied as leukaemias represent different lineages of 
blood cells maturation arrested at various stages prior to terminal
24
differentiation, and many of the leukaemic cell-lines can be induced 
to terminally differentiate, usually by chemical inducers. Two 
leukaemic cell-lines that have been employed extensively in these 
studies are the promonocytic cell-line U-937 (48) and the
promyelocytic cell-line HL-60 (49), both of which can be induced to 
differentiate to macrophage-like cells after treatment with TPA (50, 
51) . Treatment of U-937 and HL-60 cells with TPA results in a rapid 
induction of c-fos expression which peaks around 30 minutes after 
treatment and decreases thereafter; although the levels of expression 
do remain elevated in comparison to basal levels for at least 90 
hours (52 - 55) . Treatment of HL-60 cells with DMSO or retinoic acid 
results in differentiation to granulocyte-like cells (56), but no 
induction of c-fos expression is observed following these treatments. 
Supporting the link of c-fos expression to macrophage differentiation 
is the observation that c-fos expression in HL-60 cells decreases 
upon "de-differentiation" of macrophage-like cells (57) . This 
observation was made with sub-lines of HL-60 cells treated with
1,25-dihydroxy-vitamin which results in the cells sticking to the 
plastic culture dishes and gaining macrophage like properties which 
resulted in an increased expression of c-fos. However, upon removal 
of 1,25-dihydroxy-vitamin from the medium the cells apparently 
"de-differentiated" losing their macrophage-like properties and 
regaining those of undifferentiated HL-60 cells. This 
"de-differentiation" is accompanied by a decrease in c-fos expression 
to undetectable levels suggesting that c-fos expression is involved 
in the differentation of HL-60 cells to macrophages.
In leukaemic blood cell populations c-fos expression is restricted to
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acute leukaemias with monocytic phenotypes in most reports, although 
samples representing precursors of granulocyte-like cells have also 
been reported as showing elevated levels of c-fos expression (59-61) . 
Primary cells from some of the leukaemic samples could be induced to 
differentiate with TPA into monocytic-like cells and these inductions 
were accompanied by an increase in the levels of c-fos expression, 
once again suggesting that c-fos expression may be linked to the 
monocyte-macrophage differentiation pathway.
The above results indicate that c-fos expression may play a role in 
the monocyte-macrophage differentiation pathway. However, there have 
been several reports suggesting that this is not the case. The 
murine myeloid leukaemia cell-line WEH1-3B (D+ subline) (62) can be 
induced to differentiate into macrophage-like cells after treatment 
with granulocyte-colony-stimulating factor plus actinomycin D (63) 
and c-fos expression is not elevated in these cells until 48 hours 
after treatment when most of the cells have already differentiated. 
This expression at later stages of macrophage development does not 
preclude a role for c-fos expression in the maturation of 
macrophages. More direct evidence against the idea of c-fos 
expression playing a crucial role in the macrophage differentiation 
pathway has come from studies of HL-60 and U-937 cells. It has been 
shown that c-fos expression is neither sufficient nor necessary for 
the differentiation of these two cell-lines to macrophage-like cells 
(64, 65) . When U-937 cells were treated with a protein kinase C
agonist (diacyl glycerol), or serum deprived and then serum 
stimulated, c-fos expression is induced in a similar fashion to that 
obtained following TPA treatment, but this induction does not result
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in an induction of macrophage-like differentiation. A similar 
treatment was also given to HL-60 cells resulting in a rapid increase 
in c-fos expression but no differentiation to macrophage-like cells. 
These results showed that the induction of c-fos expression was not 
sufficient by itself to induce macrophage-like differentiation in
either of these cell-types. HL60 sub-lines that were resistant to 
induction of differentiation by TPA were employed to analyse whether 
c-fos expression was necessary for the macrophage differentiation 
pathway. When these sub-lines were treated with
1,25-dihydroxy-vitamin they differentiated into macrophage like
cells but did not show the rapid induction of c-fos expression.
Similarly, when HL-60 cells were treated with TPA in the presence of
retinal (an inhibitor of protein kinase C) the induction of c-fos 
expression is rapidly reduced although the cells differentiate to
macrophage-1ike cells in a normal fashion. Both of these results 
suggest that c-fos expression is not necessary for the 
macrophage-like differentiation of HL-60 cells.
In normal blood cell populations there is confusion in the reported 
levels of c-fos expression in monocytes and macrophages in comparison 
with other cell-types. Several studies suggest that c-fos expression 
is indeed restricted to monocyte and macrophage cells (61, 66)
whereas others have identified elevated levels of c-fos expression 
in granulocytes when compared to monocytes and macrophages (67, 69) .
The reason for these discrepancies is not clear but could involve the 
different methods of isolation of the blood cell populations which 
may result in different micro-environments containing different 
growth factors which may have v<*-liable effects on c-fos expression.
27
However, in summary it would seem that c-fos expression is not linked 
exclusively to marcophage-like differentiation and indeed is 
apparently not necessary or sufficient for such differentiation. It 
would seem that the induction of the c-fos expression in 
haematopoietic cells is more the cause of the stimulus on the cell 
rather than the differentiation that results from these stimulations. 
Several pieces of evidence support this hypothesis,c-fos expression 
can be induced in terminally differentiated mouse peritoneal 
macrophages by treatment with CSF-1 (53, 70) and by activation of
protein kinase C (71) . c-fos expression can also be induced in HL-60 
cells induced to differentiate to granulocyte-like cells following 
treatment with dibutyryl cAMP (88) showing that c-fos expression is 
not restricted to the macrophage-like differentiation of these cells. 
So, it would seem that c-fos expression can be induced in 
haematopoietic cells by many external stimuli and that this 
expression is most likely due to the extemal-stimuli and is not 
linked to any particular differentiation pathway.
1.3.3 Role of c-fos expression in the differentiation of embryonal 
carcinoma cell lines.
The strongest evidence implying a role for c-fos expression in the 
differentiation process has come from studies on murine embryonal 
carcinoma cell lines (72) . These cells have been used as a model 
system to study differentiation and development as they can be 
induced to differentiate into a variety of cell types by treatment 
with chemical inducers. Upon transfection of plasmid constructs 
which lead to constitutive expression of either the human or mouse
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c-fos genes into the embryonal carcinoma cell line F9 (73), 
morphologically altered cells appear which express specific markers 
characteristic of differentiated cells (74). The expression of c-fos 
in these cells is usually very low (75) and it was established that 
the appearance of markers indicating differentiation of the cells was 
due to increased levels of c-fos mRNA. and protein. These
morphologically differentiated cells were not recognisable as any 
previously identified cell-type and did not express a complete set of 
differentiation markers characteristic of any previously identified 
differentiated cell. These observations suggest that the increased 
exogenous c-fos expression leads to the expression of certain
differentiation markers but that terminal differentiation to an
identifiable phenotype may require the expression of other genes as 
well as c-fos. Interestingly, F9 cells can be induced to 
differentiate with retinoic acid treatment without any elevated 
levels of c-fos expression at any time point and constructs
efficiently expressing anti-sense c-fos ENA failed to prevent the 
differentiation of these F9 cells (76). However, as mentioned in
1.3.1, treatment of F9 cells with retinoic acid plus dibutyryl cAMP 
leads to a rapid but transient induction of c-fos expression which 
may be due to the added dibutyryl cAMP or a combination of effects 
between the two inducers (44) . So, the studies on c-fos expression 
in differentiating F9 cells suggest that egression of this gene is 
neither sufficient by itself nor necessary to produce recognisable 
differentiated cells although high levels of expression certainly do 
affect the morphology of these cells.
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When the plasmid constructs transfected into F9 cells have c-fos 
expression under the control of an inducible metallothionein promoter 
(77) it was observed that increasing the c-fos expression 100-fold 
(by treatment with cadmium) in the transfected cells did not result 
in any progression in the differentiated state of the F9 cells, 
suggesting that the induction of differentiation markers by c-fos 
expression is not dose dependent. These constructs were transfected 
into other embryonal carcinoma cell lines which yielded different 
results. After expression of exogenous c-fos, PI9 cells (a murine 
embryonal carcinoma cell line (78)) showed expression of 
differentiation markers similar to those detected in F9 cells 
although the cell line PC13 (another murine embryonal carcinoma cell 
line (73)) failed to express any such morphological differentiation 
markers. An explanation for this observation could be that F9 cells 
have less pronounced stem cell characteristics than either P19 or 
PC13 cells as the F9 cells show higher levels of EGF receptor and 
transferrin expression (79), suggesting that these cells are more 
mature than PI9 or PC13 cells. So, this evidence suggests that 
certain events have taken place in F9 cells, but not PC13 cells, that 
may be required for the exogenous c-fos expression to cause its 
observed differentiation effects. c-fos expression can be detected 
in P19 cells at later stages of differentiation (after 12 days of 
treatment) following treatment with DMSO or DMSO plus retinoic acid 
(80, 81), so it is rather surprising that exogenous c-fos expression
should have such an effect on the immature undifferentiated PI 9 
cells.
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Although the evidence is once again confusing these studies with
embryonal carcinoma cell lines provide the strongest evidence linking 
c-fos expression to differentiation. The apparent presence of a 
sub-set of differentiation markers on the altered cells would suggest 
that c-fos expression on its own is not capable of inducing a 
terminal differentiation process, but rather it requires co-operation 
with other genes which are as yet unidentified. This is not
surprising as it is not to be expected that expression of one single 
gene should control a complex process such as differentiation.
1.3.4 c-fos expression in differentiating PC12 cells and in neuronal 
tissues in vivo.
PC12 cells are a rat pheochromocytoma cell line (82) that can be
induced to differentiate into neurite-like cells by treatment with 
nerve growth factor (NGF) (82) or to chromaffin-like cells upon 
treatment with dexamethasone (83) NGF acts on a specific receptor on 
these cells and increases c-fos expression both rapidly and
transiently with a peak in expression occuring after 30 minutes 
before becoming undetectable again by 120 minutes (84, 86) . PC12
cells represent an asynchronously growing population of cells and the 
induction of differentiation by NGF leads to a cessation or reduction 
in the rate of cell division. Several other extra-cellular stimuli 
will induce rapid and transient c-fos expression in PC12 cells and 
some of these stimuli result in the differentiation of PC12 cells to 
neurites while others do not lead to any recognisable 
differentiation. So, although c-fos expression can be induced when 
PC12 cells differentiate to neurite-like cells (induction by
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dexamethasone treatment to chromaffin-like cells does not induce 
c-fos expression) this induction is not sufficient for 
differentiation. In PC12 cells stably transfected with a plasmid 
encoding an inducbile N-ras oncogene the cells can be induced to 
differentiate by NGF to neurite-like cells when N-ras expression is 
induced, but this induction occurs without the familiar rapid and 
transient increase in c-fos expression (87). Together these results 
suggest that c-fos expression is neither sufficient nor necessary for 
the differentiation of PC12 cells to neurite-like cells, which is a 
similar conclusion to that obtained with haematopoietic cells (see 
sub-Section 1.3.2.). As with the haematopoietic cells it seems more 
likely that the induction of c-fos expression in PC12 cells is a 
response to the extra-cellular stimuli and does not play a crucial 
role in the differentiation of these cells. Several observations 
agree with this hypothesis such as the ability of NGF to re-induce 
rapid and transient c-fos expression in NGF-induced differentiated 
PC12 cells. NGF can also induce c-fos expression in PC12 cells 
induced to differentiate to chromaffin-like cells, even after 5 days 
of dexamethasone treatment.
Although c-fos expression is not crucial to the differentiation of 
PC12 cells it does seem to play a role in neuronal tissues in vivo. 
It was observed that a calcium ion influx into PC12 cells induces 
rapid and transient egression of c-fos (88, 89) . Calcium influxes
are a normal aspect of neuronal physiology in vivo and so studies of 
c-fos expression were extended to determine whether this expression 
could be induced in the neuronal tissues of intact animals (90 -98) .
Most of these studies involved the analysis of c-fos expression in
mouse or rat brain by RNA. analysis or by immunohistochemical 
analysis. Several stimuli were shown to induce rapid and transient 
c-fos expression in certain areas of the brain and these included 
treatment with the convulsant drug Metrazole or electrical 
stimulations. The role of c-fos expression in response to such 
treatments is not clear, but it is thought that c-fos may co-operate 
with other gene products in the long-term adaptive response of these 
c-fos expressing neuronal cells. This could involve an increase in 
particular cell-surface receptors, an increase in certain 
intracellular proteins, or an increase in specific proteins excreted 
from the affected cells.
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1.4 c-fos Expression is Induced by a Wide Variety of
Extra-cellular Stimuli.
1.4.1 c-fos expression in stimulated quiescent fibroblasts.
The induction of c-fos expression has been described previously 
(sub-Sections 1.3.2. and 1.3.4.). These inductions involved the 
treatment of asynchronously growing haematopoietic cell tines or the 
rat pheochromocytoma cell line PC12 with growth factors, phorbol 
esters and other agents. These stimulations resulted in a rapid and 
transient induction of c-fos expression in most cases, although in 
HL-60 cells treated with TPA the level of c-fos expression remains 
above basal levels for at least 90 hours post-stimulation. No clear 
function can be assigned to these inductions but it seems most likely 
that they are related to the stimulus to the cell rather than to any 
biological process, such as differentiation, that occurs following 
stimulation. Because cellular oncogenes (or their viral 
counterparts) can cause cellular transformation (99) it was thought 
that in normal cellular functions their products may be involved in 
biological processes such as growth and differentiation. No 
conclusive link has been made between c-fos expression and 
differentiation, so its role in growth was examined along with that 
of other oncogenes.
The system chosen to examine the role of oncogene expression in 
growth has frequently been the stimulation of quiescent fibroblasts 
with growth factors. Most of these studies have employed murine 3T3 
fibroblast cell lines which are immortal but not transformed, and
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upon serum deprivation they can enter a state (Go) in which cell 
division and growth stops and many metabolic processes are reduced 
(100). The addition of serum to these serum-deprived (quiescent) 
cells initiates a conplex series of events (G1 phase) which 
culminates 14 to 20 hours later in DNA synthesis (101). Nuclei of 
Balb/c 3T3 cells were isolated at various times following stimulation 
of quiescent fibroblasts with serum and nuclear run-off transcription 
assays (102, 103) were carried out to determine whether the
stimulation of these cells alters the transcription rate of any 
proto-oncogenes (104, 107). Seventeen proto-oncogenes were analysed
but only c-fos, and to a lesser extent c-myc (which also encodes a 
nuclear protein (108)) were shown to increase their transcription 
rates in response to serum stimulation. An increase in the 
transcription of the c-fos gene could be detected within 5 minutes of 
stimulation, peaked around 10 minutes, started decreasing after 15 
minutes and returned to basal levels within 30 minutes. This 
increase in transcription was due entirely to polymerase II 
transcription as a-aminitin (a polymerase II inhibitor) completely 
abolished any increase in c-fos transcription following serum 
stimulation. This increase in c-fos transcription was reflected in 
the levels of c-fos mRNA detected in 3T3 cells following stimulation, 
which peaked at around 20 minutes, decreased by 30 minutes and became 
undetectable after 60 minutes. The c-Fos protein showed a similar 
induction as it becomes detectable after 30 minutes, peaks in 
expression around 60 minutes before becoming undetectable after 120 
minutes. As reported previously the c-Fos protein is present as a 
heterogenous population ranging in size from 55 to 62kD and it is 
also found exclusively in the nucleus, c-myc transcription increases
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at a later time point than c-fos and this transcription peaks at 
around 30 minutes before decreasing and becoming undetectable after 
60 minutes, c-myc transcription increases at a later time point than 
c-fos and this transcription peaks at around 30 minutes before 
decreasing and becoming undetectable after 60 minutes. This later 
switch on of c-myc transcription results in c-myc mRNA expression 
peaking at around 60 minutes before decreasing thereafter.
The increase in the transcription rate (and mRNA. levels) of c-fos in 
quiescent fibroblasts can be induced by individual mitogens such as 
growth factors and phorbol esters as well as by whole serum. PDGF, 
FGF and TPA all increase c-fos transcription with similar timing 
although the degree of the transcriptional increase is less marked 
than that obtained with serum. Certain factors, such as EGF and 
insulin, fail to induce the familiar induction in c-fos 
transcription. The implications of these results will be discussed 
in the following sub-Section (1.4.2.) . Infection of quiescent 
fibroblasts with SV40 stimulates the cells to enter S phase (109) . 
This infection results in an increase in transcription of c-fos and 
c-myc genes, and seems to induce growth stimulating activities as 
medium taken from SV40 infected quiescent fibroblasts can activate 
other quiescent cells to re-enter the cell cycle.
Cultivation of quiescent 3T3 cells for 4 hours with the protein 
synthesis inhibitor cycloheximide resulted in a slightly increased 
level of both c-fos and c-myc mRNA. Moreover, stimulation of 
quiescent 3T3 cells with serum in the presence of cycloheximide led 
to the accumulation of both c-fos and c-myc mRNAs to concentrations
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that were several-fold higher than the maximum levels observed in the 
absence of cycloheximide. This increase in c-fos mRNA. levels is 
probably due to an increased rate of transcription of the gene (110) 
and also an increase in the stability of the mRNA suggesting that 
cycloheximide acts to prevent the synthesis of both a transcriptional 
repressor protein and a protein that acts to enhance the degradation 
of the c-fos mRNA. Another protein synthesis inhibitor, anisomycin, 
has a similar effect in these cells (110). Interestingly, the 
transcriptional control of c-myc seems to operate through . a 
different mechanism in PC12 cells (110) as in these cells c-myc 
expression is not superinduced following NGF stimulation (c-fos 
expression is), and indeed its usual increase in transcription 
following this stimulation is abolished by cycloheximide and 
anisomycin. This suggests that there may be tissue-specific 
mechanisms involved in the transcriptional control of proto-oncogenes 
such as c-myc. The transcription of a gene coding for a major 
excreted protein (MEP) is induced with similar timing to that of 
c-myc in quiescent fibroblasts by treating proliferating fibroblasts 
with TPA (111) MEP is also elevated in transformed cells but its 
transcription cannot be super-induced by cycloheximide treatment of 
TPA-stimulated fibroblasts. Transcription of c-fos is also 
stimulated by TPA in proliferating fibroblasts (to a lesser extent 
than in quiescent fibroblasts) and can be superinduced by 
cycloheximide treatment. This suggests that in fibroblasts there is 
a set of genes, such as c-fos and c-myc, that can be 
transcriptionally activated by TPA without prior protein synthesis 
but that another set of genes, including the MEP gene, require prior 
protein synthesis.
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Because of the large transient increase in c-fos expression in th Go 
to phase of the cell-cycle, the levels of c-fos expression 
throughout the cell cycle were determined (112) . Cells grown in 10% 
foetal calf serum (FCS) represent an asynchronously growing 
population and any specific fluctuation in c-fos expression 
throughout the cell-cycle might be masked. To overcome this problem 
cells were synchronised by chemical methods and it was shown that the 
levels of c-fos expression throughout the normal cell-cycle remain 
barely detectable, with no fluctuations occuring. It was also 
observed that the induction of c-fos expression can occur at any time 
in the cell-cycle as after only 2 hours of serum deprivation (when
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the cells are not in a quiescent state as estimated by H-thymidine 
incorporation) c-fos expression can be induced by the addition of 
serum. This induction becomes maximal after serum deprivation for 6 
hours (when the cells are still not in a quiescent state), with 
longer periods of serum deprivation failing to increase the degree of 
c-fos induction any further (112) .
Nucleosomes associated with transcriptionally active DNA are in a 
relatively unfolded state in comparison to those associated with 
transcriptionally inactive DNA (113) . This observation has been 
exploited to isolate these unfolded nucleosomes by an affinity 
chromatography procedures (114) . The c-fos gene is present in the 
unfolded nucleosome fraction isolated from the chromatin of 
stimulated quiescent fibroblasts (115) and this association persists 
when c-fos mRNA levels are superinduced with protein synthesis 
inhibitors. This observation supports previous studies which 
suggested that the superinduction of c-fos egression by these
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protein sysnthesis inhibitors is at least in part due to a prolonged 
transcriptional activation (106, 107, 110). There are several
topoisomerase II sites (116, 117) around the c-fos gene (118) which
could be responsible for the "relaxing" of the DNA and thus allowing 
the transcriptional machinery access to the c-fos gene. So, it is 
possible that topoisomerase II is involved in the mediation of 
mitogen-induced c-fos transcription.
1.4.2 The c-fos gene may be a 'competence' gene.
Serum contains two types of growth factors that function sequentially 
to stimulate mitosis in density-arrested Balb/c-3T3 cells, and 
possibly other anchorage-dependent cell-types as well (119). 
Platelet-derided growth factor (PDGF) is the serum component that 
renders quiescent Balb/c-3T3 cells 'competent' to respond to 
progression factors in platelet poor plasma (PPP) (120) . In the 
studies described in the previous sub-Sect ion (1.4.1.) examining the 
change of c-fos expression in response to growth factors, PDGF and 
fibroblasts growth factor (FGF) could both induce c-fos expression 
with similar timing and to similar levels as whole serum whereas EGF 
and insulin could only very weakly induce c-fos expression (although 
it has been reported that a combination of the two can induce c-fos 
expression (121)) (114). Interestingly PDGF and FGF are 'competence' 
factors that enable the cells to become competent for DNA. synthesis 
while EGF and insulin are 'progression' factors that require the 
cells to be in a competent state before the cells can progress into 
the S-phase of the cell-cycle. Because of these oberservations a 
series of studies were carried out investigating the role of c-fos
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expression in the competent state of quiescent fibroblasts.
After a brief treatment of quiescent fibroblasts with PDGF, which 
induces c-fos expression, the cells remain conpetent for several 
hours (122). The addition of PPP, which lacks PDGF, allows these 
cells (but not those untreated with PDGF) to progress through G^ and 
enter S-phase. A reduction in the response to PPP of PDGF treated 
cells occurs 8 hours after PDGF treatment and the half-life of the 
conpetent state is estimated to be 16 hours suggesting that the 
expression of c-fos (the c-Fos protein is undetectable 2 hours after 
PDGF treatment) is not responsible for the maintenance of the 
competent state although this expression could certainly be involved 
in the establishment of this state. Basic calcium phosphate crystals 
acts as a 'competence' factor (123) and also induce c-fos expression 
(124) and there are several other studies reporting the induction of 
c-fos expression with a host of different competence factors on 
different cell lines (125-127) strongly suggesting that the 
expression of c-fos may be related to the establishment of the 
conpetent state in these cells.
It has been shown that quiescent Balb/c-3T3 cells enter the 
cell-cycle and reach S-phase when a confluent monolayer is wounded in 
the presence of PPP, indicating that wounding is equivalent to 
treating these cells with a competence factor. The expression of 
c-fos has been analysed in such a situation (128, 129) . The
scratching of a monolayer of NIH 3T3 cells results in the induction 
of c-fos expression in an area surrounding the wound up to five 
cell-widths away from the scratch. This induction can be detected by
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antibodies (129) and can occur in cells that were completely serum 
deprived for 50 hours before wounding or in cells that were grown in 
10% FCS throughout the treatment, suggesting that any induction of 
c-fos expression is due to the wound on the monolayer rather than an 
increased access of growth factors from the medium to the cells. The 
observation that wounding resulted in the conpetent state in the 
cells surrounding the wound led to the analysis of c-fos expression 
in regenerating tissue in vivo and c-fos expression has indeed been 
detected in damaged brain tissue (94) and during liver regeneration 
at a period corresponding to cell proliferation (130) .
All of the evidence described above strongly indicated that c-fos 
expression plays a role in the attainment of the conpetent state of 
certain cells, suggesting that this expression is related to the 
growth of the cells. To establish whether this was the case two 
studies were carried out using plasmid constructs coding for 
inducible anti-sense fos sequence (131, 132). Previous studies had
shown that anti-sense RNA production in cells can prevent the 
translation of the targeted mRNA (133) . In both of these studies the 
anti-sense fos sequence was under the control of the mouse mammary 
tumour virus (MMTV) promoter which was induced by the addition of 
dexamethasome to the medium. When the transfected cells were 
selected in the presence of dexamethasone there was a 90-96% decrease 
in the number of colonies obtained compared to a selection carried 
out in the absence of dexamethasone, this suggested that the 
inhibition of c-Fos protein production was lethal to the growth of 
the cells. The transfected cells were also unable to proliferate 
when they were made quiescent and stimulated with PDGF plus
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progression factors in the presence of dexamethasone and no c-Fos 
protein was detected in the treated cells suggesting strongly that 
the expression of c-Fos is necessary for the proliferation of these 
cells.
The injection of Fos antibodies into cells can stop the synthesis of 
DNA and therefore prevent the cells from progressing through the 
S-phase of the cell-cycle (134). This evidence, when taken together 
with the points mentioned above, strongly suggests that the 
expression of c-fos plays an important, if not crucial, role in the 
proliferation of certain cell types and that this role could be the 
establishment (although not the maintenance) of the conpetent state 
in the relevant cells.
1.4.3. Intracellular pathways leading to the induction of c-fos 
expression.
Various reports have been described which detail the activation of 
c-fos transcription by a variety of extra-cellular stimuli (see 
sub-Section 1.3.2, 1.3.4., 1.4.1, 1.4.2). Several studies have
attempted to identify the intracellular pathways that many of these 
extra-cellular stimuli operate through. TPA, which activates c-fos 
transcription in a variety of cell types, directly activates protein 
kinase C which can also be activated by diacyl glycerol which is 
produced at the cell membrane in response to growth factor-induced 
processes (135, 136) . This activation of protein kinase C presumably 
triggers a phosphorylation cascade that results in the induction of 
c-fos transcription (52-55, 137-140). Growth factors also seem to
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employ a protein kinase C independent cellular pathway to activate 
transcription as depletion of protein kinase C in quiescent 
fibroblasts does not abolish the increase in c-fos transcription 
following growth factor stimulation, although the induction is 
certainly attenuated in comparison to that obtained with normal cells 
(141).
An increase in intracellular levels of cAMP, which activates the 
cAMP-dependent protein kinase A, can also induce c-fos transcription 
in a variety of cell types (137, 142-144) . Again, this activation 
presumably results in a phosphorylation cascade that activates c-fos 
transcription. Interestingly, in mouse bone marrow derived 
macrophages and in a mouse macrophage cell line P388D, an increase in 
intracellular levels of cAMP results in a stable induction of c-fos 
expression which peaks after 6 hours and remains elevated even after 
12 hours of treatment. This is the only reported case of a stable 
induction of c-fos expression which is the result of a stable 
increase in transcription.
An influx of calcium ions also results in an increase in c-fos 
transcription. This phenomenon has been described previously for 
PC12 cells (88, 89) and A23187, a calcium ionophore, can also induce 
c-fos expression in a variety of other cell types (137, 140, 141,
145) . This chemical can also induce c-fos transcription in protein 
kinase C depleted cells (although the induction is attenuated) and 
can act in an additive fashion to increase c-fos transcription. 
These observations suggest that the calcium ion influx caused by 
A23187 can activate c-fos transcription through activation of protein
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kinase C-dependent and -independent pathways in a similar manner to 
that reported for growth factors.
So, there would appear to be three main intracellular pathways that 
lead to the induction of c-fos transcription in a variety of 
cell-types:-
1) activation of a protein kinase C-dependent pathway;
2) activation of a cAMP-dependent protein kinase A pathway;
3) activation of a protein kinase C-independent pathway that perhaps
involves the mobilisation of calcium ions.
However, there are other intracellular mechanisms which can be 
employed to induce c-fos transcription. For example, injection or 
egression of a ras oncoprotein in quiescent fibroblasts results in 
an induction of c-fos expression (146) which seems to errploy part of 
the growth factor induced intracellular signalling pathway (147, 
148). Several hormones also activate c-fos transcription (138, 149,
150) and although some of these operate through previously mentioned 
intracellular pathways there have been suggestions that estrogen 
bound to its receptor can bind directly to DNA regions upstream from 
the c-fos gene to activate transcription (150).
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1.5. Post-transcriptional Regulation of c-fos Expression.
The induction of c-fos expression can be superinduced in many 
cell-types by treatment of stimulated cells with inhibitors of 
protein synthesis, particularly cycloheximide, prior to or during the 
stimulation (105, 107, 110, 115, 127, 149) . This superinduction
gives elevated levels of c-fos expression for prolonged periods of 
time, and is due to a relatively small increase in transcription of 
the c-fos gene and a stabilisation of the c-fos mRNA leading to an 
increased half-life. Studies have been carried out to determine the 
sequences and mechanism (s) that lead to the post-transcriptional 
control of c-fos mRNA expression.
An indication of the sequences involved in the regulation of c-fos 
mRNA stability came from studies examining the activation of the 
transforming potential of the c-fos gene (26-28) . These studies 
showed that the c-fos gene could transform fibroblasts if the 3' 
untranslated region of the c-fos mRNA was replaced with an unrelated 
sequence, and these alterations led to a stabilisation of the c-fos 
mRNA and therefore to an accumulation of c-Fos protein (28) . Also, 
in transgenic mouse studies (33) this same sequence had to be 
replaced with an unrelated sequence in order to obtain expression of 
c-fos mRNA in the mouse tissues. These studies therefore pointed to 
sequences in the 3' untranslated region of the c-fos mRNA between the 
translation stop codon and the polyadenylation site being involved in 
the regulation of c-fos mRNA stability. Several studies have been 
carried out to examine this possibility (151-155). The half-life of 
c-fos mRNA in a variety of cell-types was determined by treating
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cells with the transcription inhibitor actinomycin D and was found to 
range from 10 to 20 minutes. In transfection studies with hybrid 
genes containing fragments of the c-fos 3' untranslated region 
attached to reporter genes it was shown that this sequence was 
capable of markedly reducing the half-life of previously stable mRNAs 
(such as gjobin (151)), and removal of the 3' untranslated region from 
the c-fos gene led to an elevated and prolonged accumulation of c-fos 
transcripts following stimulation of c-fos expression. Cycloheximide 
treatment led to an increase in the half-life of the endogenous c-fos 
gene as well as activating transcription by as much as 9-fold (154) 
in certain cells.
The region in the 3' untranslated region of the c-fos mRNA that is 
responsible for the destabilisation of the c-fos mRNA is AU-rich and 
similar sequences can be found in other 3' untranslated regions of 
mRNAs that have short half-lives including those of c-myc and many 
inflammatory mediators (for a list see 156, 157) . When this sequence 
is taken from the human lymphokine gene GM-CSF and added to the 3' 
end of a construct coding for fV-globin mRNA, the resultant mRNA 
becomes as unstable as that of GM-CSF itself suggesting that this 
sequence is solely responsible for determining the stability of the 
GM-CSF mRNA (157) . Further studies using these AU-rich sequences of 
other inflammatory mediator genes have revealed that this sequence 
can destabilise other reporter mRNAs (such as CAT (158)) . In vitro 
transcribed RNA containing these AU-sequences are preferentially 
degraded when they are incubated with nuclear protein extracts 
suggesting that there is an RNAse present in the nucleus of certain 
cells that selectively degrade mRNAs containing the AU-sequence
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(158).
The reports described so far suggest that there is a family of 
short-lived mRNAs that contain an AU-rich sequence in their 3' 
untranslated regions that is responsible for the selective 
degradation of these mRNAs by a nuclear ribonuclease. The fact that 
cycloheximide treatment of cells results in a stabilisation of these 
mRNAs suggests that this ribonuclease is extremely labile and 
requires protein synthesis to maintain its control over the 
egression of these short-lived mRNAs. However, such a hypothesis 
has been contradicted by several pieces of evidence. In a monocytic 
tumour cell-line (159) GM-CSF is over-expressed as a result of the 
stabilisation of its mRNA as hybrid constructs containing the GM-CSF 
3' untranslated region are stable in this cell line in comparison to 
others. When similar c-fos and c-myc hybrid constructs were 
transfected into this cell line they are degraded as expected. 
Therefore, GM-CSF mRNA is specifically stabilised in this cell-line, 
suggesting that there is no universal pathway leading to the 
degradation of all mRNAs that contain the AU sequence in their 3' 
untranslated region. Several studies examining the induction of 
c-fos expression in response to a mitogenic stimulation have 
suggested that there is a decrease in the size of the mRNA throughout 
the induction period prior to its final degradation (151, 153) . The 
role of this mRNA shortening has been examined with regard to mRNA 
stability (160) . Cycloheximide treatment of NIH 3T3 cells 30 minutes 
after stimulation with serum resulted in an immediate stabilisation 
of c-fos mRNA and prevented the shortening of the mRNA (which is due 
to sequential degradation of the poly (A) tail) suggesting that c-fos
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mRNA degradation required on-going translation for shortening of the 
mRNA and for degradation of the mRNA. This was proved by 
transfection studies using various plasmid constructs where it was 
shown that the AU-rich sequence is required for the removal of the 
poly (A) tail from the c-fos mRNA during translation, and any removal 
or mutation of this AU sequence led to a stabilsation of the c-fos 
mRNA and a cessation in the degradation of the poly (A) tail. This 
argues against the idea of a universal ribonuclease that is present 
in the cytoplasm and can degrade mRNAs containing the AU sequences. 
The most likely model for c-fos mRNA (and related mRNAs) degradation 
involves the degradation of the mRNA by a ribonuclease attached to 
the polysomes. This would recognise a sequence or configuration 
resulting from the AU-rich sequence and would remove the poly (A) tail 
from these mRNAs. The de-adenylated RNA could then be degraded by 
endonucleases. Cycloheximide prevents translation by freezing 
polysomes on mRNA and could lead to a stabilisation of c-fos mRNA not 
by preventing synthesis of a labile ribonuclease, but by preventing 
access of a polysome-associated ribonuclease. In the monocytic 
tumour mentioned above (159) it could be hypothesised that a further 
protein recognises the O^-CSF mRNA on the polysomes and prevents 
access of the degradative ribonuclease that removes the poly (A) 
tail.
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1.6. Transcriptional Control of c-fos Expression,
1.6.1 Identification and definition of cis-acting transcriptional 
control elements.
The first DNA sequences implicated in the role of transcriptional 
control were identified upstream from prokaryotic genes (161), where 
conserved DNA sequences which bind RNA polymerase are located at 
about 10 and 35bp upstream of the initiation of transcription. In 
addition to these two sequences further upstream sequences were 
responsible for the negative and positive regulation of individual 
gene expression which bind repressor or activator proteins (162) . 
This level of corrplexity in the prokaryotic transcriptional control 
mechanism seemed to be sufficient to control all gene egression. 
The situation in higher eukaryotes at first seemed very similar to 
that found in prokaryotes with the identification of a conserved 
sequence 30bp upstream from the transcriptional initiation site. 
This sequence, termed the TATA box, is very similar in sequence to 
the Pribnow box situated lObp upstream from prokaryotic gene 
transcriptional initiation sites. In addition to the TATA box many 
eukaryotic genes contained a further conserved sequence called the 
CAAT box which is situated upstream from the TATA box and is typical 
of an upstream promoter element (UPE) (163) .
Many of the earlier studies carried out to examine eukaryotic 
transcriptional control involved studies of DNA tumour viruses, with 
the major discoveries coming from studies on the genome of the simian 
virus, SV40 (164) . This tumour virus has a complex mechanism
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controlling the transcription of its early gene which encodes a 
tumour antigen. This gene has a TATA box followed by three 21bp 
repeats, each of which contain two GC-rich hexanucleotide sequences 
which are involved in transcriptional control. The TATA box can be 
deleted from this upstream sequence without any serious effect on 
either the rate or site of transcription initiation (which is not the 
case with eukaryotic cellular genes) while only two of the six 
GC-hexanucleotide sequences are required for the propagation of 
viable virus. These 21bp repeats bind the cellular protein Sp-1 
(165) which specifically interacts with the GC-rich sequences. This 
protein has also been found to interact with similar upstream 
sequences present in cellular genes (for a review see 166) . These 
GC-hexanucleotide elements can be classed as UPEs.
Further upstream from the 21bp repeats there are two copies of a 72bp 
element that enhances transcription from heterologous promoters 
(167-169). These are distinct from previously described cis-acting 
transcriptional control sequences as they enhance transcription when 
placed in either orientation upstream of a promoter, and can operate 
over long distances when placed either upstream or downstream from a 
promoter. This element was the first described and defined enhancer 
element. Following the discovery of this element many enhancer 
elements were identified in viral and cellular genes (for reviews see 
170-173) and these elements fulfill the following strict criteria:
a) strong activation of transcription of linked gene from the 
correct initiation site;
b) activation of transcription independent of orientation;
c) ability to function over long distances (more than lOOObp),
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whether from an upstream or downstream position relative to the 
transcription initiation site.
Since the discovery of the enhancer element present in the SV40
genome there have been precise definitions of the sequences involved 
in enhancer function. However, these are too many to consider here 
and a brief description of the characterisation of the SV40 enhancer 
region will serve as a paradigm for other enhancers, both viral and
cellular. Characterisation of the SV40 enhancer has come about from
studies of mutant viruses isolated from CV-1 cells in culture and 
from studies using synthetic enhancer elements with inserted
mutations (174). These studies showed that a single-copy of the 72bp 
repeat was sufficient for propagation of the virus, and that the area 
incorporating enhancer activity in fact spanned lOObp (175) . 
Revert ants of mutant viruses and point mutation studies revealed that 
the enhancer can be separated into three separate regions (A, B and 
C) (175, 176), each of which fail to enhance transcription on its own 
but which do so when either duplicated or paired with other elements 
within the enhancer. The great complexity of this lOObp regions was 
realised with the observation that multimers of A, B and C sequences 
showed different cell-type specific enhancer properties (177, 178),
and indeed a further element outwith the lOObp was also shown to 
confer cell-type specificity on transcription (179).
So, the SV40 enhancer consists of at least 3 independent enhancer 
elements which co-operate with duplication of their own sequence, or 
with copies of other enhancer elements to enhance transcription. 
Some of these enhancer elements display cell-type specific enhancer
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properties Which is the situation for many cellular enhancer elements 
(for a review see 173) . However, within the individual enhancer 
elements there exists a further degree of complexity (180, 182). A, 
B and C are 15bp to 20bp in size and are bipartite, being composed of 
sub-units called enhansons which can be duplicated or interchanged to 
create new enhancer elements. These enhansons are obviously very 
short, being some 8 to lObp in size. It is possible to differentiate 
between an enhanson and an enhancer element by the following 
criteria:
a) some enhanson elements do not enhance activity when present as 
multimers although they can enhance transcription when linked to 
a single copy of another enhanson which by itself is incapable of 
enhancing transcription.
b) enhanson elements are very sensitive to spacing between them. 
Insertions of 1 or 2bp decreases the enhancing activity of 
duplicated enhansons and insertions of 5bp or more conpletely 
abolishes any enhancer activity. This is not true of the 
enhancer elements A, B and C in SV40, which can be separated by 
over lOObp while retaining the capacity to co-operate and
enhance transcript ion.
The discovery of enhansons led to the characterisation of very
complex level of organisation present in the SV40 enhancer. This
r
enhancer seems to be arranged in a hier^pncal order, with the 
enhansons being the basic elements that lead to the formation of 
enhancer elements, which then co-operate with other enhancer elements 
to enhance transcription. To date this is the most complex 
organisation of any characterised en hancer, and probably reflects
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the wide range of cells that can be infected by SV40. Perhaps this 
pattern of enhancer organisation evolved to allow the virus such 
flexibility in its host range.
Many cellular enhancer sequences have been characterised and several 
of these enhancers share sequence motifs with the SV40 enhancer 
(183, 184, for a review see 166). These cellular enhancers have also 
been shown to be short DNA sequences, although the complexity 
observed with the SV40 enhancer has not been found in any cellular 
enhancer described to date. Like the enhancer elements present in 
SV40 many of these cellular enhancer sequences display a restricted 
cell-type activity (for a review see 173) .
1.6.2 The c-fos gene has an inducible enhancer.
As described in the previous sub-Sect ion (1.6.1.) there are at least 
two types of transcriptional control elements: the upstream promoter
elements (UPEs) and the enhancer elements. The c-fos gene has a 
traditional TATA box sequence 30bp upstream from the transcription 
initiation site although it does not contain any Spl binding 
sequences (165) or CAAT box sequences (164) which are the two most 
common UPEs found in other cellular genes. However, two sequences in 
the promoter regions of the mouse and human c-fos genes bind 
nuclear proteins (185, 186) . One of these sequences was common to
both the mouse and human c-fos genes, situated at -60bp relative to 
the c-fos mRNA cap site, and probably binds the cAMP response element 
binding protein CREB (187). The deletion of these sequences, 
particularly the CREB protein binding site, significantly reduces the
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basal activity of the respective promoters. Figure 2 details the 
transcriptional control elements of the c-fos gene.
To examine the transcriptional control of the c-fos gene, promoter 
and upstream sequences were cloned into a plasmid vector upstream of 
the prokaryotic reporter gene chloramphenicol acetyl transferase 
(CAT) (188) and the resultant vectors transfected into murine NIH 3T3 
cells (189, 190) . These studies revealed the presence of an element 
between -400bp and -200bp relative to the c-fos mRNA CAP site that 
enhanced the transcription of these constructs 10-fold. DNAse 1 
hypersensitivity studies revealed the presence of a DNAse 1 
hypersensitivity site at -290bp + 40bp; in this region there is an 
element of dyad symmetry (for a review see 191) and so it was thought 
that this sequence present upstream (centred around -308bp) from the 
c-fos gene may be involved in transcriptional control.
Many studies have revealed the transcriptional activation of the 
c-fos gene in quiescent fibroblasts stimulated by agents such as 
serum, growth factors and phorbol esters. In a bid to identify 
cis-acting elements that may be involved in this transcriptional 
activation transfection studies were carried out with the entire 
human c-fos gene in murine fibroblasts. The human c-fos mRNA can be 
distinguished from the endogenous mouse mRNA by ribonuclease 
protection assayS (151) . These studies revealed that the dyad 
symmetry element (DSE) was responsible for the transcriptional 
activation of the c-fos gene in response to serum stimulation and 
this element operates in either orientation and when placed 1.6kbp 
downstream from the c-fos gene. Thus, the element satisfies the
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j*E Sj^ TF/AP-1 UPEs f3PQ-p--------0—0-- C.
-342 -300 -90 -60
-295
Figure 2. Transcriptional control elements of the human c-fos gene.
This figure details the previously described transcriptional control 
elements of the human c-fos gene. Cap : transcription initiation
site (+1). UPEs: upstream promoter elements. ATF/AP-1 : adenovirus
transcription factor site/ activator protein 1 site. SRE : serum
response element. SCM-RE : v-sis conditioned medium response
element.
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criteria of an enhancer and is therefore an inducible enhancer 
element. It was called the serum response element (SHE). When this 
element was replaced by either the SV40 or Moloney murine leukaemia 
virus enhancers the transcription of the c-fos gene became 
ubiquitous; that is, it failed to stop in serum deprived cells or to 
increase upon serum stimulation. These results indicate that the SRE 
may not be classified as a classical enhancer. The SRE also 
stimulates transcription from a heterologous promoter (p-globin) in 
response to serum (151), although this stimulation is lower than that 
observed with the intact c-fos promoter indicating that there may be 
an interaction between sequences in the c-fos promoter and the SRE.
The c-fos gene is not the only gene to contain the DSE present in the 
SRE. Two other genes that were transcriptionally activated during 
the Go to transition in fibroblast cell lines were isolated and 
found to contain sequences very similar to the SRE (192) . Actin 
genes are also transcriptionally activated in the transition of 
fibroblasts from Go to G^ (104) . Many actin genes have been found to 
contain a CArG box that bears a close sequence homology to the c-fos 
SRE and apparently binds the same cellular protein (193 - 199) . The 
CArG box is found in actin genes present in Xenopus laevis (193) and 
humans (196), indicating that the transcriptional control mechanism 
operating through the SRE sequence is highly conserved throughout 
evolution. The CArG sequence present in the X. laevis cytoskeletal 
actin gene can act as an enhancer element when a synthetic copy is 
inserted upstream from a X. laevis cytoskeletal actin promoter - CAT 
construct, and can also respond to serum in a similar fashion to the 
c-fos SRE when placed upstream from the c-fos promoter. These
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studies demonstrate tha the SRE (CArG) sequence can operate as a 
constitutive enhancer element and/or an inducible enhancer element, 
and is probably involved in the co-ordinated transcriptional 
activation of a set of genes in growth-factor stimulated fibroblasts. 
The expression of the actin genes which contain the CArG (SRE-like) 
boxes is controlled in a cell-type-specific manner. However, it 
seems unlikely that this sequence on its own can dictate this 
restricted expression as c-fos is not expressed in a similar manner 
therefore it is probable that the CArG boxes co-operate with other 
cis-acting DNA elements present in the promoter sequences of these 
genes to confer the cell-type-specific expression.
1.6.3. The c-fos serum response element binds a nuclear protein.
The c-fos SRE forms a coirplex with a nuclear protein (called the 
serum response factor (SRF)) present in extracts of a variety of 
cell-types (185,193, 200 - 204) including HeLa, mouse 3T3s, PC12,
WEHI and in X. laevis oocytes. In all of these cell-types the 
induction of c-fos transcription makes no difference to the affinity 
that the SRF has for the SRE, suggesting that the activiation of 
c-fos transcription probably results from the modification of the SRF 
that is already bound to the SRE. This would require no new protein 
synthesis prior to c-fos transcription and therefore agrees with the 
observation that the stimulation of c-fos transcription occurs in the 
presence of inhibitors of protein synthesis. Mutations in the SRE 
that abolish SRE binding in vitro also prevents the SRE inducing 
c-fos transcription in transfection studies, confirming that the 
SRE-SRF complex is responsible for the transcriptional activation of
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the c-fos gene.
There has been one report detailing the induction of binding of a 
nuclear protein to the SRE (204) . Treatment of the human epidermal 
cell-line A431 (which overexpresses the EGF receptor) with EGF 
results in the induction of c-fos expression (139). Before EGF 
treatment these cells do not possess a protein with SRE binding 
activity. However, 20 minutes after treatment a nuclear protein 
(presumably the SRF) binds to the SRE which is responsible for the 
transcriptional activation of the c-fos gene. This protein remains 
bound to the SRE for a period extending beyond the transcriptional 
shut-down of the c-fos gene following EGF treatment. This suggests 
that there is not a simple "on-off" mechanism activating and then 
repressing c-fos transcription, but that other proteins are involved 
which may modify the already bound SRF or bind directly to other 
DNA-elements to repress transcription.
To characterise further the complex that forms between the SRE and 
SRF, the SRF protein was purified (205 - 207) . It was found to be a 
phosphoprotein (208) of molecular weight 67kD (p67) (205, 207) or
62kD (p62) (206) . The discrepancy in the measured molecular weight 
of the protein is probably due to the use of different techniques for 
determining its size rather than there being two different proteins, 
since the source of crude protein extract and method of purification 
was similar in each report. A cDNA coding for the SRF has been 
isolated (209). The SRF gene encodes two mRNAs that are both induced 
following serum stimulation of quiescent fibroblasts, irrespective of 
the presence of inhibitors of protein synthesis. This suggests that
58
the SRF gene, along with c-fos and others (210, 211), is a memeber of 
the cellular immediate-early genes whose expression is elevated 
almost immediately following the stimulation with growth factors of 
cells resting in Go. The SRF binds to the SRE as a homodimer which 
is not surprising as the SRE is a dyad symmetry element. There is a 
short stretch of the SRF protein which is capable of both forming 
homodimers and binding to the SRE. This region bares significant 
homology to a region present in the S.cerevisiae protein PRTF/GEM, 
which can also bind to the SRE, and is involved in control of 
cell-type-specific gene expression (212-214) . No significant 
homology between SRF and PRTF/GRM exists outwith this region. It has 
also been shown that another nuclear protein of 62kD is involved in 
the SRF-SRE complex (this protein is distinct from the p62 that was 
isolated as the SRF (205, 215). This protein cannot by itself bind
to the SRE but it can join a SRF-SRE complex and it also requires 
three bp upstream of the DSE for binding to the SRF-SRE complex. 
Significantly, if these three bp are removed, the 62kD protein fails 
to complex, and the resultant DSE is very poor at responding to serum 
stimulation in transfection studies.
So, the SRF is expressed in many different cell-types and appears to 
be highly conserved throughout evolution. It is a phosphoprotein and 
it seems possible that the mode of activation of this transcription 
factor involves phosphorylation of sequences present in the protein 
that show homology to previously identified phosphorylation sights. 
It also appears to co-operate with a further nuclear protein (of 
62kD) in mediating the transcriptional activation of c-fos following 
serum stimu lation.
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1.6.4. The c-fos SRE responds to a variety of extra-cellular 
stimuli.
Although the c-fos SRE was first identified as inducing c-fos 
transcription in response to the stimulation of quiescent fibroblasts 
with serum (151), there have been many studies carried out detailing 
this elements response to a wide vairety of extra-cellular stimuli in 
several cell-lines. These studies have indicated that there are 
several intracellular pathways that activate c-fos transcription 
through the element and also that there is a degree of cell-type 
specificity involved in the transcriptional control exerted by the 
SRE.
Treatment with TPA results in the induction of c-fos transcription 
through the SRE in 3T3 cells (216 - 218), PC12 cells (186, 220), HeLa 
cells (185, 216) and Chinese hamster ovary (CHO) cells (203).
However, in A431 cells TPA treatment does not induce the 
transcription of c-fos through this element, and indeed fails to 
activate transfected constructs containing up to 2kbp of upstream 
c-fos sequence. This indicates that, in these cells, there are 
alternative cis-acting DNA elements responsible for the 
transcriptional activation of the c-fos gene that have as yet not 
been identified (185). In PC12 cells the calcium ionophore A23187 
induces c-fos expression through the DNA element centred at -60bp 
relative to the mRNA CAP site (which binds the CREB protein (187)) 
that is conserved between the mouse and human gene (186) . In A431 
and HeLa cells this agent fails to induce the transcription of 
transfected constructs containing up to 2kbp of c-fos upstream
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sequence indicating that there is a difference in the control of 
c-fos transcription in response to A23187 in HeLa and A431 cells 
compared to PC12 cells. A previous sub-Section (1.4.3.) described 
the activiation of c-fos transcription by several intracellular 
pathways. The SRE seems to respond to at least two of these pathways 
to activate c-fos transcription. Firstly, TPA treatment leads to the 
induction of c-fos transcription in many cell-types and this 
induction requires the presence of an intact SRE. TPA operates 
solely through protein kinase C and when this enzyme is depleted from 
the cell (by chronic exposure to TPA) serum or growth factors can 
stimulate c-fos transcription through the SRE. This stimulation is 
attenuated but shows that c-fos transcription can be induced through 
the SRE by protein kinase C -dependent and -independent pathways. 
The independent pathway is not known but is not due to the 
mobilisation of calcium ions as the calcium ionophore A23187 fails to 
activate c-fos transcription through this sequence. Similarly, 
activation of c-fos transcription through the cAMP-dependent protein 
kinase A pathway does not require an intact SRE. Matations in this 
element that abolish the response of transfected constructs to serum 
and TPA do not affect the induction of transcription in response to 
elevated levels of cAMP (218) . NGF (185, 219), insulin (203) and
U.V. irradiation (218) induce c-fos transcription through the SRE in 
PC12, CHO and NIH 3T3 cells respectively, but the intracellular 
pathways involved in the cellular response to these factors is 
unknown.
There is a further DNA element in the c-fos promoter region that can 
activate transcription in response to serum (220) . This element is
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downstream from the SRE and contains several repeated sequences 
similar to those found in the HSP 70 promoter region which is also 
responsive to serum (219). This element does not seem to be additive 
with the SRE in its response to serum, and can function as a 
serum-response element in the absence of the SRE, indicating that no 
co-operation occurs between the two elements. This element was
called SRE-2 and it also stimulates transcription in response to NGF 
treatment of PC12 cells (219) . A sequence upstream of the SRE binds 
a nuclear protein following treatment of 3T3 cells with v-sis 
conditioned medium which contains proteins similar in activity to 
PDGF (222) . The function of this inducible binding is not clear as 
c-sis or PDGF treatment of cells increases the transcription of the 
c-fos gene mainly through the SRE (216, 217) .
So, the SRE is the target of many extra-cellular stimuli and 
intracellular pathways that lead to the activation of c-fos 
transcription. Some of these pathways clearly differ between 
cell-types but it is not yet known what leads to this cell-type 
variation in response to extra-cellular stimuli. The SRF also seems 
to interact with the protein that binds to the CREB binding site in 
the c-fos promoter as deletion of this sequence markedly reduces the 
transcriptional response of the c-fos promoter to serum or TPA 
stimulation.
1.6.5. cAMP stimulation of c-fos transcription.
There are a number of eukaryotic genes that are transcriptionally 
activated by cAMP stimulation and the transcriptional control of
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these genes has been the focus of many studies in recent years (for a 
review see 223) . The first study to identify an element responsible 
for the induction of gene expression by cAMP came from transfection 
analysis of the promoter region of the rat phosphoenolpyruvate 
carboxykinase gene which revealed a short 12bp element present in the 
region that was sufficient to confer cAMP inducibility that was also 
present in the promoter region of other cAMP regulated region (224 
and references therein) . This led to the study of the transcription 
control regions of many other cAMP inducible genes. These studies 
clearly revealed a region of DNA homology between all of these genes 
that can confer cAMP inducibilty on their respective promoters. This 
element was called the cAMP responsive element (CEE) (225 - 230) . 
This CRE is a small palindromic element of 8bp with the consensus 
sequence TGACGTCA. It is often duplicated to form inverted repeats 
in several cAMP inducible promoter regions and this duplication 
increases the transcriptional response of these genes to cAMP 
stimulation (229) . These repeats are often separated by lObp, i.e. 
one turn of a DNA helix, and insertion of sequences disturbing this 
periodicity affects the response of the duplicated elements to cAMP 
stimulation CREs can act as enhancer elements as they increase the 
basal level of transcription from their respective genes in most 
cases, and can operate in an orientation and distance independent 
manner.
The CRE has also been implicated in tissue-specific expression of the 
human glycoprotein a-subunit gene (226) . The CRE can confer cAMP 
inducibility on the promoter region of this gene in many cell-types, 
but the contribution this element makes to basal transcription is
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restricted. Deletion of the CRE prevented the tissue-specific 
expression of this promoter but the control of the tissue-specific 
expression was found to depend upon a sequence upstream from the CRE 
which binds a protein factor in a tissue-specific manner (which the 
CRE does not - this element binds a protein in a ubiquitous fashion 
(226)). Thus, the protein binding to the upstream element must 
co-operate with the protein binding to the CRE to activate 
transcription of this gene in a tissue-specific manner as neither 
sequence by itself can confer tissue-specific expression. Although 
the CRE by itself cannot confer tissue-specific expression the cAMP 
inducibility via this element is cell-type-specific (230). This 
sequence will confer cAMP inducibility on a heterologous promoter in 
PC12 cells but not in HeLa cells which reflects the cAMP induction of 
the endogenous gene transcription in these different cell-types. All 
of these results indicate that the CRE will co-operate with other DNA 
sequences in order to confer basal and induced transcription from 
heterologous promoters.
The transcription of the c-fos gene is activated rapidly following 
treatment of certain cell-type with analogues of cAMP or adenylate 
cyclase agonists (for a summary see sub-Section 1.5.3.). The c-fos 
promoter region has an element situated at -60bp relative to the mRNA 
start site that bears a close homology to the previously identified 
CREs. When c-fos promoter sequences upstream from -60 are deleted 
c-fos-CAT gene hybrids retain the ability to respond to cAMP in PC12 
and JEG 3 cells (231) . Also, the sequence around -60 can confer cAMP 
inducibility upon a heterologous promoter and both of these results 
indicate that the sequence around -60 in the c-fos promoter region
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(which is conserved between the mouse and human c-fos genes) is a 
CRE. A further study revealed that the c-fos promoter region has 
several cAMP inducible DNA elements including the SRE, the -60 
element and two other sequences (232). These elements do not operate 
additively as deletion of one has no effect on the degree of 
induction obtained following cAMP stimulation. The reason for this 
failure to operate in an additive fashion could be that all of the 
CREs contribute to basal levels of expression, therefore deletion of 
one CRE decreases the basal level of transcription resulting in a 
similar induction of transcription via the remaining elements 
following cAMP stimulation.
The nuclear protein that binds to the CRE of the set of cAMP 
inducible genes was purified by DNA affinity chromatography and this 
protein can footprint on the c-fos -60 CRE (187) . This protein is 
phosphorylated after cAMP stimulation of PC12 cells (233) and is 
phosphrylated in vitro when incubated with the catalytic subunit of 
cAMP-dependent protein kinase. Interestingly, injection of this 
catalytic sub-unit into PC12 cells transfect with CRE containing 
constructs stimulates their transcription to similar levels as those 
obtained following cAMP treatment (234) . Similarly in in vitro 
transcription assays addition of the catalytic sub-unit increases 
transcription from a CRE containing construct to a greater extent 
than treating the nuclear extracts with cAMP (235) . This in vitro 
transcription induction operates only with PC12 cell nuclear extracts 
and not with those from HeLa cells which reflects the in vivo 
transfection results (230).
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Study of the human proenkephalin gene transcriptional control region 
has led to some significant discoveries with regard to the 
stimulation of eukaryotic transcription by cAMP. This gene is 
stimulated following treatment of cells with cAMP and was found to 
contain an element upstream from the promoter that could confer 
basal, cAMP-induced and TPA-induced transcription on the 
proenkephalin gene promoter (236). This element can operate as an 
enhancer as it enhances transcription (both basal and induced) in an 
orientation and distance-independent manner. This sequence contains 
binding sites for several nuclear proteins (237) one of which, 
ENKTF-1, binds to an element that thas not been previously implicated 
in the response of any other cAMP-inducible genes. This protein 
binds to a DNA sequence called ENKCRE-1 which is situated lObp 
upstream from another transcription element termed ENKCRE-2 which 
binds a factor that can be carpeted for by sequences from previously 
identifed CREs (237). Mutations of either of these elements results 
in a drastic reduction in basal and inducible transcription 
indicating they act synergistically to affect transcription from the 
proenkephalin promoter (238). The c-fos upstream region contains a 
sequence that is identical to that found in ENKCRE-2 and this 
sequence is continuous with the previously characterised SRE. 
Interestingly this sequence is one of the four sequences that were 
identified in the c-fos upstream region that can increase 
transcription from the c-fos promoter in response to cAMP (232) . 
There exists a clear difference therefore between the activity of 
this sequence when situated upstream from different promoters. In 
the proenkephalin gene it is very poor at responding to cAMP 
treatment when the ENKCRE-1 sequence is effectively removed, but in
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the case of the c-fos promoter this sequence can respond to cAMP 
stimulation resulting in transcriptional activation.
In summary, the c-fos gene has four cAMP inducible DNA elements, with 
the sequence at -60 and the sequence that is identical to that 
found in the proenkephalin enhancer complexing with the nuclear 
protein CREB that binds to other CREs. This latter sequence, 
TGCX3TCAG, resembles the CRE consensus sequence but it also closely 
resembles that for the transcription factor AP-1 (239) which induces 
the transcription of a set of genes in response to TPA treatment. 
This sequence can bind purified AP-1 protein in vitro but apparently 
is also capable of binding the factor that complexes with CREs (238) . 
These two proteins are distinct from one another (see later in 
sub-Section 1.7.4.) and it is possible that in vivo this c-fos 
sequence is capable of complexing with either of the proteins to 
increase c-fos transcription in response to cAMP (CREB) or TPA 
(AP-1). It is also of interest to note that the stimulation of c-fos 
transcription in PC12 cells in response to the calcium ionophore 
A23187 operates through the -60 CRE (234) as this induction is 
cAMP-dependent (240).
1.6.6. TPA stimulation of c-fos gene transcription.
A cis-acting DNA element that activates transcription from adjacent 
promoters in response to TPA treatment of cells was identified in the 
upstream regions of genes that are transcriptionally activated by 
this agent. These genes were identified by differential screening of 
stimulated and unstimulated human primary fibroblasts (241) . One
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such was the human metallothionein IIA gene (hMTIIa) which can be 
transcriptionally activated by serum growth factors and activators of 
protein kinase C (242) . It contains five distinct transcriptional 
control elements in the 5'-flanking region of the gene that mediate 
specificity and regulation of transcription (243, 244) . The
collagenase gene is also transcriptionally activated by TPA and 
transfection studies revealed a short DNA element in the 5' flanking 
sequence that is responsible for this activation. This element
operates in either orientation and up to 2kbp 3' of the gene
indicating that this sequence is an inducible enhancer element. One
of the basal level enhancers present in the hMTIIa gene promoter
region has a stretch of homology with a sequence within this 
collagenase transcriptional control region that is also present in 
the P-motif of the SV40 enhancer (see sub-Section 1.6.1.). The SV40 
enhancer is a TPA-inducible enhancer element (245) and analysis of 
the constitutive parts of this complex enhancer revealed that all of 
the previously described enhancer elements (A, B and C, see 
sub-Section 1.6.1.) responded to TPA stimulation resulting in 
transcriptional activation (246) . The P-motif which is present in 
the 3' region of the 72bp SV40 enhancer also acts as an enhancer 
element and is inducible by TPA treatment. The DNA sequence that is 
conserved between the SV40 P-motif, the hMTIIa transcriptional 
control region and the collagenase element that activates 
transcription in response to TPA, TGAG/CTCA, binds a HeLa cell 
nuclear protein in DNase I footprinting studies (247). This element 
was capable of activating transcription in in vivo transcription 
assays and any mutations of the consensus sequence that resulted in a 
failure to activate in vitro transcription also failed to compete for
the protein binding to this sequence in DNase I footprinting 
experiments. This indicated that the protein binding to this 
sequence was responsible for the transcription activation via this 
sequence and was called activator protein 1 (AP-1).
Synthetic copies of TPA-responsive sequences (called the TRE-TPA
responsive elements) conferred TPA inducibility on heterologous
promoters (248) and this short sequence operates as an inducible
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enhancer element as it operates in an orientation indpendent manner 
and when placed either upstream or downstream from a heterologous 
promoter. Interestingly, following TPA treatment of HeLa cells, the 
DNA binding activity of AP-1 is increased 3 to 4-fold but this 
activation does not involve fresh protein synthesis as the same 
phenomenon can be observed in cells treated with cyclohe^mide during 
the TPA treatment. This indicates tht TPA treatment leads to a 
post-translational modification of pre-existing protein leading to an 
increased DNA binding activity. It is possible that phosphorylation 
of the protein is involved in this activation as phosphatase 
treatment reduces the DNA-binding properties of this protein (249) . 
AP-1 was purified using a DNA-affinity procedures and was shown to 
footprint the SV40, hMTIIa and collagenase TREs (239) and the polyoma 
a-enhancer also has an AP-1 binding site and is responsive to TPA 
stimulation (250). AP-1 sequences are also present in an element 
700bp upstream from the vimentin gene promoter that can act as a 
basal level enhancer and can also activate transcription in response 
to both serum and TPA stimulation (251).
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The sequence in the c-fos promoter region that is continuous with the 
SRE and activates transcription in response to cAMP (see sub-Section 
1.6.4.) TGCGTCA, centred at position -296, bears a close homology to 
the AP-1 consensus sequence, TGAG/CTCA. It has been mentioned 
previously that this sequence can bind purified AP-1 (238) and it has 
also been reported that the polyma a-enhancer can compete for the 
factor binding to this sequence in a DNase 1 footprinting assay (250) 
and, as mentioned above, this viral enhancer contains an AP-1 binding 
site. Transfection analyses of c-fos promoter mutants with this 
sequence inserted revealed that it can activate transcription in 
response to both TPA and EGF stimulation almost to the same levels as 
those obtained with constructs containing the SRE (252) . The time 
course for the induction by the AP-1 like sequence is similar to that 
observed with the SRE, being both rapid and transient, which is 
different from the induction observed with previously mentioned AP-1 
binding sites that required overnight stimulation by TPA to increase 
transcription. It was also noted that this sequence is not additive 
with the SRE in the TPA or EGF induction of c-fos transcription 
perhaps because there is a mutual exclusion of the proteins binding 
to these sequences in vivo resulting in only one of them contributing 
to the transcriptional activation of the c-fos gene in response to 
extra-cellular stimuli.
This sequence in the c-fos promoter, TGCGTCA, is therefore responsive 
to TPA, EGF and cAMP stimulation and apparently binds the AP-1 
protein (238) in vitro. This agrees with a report showing that AP-1 
consensus sequences can activate transcription in response to both 
TPA and cAMP stimulation (253) . In this study the collagenase AP-1
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sequence was used and insertion of a G residue into this sequence 
coverts it into a CRE that fails to activate transcription in 
response to TPA although the native sequence responds to both cAMP 
and TPA stimulation with approximately equal effect. So, there 
exists a degree of "cross-talk" between the TPA and cAMP responses, 
and c-fos AP-l-like sequence falls into a category of transcriptional 
response elements that will activate transcription in response to 
either of these extra-cellular stimuli. Therefore the c-fos promoter 
region contains at least two upstream sequences that will activate 
transcription in response to TPA and four upstream sequences that 
will activate transcription in response to cAMP, with the SRE and 
AP-l-like element being responsive to both.
1.6.7. Viral proteins transcriptionally activate the c-fos gene.
Adenoviruses encode a protein, Ela 13s, that is responsible for the 
transcriptional activation of adenovirus early genes (for a review 
see 254) . This viral trans-activating protein (for a review see 255) 
can also transcriptionally activate eukaryotic cellular genes such as 
the HSP70 and (J-tubulin genes (256, 257), and its role in the 
transcriptional activation of several cellular oncogenes has been 
examined (258) . This study revealed that the Ela 13s protein 
transcriptionally activates the c-fos promoter through a sequence 
that includes the previously identified SRE and AP-l-like element and 
that deletion of these sequences abolishes any trans-activation of 
the c-fos promoter by the Ela 13s protein. However, a further study 
contradicted this observation as it reported that the Ela 13s protein 
(termed Ela 13s hereafter) could trans-activate several promoters
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through a specific TATA box sequence (TATAA), which included that of 
the c-fos gene (259). In this study a c-fos reporter gene construct 
containing only 53bp of upstream sequence was used in the 
co-transfection studes and this sequence contains none of the 
previously identified DNA elements involved in the transcription 
regulation of the human c-fos gene. The reason for the difference 
between these two sets of results is not clear but two different cell 
lines were employed in the transfection studies and it is conceivable 
that this difference is responsible for the conflicting results.
It is of interest to note here that Ela 13s trans-activates the 
adenovirus early promoters through sequences that are very similar to 
that of the CRE (260) . Several studies have attempted to determine 
whether an identical cellular protein binds to the adenovirus early 
promoter sequences and to CREs and whether Ela 13s and cAMP can 
trans-activate these sequences in transfection studies (261 - 264) .
In vitro DNA binding studies have shown by competition analysis that 
the CREs of several genes can compete for the proteins that bind to 
the adenovirus early gene promoters, and in transfection studies, 
when CREs are co-transfected with constructs containing the 
adenovirus promoters, then both basal and Ela stimulated 
transcription is reduced. These results suggested that identical 
proteins are involved in cAMP stimulation of transcription and in Ela 
13s trans-activation of adenovirus early promoters. Ela 13s and cAMP 
can synergistically activate transcription of the adenovirus early 
promoters of intact viruses that have infected tissue culture cells 
(265) . However, in transfection studies it was shown that the 
CRE-like sequences present in the adenovirus early gene promoters is
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not responsible for this synergistic-activation (262) suggesting that 
other sequences in the adenovirus early gene promoters are involved 
in this synergistic activation. Attempts to purify the cellular 
protein that binds to these adenovirus early gene promoters, called 
ATF (activating or adenovirus transcription factor) or CREB (cAMP 
responsive element binding protein) led to the purification of 
several proteins ranging in size from 72,000 to 40,000 daltons (187, 
261, 263, 266, 267) . It is certain that the CREB/ATF binding site is 
capable of binding more than one nuclear protein, suggesting that 
perhaps cAMP and Ela 13s trans-activate promoter through this 
sequence employing different proteins, all of which can bind to the 
recognition sequence.
There have been two further reports of viral trans-activators 
activating transcription from the c-fos promoter (268, 269) . Bovine 
leukaemia virus (BLV) encodes a transcriptional activator called
tclXp38 which activates viral transcription through three ATF 
sequences present in the U3 region of the viral LTR (268) . This 
protein trans-activates several other constructs containing 
adenovirus early gene promoters and cAMP responsive gene promoters 
through regions that contain ATF-like sequences. It activates the 
c-fos promoter through sequences that include the SRE and AP-l-like 
element (-361 to -225), and removal of this sequence abolishes the 
trans-activation of the c-fos promoter by this protein. Neither this 
viral trans-activatior nor Ela 13s can trans-activate the 
transcription of the c-fos gene through the protein that binds to the 
c-fos -60 element. This element has been shown previously to 
stimulate transcription in response to cAMP and to bind the purified
73
protein CREB (187) . The failure of this sequence to activate c-fos 
transcription in response to treatment with the viral 
trans-activators may be due to a lack of other proteins binding in 
the c-fos promoter region that are required for viral 
trans-activation (operating in a co-operative manner) or the fact 
that the c-fos -60 element binds a number of the CREB/ATF family of 
protiens that is unresponsive to viral trans-activators. The other 
viral trans-activiating protein that can transcriptionally activate 
the c-fos gene is the human T-cell leukaemia virus 1 (HTLV-1) encoded 
protein tax^. Co-transfection experiments revealed two elements 
upstream from the c-fos promoter that were capable of responding to 
tax^. The first element (-372 to -324) contained the DNA element 
that binds a protein after v-sis conditioned medium stimulation of 
3T3 cells (222) and the second element contains the SRE and the 
AP-l-like sequence.
These studies have identified areas of the c-fos upstream region that 
are responsive to viral trans-activators but have not clearly 
delineated the precise sequences involved (e.g. is it the SRE or the 
AP-l-like element that activates transcription in response to these 
viral proteins?) . In one case (259) the c-fos TATAA box has been 
identified as being essential in the transcriptional response of 
c-fos to Ela 13s, but for the remaining cases further studies must be 
carried out to identify the precise DNA sequences involved.
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1.7. The c-Fos Protein is a Transcription Factor.
1.7.1. Evidence suggesting a role for Fos proteins in 
transcriptional regulation.
The fact that Fos proteins are found exclusively in the nucleus 
suggests that these proteins may play a role in the regulation of 
transcription. Further circumstantial evidence for such a role came 
from studies showing that v-Fos and c-Fos proteins are associated 
with the isolated nuclei from various cell lines (270, 271) . In
these studies digestion of the chromatin with DNAse released Fos 
proteins along with the cellular protein p39 which is associated with 
Fos proteins (7) from the isolated nuclei whereas treatment with 
ribonuclease failed to cause this release. More direct evidence 
suggesting a role for Fos proteins is transcriptional regulation came 
from studies of v-fos transformed fibroblasts where it was observed 
that both the transcription and the expression of the a, (III) 
collagen gene is elevated (272) and in co-transfection experiments 
with a, (III) collagen promoter-CAT and v-fos egression plasmid 
constructs the v—Fos protein elevated the levels of transcription 
from the a, (III) collagen gene promoter region (273). The levels of 
expression of the c-Fos protein seemed to reflect the levels of 
expression of certain major histocompatibility (MHC) genes in several 
haematopoietic cell lines and in metastatic lung carcinoma cell lines 
suggesting that the c-Fos protein controlled the egression of the 
MHC genes at the transcription level (274, 275).
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Although the above evidence indicated that Fos proteins do regulate 
transcription the argument that the Fos proteins are acting through 
an intermediate protein to activate transcription could not be 
dismissed. More direct evidence implicating Fos proteins in 
transcriptional regulation came when it was observed that c-Fos 
protein is part of a nucleoprotein complex that binds to a DNA
element upstream from the adipocyte lipid binding protein aP2 (276,
277) . This gene is inactive in pre-adipocyte cells due to the 
repression of its transcription by the protein complex that binds to 
a sequence upstream from the aP2 transcription initiation site called 
the fat-specific-element 2 (FSE-2) . Antibodies to the c-Fos protein 
disrupt the formation of the nucleoprotein complex with this sequence 
in gel mobility shift assays and specifically immunoprecipitate
protein complexes covalently bound to FSE-2 DNA by U.V. crosslinking.
Further evidence implicating c-Fos proteins in transcriptional
repression has come from studies on the transcriptional control of 
the c-fos gene itself. The fact that c-fos transcription is not 
shut-down following its induction by serum stimulation of quiescent 
fibroblasts in the presence of cycloheximide (105, 107, 110, 115,
127, 149) suggested that a protein synthesised following stimulation
is involved in shut-down of c-fos transcription. The c-Fos protein 
itself has been identified as a possible candidate for this
repression in two independent studies (220, 278). Firstly,
co-transfection of a construct coding for the c-Fos protein with 
c-fos promoter-CAT constructs prevented the activation of c-fos 
transcription in response to serum stimulation from both the region 
containing the SRE and the region containing the sequence homology 
with the HSP 70 promoter SRE (the HSP 70 transcriptional activation
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by serum stimulation is also repressed by the c-Fos protein) . 
Secondly, c-Fos protein mutants that contain foreign carboxy 
terminals prevent the shut-down of c-fos transcription following 
serum stimulation and it is thought that these aberrant proteins 
operate by complexing with cellular factor that interact with the 
native c-Fos protein to shut-down transcription. These mutant 
proteins are dominant in their effect and prevent transcriptional 
shut-down of transfected c-fos promoter-reporter gene plasmids and of 
the endogenous c-fos gene. It is interesting to note that the v-Fos 
protein, which has a different carboxy-terminus from that of the 
c-Fos protein (13), fails to repress the transcriptional activation 
of the c-fos promoter in response to serum in co-transfection 
experiments. This has an interesting implication for the 
transformation mechanism of the v-Fos protein. Perhaps it operates 
by preventing the transcription repression of a set of genes by the 
native c-Fos protein leading to cellular transformation. However, 
this cannot be the only mechanism by which Fos proteins trigger 
cellular transformation as the c-Fos protein itself, if expressed to 
high enough levels, can also cause transformation.
The c-Fos and v-Fos proteins can positively regulate transcription 
when attached to promoter regions in yeast cells (279) . This study 
used plasmid constructs encoding hybrid proteins containing Fos (both 
viral and cellular) and the bacterial DNA binding protien Lex A. Lex 
A binds to operator sequences upstream from transcriptional 
initiation sites and represses transcription in prokaryotic cells. 
The fusions, Lex A-c-fos and Lex A-v-fos, encoded the DNA binding 
domain of the Lex A protein and the coding sequences for the fos
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genes and these constructs activated transcription of plasmid 
constructs transfected into yeast cells which contained operator 
sequences in their promoter region. This study showed that Fos 
proteins could activate transcription in eukaryotic cells when bound 
to DNA upstream from a transcription initiation site.
1.7.2. Fos protein forms complexes with the AP-1 DNA sequence.
The previous section detailed several reports implicating the Fos 
protein in the regulation of transcription. A target DNA sequence 
for the Fos protein was discovered by analysis of the FSE-2 sequence 
which contains a consensus recognition sequence for the previously 
described transcription factor AP-1 (see sub-Section 1.6.6.). 
Further DNA-protein interaction analysis using the FSE-2 sequence 
showed that the DNA binding activity of the nucleoprotein complex 
that binds to this sequence could be increased by preparing protein 
extracts from the nuclei of serum-stimulated cells that contain 
elevated levels of Fos protein (280) . This suggested further that 
the Fos protein plays a pivotal role in the complex that binds to 
this sequence and that perhaps the c-Fos protein interacts with the 
previously purified AP-1 protein to regulate transcription. Using 
several other AP-1 consensus containing sequences a further study 
employing in vitro DNA-protein interaction studies revealed that in 
all cases the c-Fos protein is involved in the nucleoprotein complex 
that binds to this sequence (281) . Transfection studies using 
AP-l-binding sequence containing reporter plasmids and Fos protein 
expressing constructs co-transfected into tissue culture cells 
revealed that the c-Fos protein can stimulate transcription from the
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AP-1 containing promoters (282 - 278) and that the over-expression of 
c-Fos protein can repress transcription from the c-fos promoter. 
This observation agrees with previous reports showing that the c-Fos 
protein can auto-regulate its own transcription by repressing 
transcription following stimulation (220, 278). All of the evidence 
described so far directly implicating c-Fos protein in 
transcriptional regulation has suggested that this protein interacts 
with the transcription factor AP-1. Several studies have been 
undertaken to prove that this is the case, but it is important that 
the discovery of the AP-1 encoding gene is described at this point.
In 1985 a virus was isolated from a spontaneous chicken tumour; it 
was called avian sarcoma virus (ASV) 17 (285) . This virus has a 
genome of 3.4kb (286) and is defective in replication as it encodes a 
gag-fusion protein which contains cellular sequences called jun
(287) . The gag-jun region encodes a fusion protein of 65kD 
(p65^a<^  -'un) and this sequence can transform chick embryo 
fibroblasts. The amino acid sequence derived from the nucleotide 
sequence shows homology to the yeast transcription factor GCN4 (288) 
which is a component of the general control system of amino acid 
suynthesis in yeast (289) . GCN4 has a functional domain in the 
carboxy-terminal region that is responsible for the specific DNA 
binding properties of this protein and the homology to the jun 
sequence is restricted to this region. GCN4 has an acidic stretch in 
the centre of the molecule which is responsible for its transcription 
activation properties and the Jun protein contains two such acidic 
stretches in its amino-terminal region. The carboxy-terminal region 
of Jun can replace that of GCN4 in a fusion protein that is capable
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of complementing GCN4 minus yeast mutants. This fusion protein also 
requires the DNA-binding domain of the Lex A protein but in this case 
the Lex A sequence facilitates dimerisation the GCN4-Jun fusion 
protein which then binds to the GCN4 recognition sequence. Intact 
GCN4 binds to its recognition sequence as a dimer (290) .
The DNA element to which the GCN4 dimers bind in yeast cells is 
identical to that of the AP-1 binding site suggesting that Jun and 
AP-1 protein may be related. To test this hypothesis two antibodies 
were raised against peptides of Jun sequences. These two antibodies 
can precipitate the p65^a<^  -|un protein (which is exclusively nuclear) 
and can specifically react with DNA-affinity-purified AP-1 p47 in 
immunoblots (291) . Further evidence supporting the relationship 
between Jun and AP-1 came when it was observed that Jun protein 
synthesised from a human c-jun clone showed identical footprinting 
properties as DNA-affinity purified AP-1 (291, 292) . In addition,
the p65^a<^  -|un fusion protein also protected the same sequences in 
footprinting assays as purified AP-1 (287) . Cellular DNA sequences 
corresponding to that of the viral jun have been isolated (291, 292) . 
The main difference between the cellular and viral protein sequences 
is a 27 amino acid deletion from the cellular sequence to form the 
viral sequences although it is not yet clear whether this deletion 
contributes to the transformation properties of the viral sequences. 
However, all of the above evidence suggests tha the cellular Jun DNA 
sequence encode the transcription factor AP-1. This was the first 
nuclear oncogene that had its cellular function identified.
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Another interesting aspect of the c-jun gene is that, like c-fos, it 
is a number of the "immediate-early" cellular gene family that are 
transcriptionally activated following stimulation of cells in the Go 
phase of the cell-cycle (293 - 297). Like c-fos, c-jun can also be 
transcriptionally activated by tumour growth factor-p (TGF-p) (298 -
300), tumour necrosis factor-a (TNF-a) (301, 302) and the c-Ha-ras
oncogene (146, 147, 303). However, c-fos and c-jun are not always
co-induced as following membrane depolarisation of PC12 cells 
transcription of c-fos is induced but that of c-jun is not (304) . 
So, although both c-fos and c-jun are members of the 
"immediate-early" family of cellular genes and regulate transcription 
through the same sequence their transcriptional control is not 
identical. This observation suggests that different stimuli may 
transcriptionally activate distinct sets of "immediate-early" genes 
leading to the distinctive effects of each individual stimulus.
A combination of in vivo and in vitro techniques were used to 
establish the relationship between the c-Fos and c-Jun proteins that 
presumably co-operate in binding to the AP-1 recognition sequence 
(305 - 309) . Immunoprecipitation of Fos protein5 results in the
co-precipitation of a cellular protein p39 (7) . Further
precipitation of these Fos-immunoprecipitated proteins with 
Jun-specific antibodies results in the specific precipitation of p39 
(305, 306) . The p39 protein eluted from a gel is capable of binding
to the AP-l-recognition sequence further suggesting that p39 is c-Jun 
protein. p39 and c-Jun (DNA-affinity purified AP-1) proteins also 
show identical tryptic peptide maps and all of these observations are 
consistent with the cellular Fos associated protein (FAP) p39 being
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c-Jun. In vitro translated Jun protein (from a rat cDNA clone) has a 
low level of DNA binding activity which can be detected only at high 
concentrations of protein (308) . In vitro translated Fos protein 
(once more from a rat cDNA clone) has no DNA binding activity but it 
acts co-operatively with the Jun protein to give enhanced DNA-binding 
activity which is due to a stabilisation of the protein-DNA complex. 
v-Jun protein can also complex with the c-fos protein (309) . These 
in vitro DNA-protein interaction studies agreed with co-transfection 
experiments performed with the mouse embryonal carcinoma cell line F9 
(305, 306) . This cell line lacks any detectable AP-1 binding
activity (310) making it an ideal model for the in vivo study of the 
Fos-Jun interactions. Transfection of a reporter construct
containing an AP-1 recognition sequence with a c-Jun protein 
expression construct into F9 cells results in elevated levels of 
expression from the AP-1 containing reporter construct. However, 
co-transfection with a c-Fos protein expression construct along with 
the reporter plasmid and c-Jun protein expression construct leads to 
a 100-fold increase in expression from the AP-1 containing promoter. 
This agreed with the in vitro studies showing the Jun-protein can 
indeed interact with the AP-1 site but that Fos protein greatly 
increases this interaction.
So, it has been established that c-Fos and c-Jun proteins interact to 
activate transcription and co-operate in DNA binding. The next step 
was to identify the mechanism by which these two proteins interact 
and to try and identify DNA-binding and transcriptional activation 
domains.
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1.7.3 The mechanism of the interaction between Fos and Jun proteins.
When considering the mechanism of interaction between Fos and Jun 
proteins it was of interest to note that deletion of the 
carboxy-terminal region from the v-Jun protein prevented any 
interaction with Fos protein taking place (309) . In this region, 
which has sequence homology with the DNA-binding domain of GCN4
(288), there exists a motif that has been implicated in the DNA 
binding properties of certain proteins called the leucine zipper. 
c-Jun, c-Fos (and their viral counterparts), C/EBP (311, 312), c-myc 
(313) and GCN4 all contain this region. Leucine zippers are 
amphipathic p-helices that contain 4 or 5 leucine residues at 
7-residue intervals which locates the leucines at approximately the 
same rotational position along the helix with leucine side chains 
forming a linear crest that extrudes from the helical axis. 
Dimerisation is thought to be mediated by hydrophobic interactions 
between the leucine side chains of two leucine zipper domains, hence 
the term "zipper". GCN4 binds to its recognition sequence as a dimer 
(290) and this dimerisation requires the presence of the 
carboxy-terminal sequences containing the leucine zipper domain. 
This observation suggested that perhaps Fos and Jun proteins may also 
interact through this domain that seems to be involved in 
protein-protein interactions. To determine whether this is the case 
a series of mutation and deletion studies were carried out with the 
Fos and Jun proteins in a bid to identify the specific domains 
involved in the interaction of these proteins.
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These studies involved analysis of the interaction of in vitro 
translated Fos and Jun proteins (both mutant and wild type) and also 
involved the analysis of the DNA-binding potential of these proteins 
(314 - 320) . In vitro translated c-Jun protein can bind very weakly 
to an AP-1 site in the absence of c-Fos protein (309, 316, 318, 319). 
However if this protein is mixed with in vitro translated c-Fos 
protein (or is co-translated) then Fos-Jun complexes form that have a 
much higher affinity for the AP-1 recognition site (the precise 
degree of this increase in affinity is variable between labs but is 
never less than 10-fold and is usually much greater) (308, 314, 316,
318, 319) . This presented the ideal model to examine the role of the 
leucine zipper in both the protein-protein interactions between Fos 
and Jun and in DNA-binding. The c-Fos protein is the only one as yet 
reported that has the leucine zipper domain in the centre of the 
protein molecule - all other zipper-containing proteins have this 
domain at their carboxy termini. Deletions in the c-Fos protein from 
the carboxy-terminus and the amino-terminus that retain the zipper 
domain are still capable of complexing with c-Jun protein and binding 
to AP-1 recognition sequences (314 - 317, 319). Point mutations that 
replace one of the leucine residues in the c-Fos zipper domain 
generally do not greatly affect interaction with the c-Jun protein, 
nor does replacing the amino acids between the leucine resideues. 
However, mutations of two or more leucines or insertions which upset 
the periodicity of the leucine residues abolishes interactions with 
c-Jun protein (314 - 320). The region of the c-Fos protein that 
contains the leucine zipper is conserved in the v-Fos sequence and 
studies with v-Fos constructs containing similar point mutations and 
deletions were used in transformation assays. It is interesting to
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note that the loss of interaction between v-Fos protein and c-Jun 
protein is mirrored by the inability of the Fos mutant constructs to 
transform fibroblasts. This suggests that the interaction with the 
Jun protein is an essential aspect of transformation by Fos protein. 
As mentioned previously, the Jun protein also contains a leucine 
zipper domain and mutation studies on this sequence revealed that the 
periodcity and frequency of the leucine residues are essential for 
the complexing of Jun protein with that of Fos (319) . The Fos and 
Jun proteins containing double mutations in the leucine zipper domain 
were used to show that the proteins joined by the leucine zipper do 
so in a parallel configuration (319, 321), suggesting that the
interaction between the zipper regions involved a "coiled-coil" 
structure (322).
Taking into consideration all of the above evidence it seems likely 
that Fos and Jun heterodimers are formed via an interaction between 
the respective leucine-zipper domains. However, this does not 
explain how the resultant heterodimers binds to its DNA recognition 
sequence (an AP-1 site) . To the amino-terminal site of the Fos 
protein leucine zipper there is a stretch of amino acids that make up 
a basic domain that is favourable for the formation of an a-helix. 
This basic domain is conserved to a certain extent in the c-Jun 
protein and most of the other zipper domain containing proteins 
suggesting that this region may be involved in the interactions of 
these proteins with their DNA target sites. To test this hypothesis 
mutation studies were carried out that altered the content of the 
basic amino acid stretch and the resultant mutant proteins were 
analsysed for their DNA-binding properties (315, 318 - 320) .
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Mutations that appreciably alter this region of the Fos protein 
results in the abolition of the DNA binding properties of the Fos-Jun 
heterodimers complex. These mutant Fos proteins can still complex 
with the Jun proteins through their leucine zipper domains but fail 
to bind DNA suggesting that the zipper domain by itself is not 
sufficient to induce the DNA binding properties of the Fos-Jun 
heterodimer. Rather, it seems that the zipper regions interact with 
one another and perhaps juxtapose the basic domains of the two 
proteins allowing them to bind to the AP-1 consensus sequence which 
is a relatively small recognition sequence.
So, the c-Fos (and v-Fos) protein has two regions that are 
responsible for the interaction of this protein with DNA - the 
leucine zipper domain and the basic amino acid stretch domain. It is 
interesting to note here that certain c-Fos mutant proteins that 
retain the ability to complex with the c-Jun protein and bind to DNA 
fail to activate transcription in co-transfection assays with F9 
cells (316) . These mutant proteins have their carboxy terminal 
region deleted (which has been implicated in transcriptional 
activation) and this result suggests that the transcriptional 
activating properties of the c-Fos protein is not essential to its 
transforming properties (carboxy-terminal truncated Fos proteins can 
still transform fibroblasts (317)) . This suggests that the Fos 
protein has three crucial domains that are involved in 
transcriptional activation: the leucine zipper, the basic domain and
the carboxy-terminal region of the protein.
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1.7.4. c-fos and c-jun are members of gene families.
To date, c-Fos has been implicated in transcriptional activation (272 
- 275, 279, 282 - 284), transcriptional repression (276, 277, 323)
and transcriptional shut-down (220, 278). The c-jun gene is
positively regulated by its own product through an upstream AP-1 
binding site suggesting that the Fos protein may also be involved in 
the transcriptional activation of this gene. The pleiotropic effects 
of the c-Fos protein on transcriptional regulation suggest that 
perhaps there may be more than one c-fos-like gene and protein. This 
hypothesis was given support by the observation that c-Fos antibodies 
can react with a whole series of Fos-related antigen (FRAs) proteins, 
some of which are increased in abundance following serum-stimulation 
(323) . The first such gene to be isolated encoding one of these
p rota. A 1-KV3
proteins was called fra-1 (324) . The Fra-1 extensive amino-acid 
homology with the c-Fos protein including the leucine zipper and 
basic domains that are essential to the DNA binding properties of the 
c-Fos protein (see sub-Section 1.7.3.). The transcription of this 
gene can also be induced by a variety of extra-cellular stimuli 
(although these only represent a sub-set of those that can activate 
c-fos transcription) and the mRNA of Fra-1 contains the motif in the 
3' untranslated sequence that has been identified as being 
responsible for the short half-life of many mRNAs (see sub-Section
1.5.1.). In vitro translated Fra-1 protein can form complexes with 
c-Jun protein and can co-operate in binding to AP-1 recognition sites 
due to the leucine zipper and basic domains present in this protein 
(325). Another FRA gene has been isolated, fos-B, which also has a 
conserved leucine zipper and basic domain (326) and contains the mRNA
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destabilising motif in its 3' untranslated region. As with 
Fra-1, in vitro translated Fos B protein can form complexes with 
c-Jun protein, and can co-operate in the binding to the AP-1 
recognition sequence Fos B can also increase the transcriptional 
activation caused by constructs expressing c-Jun protein when they 
are co-transfected with an AP-1 sequence containing reporter plasmid 
into quiescent NIH 3T3 cells.
c-jun related genes have also been isolated from cDNA libraries. Jun 
B is transcriptioanlly activated following stimulations of quiescent 
cells, and contains the mRNA destablising sequence in its 3' 
untranslated sequence as well on the leucine zipper and basic domain 
(327) . Jun-B protein can complex with c-Fos protein (and Fos-B
protein (326)) and bind to AP-1 recognition sites (328) . Another
c-jun related gene is jun D (329) whose transcription is not affected 
by the external stimulation of quiescent fibroblasts - it remains at 
a constant, relatively elevated level, throughout stimulation. This 
gene has also conserved the leucine zipper and basic domain. It can 
form complexes with c-Fos protein that bind to AP-1 sites and can
co-operate with c-Fos protein in in vivo co-transfection experiments 
to activate the transcription of constructs containing AP-1 sites 
(329) . c-Jun, Jun-B and Jun-D proteins can all bind to AP-1
recognition sites in the absence of c-Fos protein (328). It is also 
interesting to note that these proteins can also form complexes with 
oligonucleotides containing the CRE consensus sequence, although the 
affinity of the Jun proteins for this sequence is not affected by the 
present of c-Fos protein (328). DNA-affinity purification of the CRE 
binding protein (CREB/ATF) resulted in the co-purification of AP-1
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proteins can bind to CRE consensus sequences (330) . This showed that 
AP-1 and CRE binding proteins are antigenically related (which is not 
surprising since their DNA recognition sites are so similar), and 
this was confirmed upon isolation of a cDNA encoding the CREB/ATF 
protein (331) . The protein encoded by this cDNA contains a leucine 
zipper and a basic domain and shows a degree of homology to Jun 
proteins in the region. It is not yet known whether c-Fos protein 
can complex with CREB/ATF protein and co-operate in the binding to 
the CRE sequence.
The Fos and Jun proteins seem to be highly evolutionary conserved as 
antigenically related proteins are present in Drosophila embryo 
nuclear extracts (332). These proteins were purified on an AP-1 DNA 
affinity column, and display the sequence specificity and 
transcription activation properties of the mammalian protein 
complexes that binds to AP-1 sequences. An Epstein-Barr Virus (EBV) 
encoded trans-activating protein also bears homology to the c-Fos 
protein in certain regions (333). However, this homology does not 
include the leucine zipper and, although this protein can activate 
EBV early gene transcription through an AP-1 sequence, it also 
activates through other sequecnes (334) . The precise mechanism of 
transcriptional activation by this protein is not known but is seems 
unlikely that it will include interaction with Jun-like proteins as 
no leucine zipper is present.
So, a very complex mechanism for transcriptional regulation can be 
imagined when considering the Fos and Jun protein families. All of 
the genes encoding these proteins are not transcriptionally regulated
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in an identical fashion suggesting that the sub-sets of proteins 
activated by specific extra-cellular stimuli may be responsible for
to
the pleiotropic response these stimuli. This could be due to the
A
transcriptional regulation of different sub-sets of genes by the 
different combinations of Fos-Jun heterodimers that may be formed 
following specific stimuli. The mechanism by which Fos-Jun 
heterodimers regulate transcriptional activation, repression and 
shut-down is not clear but one could imagine general ways in which 
these proteins produce their pleiotropic effects. For instance, the 
response of a promoter to Fos-Jun heterodimers could depend upon the 
members of the protein families that form the compexes with the AP-1 
binding sites, which may be dictated by the nucleotide sequence 
overlapping with the AP-1 sequence. Alternatively, the specific 
effect on transcriptional regulation of the Fos-Jun heterodimers may 
depend on the interaction these proteins have with proteins that are 
bound to the promoter (or further upstream) regions of the AP-1 
sequence containing genes. Further studies will be required to 
clarify this situation, but this problem has certainly been made 
easier by the isolation of several members of the fos and jun gene 
families.
1.7.5. Hierarchical control of Fos-Jun transcriptional activation.
It is clear from the evidence described so far that the fos and jun 
gene families play an important role in mediating the response of 
cells to external stimuli. This mediation presumably involves the 
transcriptional activation of a number of genes that are as yet 
mostly unidentified. The control of Fos-Jun interactions resulting
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in transcriptional activation seems to form a hierarchical structure 
which starts with the transcriptional stimulation of the c-fos and 
c-jun genes themselves. This results in protein synthesis which then 
form heterodimers through the leucine-zipper and these then bind to a 
DNA recognition sequence via the basic domains present in both 
proteins. These DNA-bound heterodimers then activate (or repress) 
gene transcription. The control of each step of this pathway that 
results in transcriptional activation is obviously very important, 
but perhaps the most crucial control is exerted at the level of gene 
transcription.
The purpose of this project was to analyse the transcriptional 
control of the human c-fos proto-oncogene. To do this regions of
c-fos upstream sequence were placed upstream from the prokaryotic CAT 
reporter gene and the effect these sequences had upon the 
transcription of the CAT gene was assayed following transfection of 
these constructs into CT3 cells (a derivative of NIH 3T3 cells) . 
Oligonucleotides were inserted upstream from the c-fos promoter in 
the c-fos-CAT constructs to determine the effect precise sequences 
have upon transcription from the c-fos promoter. These c-fos-CAT 
constructs were used not only for the analysis of c-fos 
transcriptional control elements in growing cells, but also to 
identify sequences that could confer serum or TPA responsiveness upon 
the c-fos promoter following stimulation of quiescent CT3 cells with 
the respective extra-cellular stimuli. These investigations
concentrated on examining the previously characterised SRE and the 
sequence continuous with this element which I have called the 
fosATF/AP-1 sequence, which had not been previously studied at the
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outset of this project. Attempts were also made to identify any 
synergistic control of transcription that these two sequences may 
exert on the c-fos promoter.
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2.1. Materials
2.1.1. General Suppliers.
All chemicals used were of Analar grade and supplied by BDH 
Chemicals, Poole, Dorset unless otherwise stated.
All radioisotopes were obtained from Amersham International, 
Amersham, Buckinghamshire.
Restriction endonucleases and enzymes employed in the manipulation of 
DNA were purchased mainly from BRL Gibco (Europe), Paisley, and 
Boerhinger-Mannheim (BCL), Lewes, East Sussex.
Tissue culture medium, supplements and serum were obtained from Gibco
(Europe) Paisley; or Flow Laboratories, Herts. Sterile disposable
2 2 2 plastic flasks of growth area 25cm , 75cm and 175cm and roller
2bottles of 800cm used in the culture of animal cells were supplied 
by Falcon, Oxford and Nunc, Paisley.
Ingredients of bacterial media such as Tryptone, Yeast Extract and 
Agar were obtained from Difco Laboratories, Surrey.
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2.2. General Procedures.
2.2.1. Preparation of total cellular RNA. from cultured animal cells.
2.2.1. a) Phenol method.
All RNA prepared by this method was made from monolayer cells. The 
culture medium was removed from the flasks and the cells washed with 
PBS. Following removal of the PBS 10ml of phenol saturated with 
lysis buffer (0.3m sodium acetate 0.5% SDS (Na2), 5mM EDTA pH8.0) was 
added to the flask along with 10ml lysis buffer. The flask was then 
gently rotated for 5 minutes and the resultant mixture transferred to 
a 50ml Falcon tube and tumbled for 5 minutes. A half-volume of 
chloroform: isoamylalchol (in a ratio of 24:1 v/v) was then added and 
the mixture was tumbled for a further 10 minutes. This solution was 
then spun at 2,700 r.p.m. (l,220xg) for 10 minutes at room 
terrperature in an IEC Centra-8R centrifuge. The upper phase was 
removed and placed in a fresh 50ml Falcon tube. Again, 10ml of 
chloroform: isoamylalcohol (24:1 v/v) was added to this mixture which 
was then tumbled and centrifuged as before. This process was 
repeated one more time. After this third spin the upper phase was 
placed into a fresh 50ml Falcon tube and mixed with two volumes of 
100% ethanol. This solution was incubated at -20°C for 1 hour and 
then spun at 2700 r.p.m. (l,220xg) for 10 minutes at 4°C. The pellet 
was then resuspended in 1 to 2ml of sterile de-ionised H20 and an 
equal volume of 4M Li Cl added to the solution. This mixture was 
then incubated overnight at 4°C and then spun at 10,000 r.p.m. for 60 
minutes at 4°C in a Sorval RC-2B Superspeed centrifuge using an H8-4
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rotor. The pellet was resuspended in 400^1 of 3mM MgCl2. This 
solution was then treated with 20 units of RNAse-free DNAse 1 for 30 
minutes at room temperature. This was then extracted with an equal 
volume of a phenol-chloroform (ratio of 1:1) solution saturated with 
lOmM Tris HC1 pH7.5 and lmM EDTA pH8.0. The resulting mixture was
then spun at 10,000 r.p.m. (8,160xg) for 5 minutes at room
temperature in an eppendorf centrifuge 5415 and the aqueous phase 
removed and placed in a fresh test tube. This was then extracted 
twice with an equal volume of a chloroform: isoamylalcohol mix and the 
aqueous phase removed and placed in a fresh test tube. A tenth
volume of 3M sodium acetate was then added followed by 2.5 volumes of 
100% ethanol. The resultant mixture was then placed at -20°C
overnight and the following day spun at 10,000 r.p.m. (8,160xg) for 
15 minutes at 4°C in an eppendorf centrifuge 5415 which pellets the 
precipitated RNA. The pellet was then drained and washed with 500jil 
of 70% ethanol and then spun at 10,000 r.p.m. (8,160xg) for 5 minutes 
in an eppendorf centrifuge 5415. This step was repeated once and the 
pellet freeze dried for 15 minutes. It was then resuspended in an 
appropriate volume of de-ionised H20 and the optical density 
determined in order to calculate the concentration of the solution 
(E :1cm, 260. 1 : 00 - 40|Jg/ml) . All aqueous solutions used in this
protocol were treated with diethyl pyrocarbonate (which destroys any 
RNAses present) and autoclaved (15 p.s.i. for 15 minutes) .
2.2.1. b) RNAzol Msthod.
RNAzol solution was bought from Biogenesis Limited, Bournemouth, 
England. RNA was prepared by this method based on that of the
99
manufacturer (335) with the following modifications. Medium was 
removed from monolayers of cells which were then washed with PBS. 
The cells were then removed from the plastic culture surface by 
treatment with a 0.25% trypsin solution and taken up in 10ml of PBS. 
This mixture was then spun at 1,000 r.p.m. (850xg) for 5 minutes at 
room temperature in an MSE Centaur 2 centrifuge. The resulting 
pellet was then taken up in RNAzol and the manufacturer's 
instructions were then followed.
2.2.2. Analytical gel electrophoresis of DNA.
Depending on the size of the expected DNA fragment restricted DNA was 
electrophoresed through an agarose or polyacrylamide gel. DNA 
samples either in restriction enzyme buffer or in distilled f^O 
(following ethanol precipitation) were mixed with one-tenth volume of 
gel loading dye (0.1% bromophenol blue, 30% sucrose, lOmM Tris HC1 pH 
8.0 and O.lmM EDTA pH 8.0) . The samples were then electrophoresed 
either in:
a) a horizontal 1% (usually) agarose (BRL) gel in 1 x T.B.E. 
(0.089M Tris-borate, 0.089M Boric acid and 0.002M EDTA pH 8.0) or 1 x 
T.A.E. (0.04M Tris-acetate and 0.001M EDTA pH 8.0) . The DNA was 
visualised under U.V. light following staining in a O.lpg.ml solution 
of ethidium bromide (EtBr) .
b) a verical neutral polyacrylamide gel (5% acrylamide, 0.18% 
bis-acrylamide, 0.08% ammonium persulphate and 0.05% 
N,N,N,N-tetramethyl-ethylene diamine (TEMED)) . The DNA was 
visualised as in a) .
Running conditions varied with convenience.
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2.2.3. Isolation of DNA. from agarose gels.
2.2.3. a) Phenol method.
A low melting point agarose gel was run and visualised as in 
sub-Section 2.2.2. A slice of gel containing the DNA fragment of 
interest was cut out and weighed, mixed with 2 volumes of 1 x T.B.E. 
and heated at 70°C for 10 minutes. After this incubation an equal 
volume of ice cold phenol (saturated with T.E.) was added to the tube 
and the two phases mixed together. The tube was then centrifuged for 
5 minutes at 10,000 r.p.m. (8,160xg) in an eppendorf centrifuge 5415 
and the aqueous phase placed in a fresh eppendorf tube. The phenol 
extraction was repeated and was followed by two 
chloroform: isoamylalcohol (1:24 v/v) extractions. The aqueous phase 
was then taken and the DNA precipitated by the addition of a tenth 
volume of 3M sodium acetate and 2.5 volumes of 100% ethanol. The 
tube was placed on dry ice/ethanol for 10 minutes, or placed at -20°C 
for at least 1 hour, and was then spun at 10,000 r.p.m. (8,160xg) for 
15 minutes at 4°C in an eppendorf centrifuge 5415. The resultant 
pellet was then washed with 500|H of 70% ethanol and freeze dried for 
15 minutes. The DNA pellet was then taken up in an appropriate 
volume of de-ionised f^O.
2.2.3.b) Geneclean method.
An agarose gel was run in 1 x T.A.E. and visualised as in sub-Section 
2.2.2.. A slice of gel containing the DNA fragment of interest was 
then cut out and weighed. Thereafter the Geneclean protocol (336)
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was followed in order to isolate the DNA. Geneclean was obtained 
from BIO 101, La Jolla, California.
2.2.4. Isolation of DNA from neutral polyacrylamide gels.
Bands from 4-6% neutral polyacrylamide gel were excised and 
transferred to a heat sealed blue tip (1ml) plugged with siliconised 
glass wool. The gel slice was crushed with a hypodermic needle and 
incubated overnight at 37°C in 200|il of gel elution buffer (1% SDS 
and 0.3M NaAc) . The DNA was eluted by piercing the bottom of the 
sealed tip and was collected by gravity. A further 200|il of gel 
elution buffer was added and collected. The solution was then spun 
at 10,000 r.p.m. (8,160xg) for 2 minutes at room temperature in an 
eppendorf centrifuge 5415 to pellet any polyacrylamide debris. The 
supernatant was placed in a fresh test tube and two volumes of 
ethanol were added. The sample was incubated at -80°C (dry ice and 
ethanol) for 15 minutes and then spun at 10,000 r.p.m. (8,160xg) for 
15 minutes at 4°C. The DNA pellet was washed with 500JLL1 of 70% 
ethanol and freeze dried for 15 minutes. An appropriate volume of 
de-ionised 1^0 was used to resuspend the DNA pellet.
2.2.5. Preparation of double stranded oligonucleotides.
Single stranded DNA oligonucleotides were made on an Applied 
Biosystems 381A DNA synthesiser. The oligonucleotides were removed 
from the synthesis column by elution with 3 x 1ml of ammonia. This 
solution was incubated at 55°C overnight to deprotect the 
oligonucleotides. To further purify the oligonucleotide an Applied
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Biosystems oligonucleotide purification cartridge (OPC) was used 
(337) . To anneal complementary single stranded oligonucleotides both 
were incubated at a concentration of 0.05M in 1 x T.E. This solution 
was then heated to 90°C and allowed to cool slowly to less than 30°C. 
This results in the formation of double-stranded oligonucleotides at 
a concentration of 0.1M. To check that the annealing had worked the 
double-stranded oligonucleotides (along with single-stranded 
oligonucleotides for comparison) were run on a neutral 8% 
polyacrylamide gel.
2.2.6. Denaturing polyacrylamide gel electrophoresis.
Denaturing polyacrylamide gel electrophoresis was carried out using a 
vertical acrylamide gel (5% acrylamide, 0.2% bis-acrylamide, 1 x 
T.B,E., 8M urea, 0.08% ammonium persulphate and 0.05% 
N,N,N,N-tetramethyethylene diamine (TEMED)) . The gel was set between 
glass plates (20cm x 45cm) separated by 0.5mm spacers and joined 
together using Sylglas tape. The running conditions varied between
2.2.7. Large scale preparation of plasmid DNA.
This technique was based on that described by Bimboim and Doly (338) 
although several modifications were adopted. A 10ml culture of 
L-Broth was set up overnight following inoculation from a glycerol 
stock. This culture was used to inoculate 500ml of L-Broth (1ml of 
the overnight culture was used) which was incubated overnight at 37°C 
in an orbital shaking incubator. The following day the bacterial
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cells were pelleted by centrifuging at 7,000 r.p.m. for 5 minutes at 
4°C in a Sorvall RC-5B Superspeed centrifuge using a GS-3 rotor. The 
pellet was well drained and then resuspended in 18ml of lysis buffer 
(25mM Tris HC1 pH8.0, lOmM EDTA pH8.0, 50mM glucose and 5mg/ml
lysozyme) and incubated on ice for 30 minutes. Following this
incubation 32ml of alkali buffer (0.2M NaOH, 1% SDS) was added to the 
mixture which was then incubated on ice for a further 45 minutes. 
This solution was then mixed with 16ml of 5M potassium acetate (60ml 
5M potassium acetate 11.5ml glacial acetic acid and 28.5ml H^O per 
100ml) and incubated on ice for 15 minutes. This mixture was then 
centrifuged at 8,000 r.p.m. for 5 minutes at 4°C in a Sorvall RC-5B
Superspeed centrifuge using a GS-3 rotor. The supernatant was poured
through gauze to remove any lumps and mixed with 0.6 volumes of 
isopropanol. The mixture was incubated at room temperature for 15 
minutes and then centrifuged at 8,000 r.p.m. for 10 minutes at room 
temperature in a Sorvall RC-5B Superspeed centrifuge in a GSA rotor. 
The pellet was then drained and taken up in 5ml of 50mM Tris HC1 
pH8.0, lOmM EDTA pH8.0 before being mixed with 5.5g of CsCl. The 
CsCl was dissolved in the plasmid solution and 0.5ml of ethidium 
bromide (lOmg/ml) was added. The refractive index of this solution 
was adjusted to 1.3915 _+ 0.001 (f^ O = 1.3303) and the tubes
containing the plasmid mix balanced using paraffin oil. The solution 
was then centrifuged at 40,000 r.p.m. for at least 36 hours at 15°C 
in a Sorvall Ultracentrifuge using a T-1270 rotor. Following this 
centrifugation the plasmid DNA forms a distinct band which is clearly 
visible in U.V. light. This band was removed from the gradient using 
a 50|H Supracaps disposable micro pipette attached to a 2ml 
disposable syringe. The plasmid solution was placed in a bijoux
bottle and extracted with CsCl-saturated isopropanol to remove the 
ethidium bromide. This extraction was carried out 3 to 4 times in 
order to remove completely the ethidium bromide. The plasmid 
solution was then dialysed against T.E. (lOmM Tris HC1 pH7.5 on ImM 
EDTA pH8.0) at 4°C for at least 6 hours (using a Sartorius colloidion 
bag) . The plasmid DNA was precipitated by mixing with 0.3M sodium 
acetate and 2.5 volumes of 100% ethanol, and incubating at -20°C 
overnight. After this incubation the plasmid DNA was pelleted by 
centrifuging at 8,000 r.p.m. for 15 minutes at 4°C in a Sorvall RC-2B 
Superspeed centrifuge using an HB-4 rotor. The pellet was drained 
and washed with 70% ethanol and centrifuged at 8,000 r.p.m. for 5 
minutes at 4°C in a Sorvall RC-2B Superspeed centrifuge using an HB-4 
rotor. The plasmid DNA pellet was drained and air dried before being 
resuspended in 0.5 to 1ml of de-ionised f^O. This plasmid DNA. 
solution was placed in a 15ml test tube and its O . D ^ q value 
determined. It could then be diluted to an appropriate concentration 
with de-ionised f^O.
2.3. Northern Blot Analysis of Total Cellular RNA.
2.3.1. Electrophoresis and transfer of RNA to nitrocellulose.
Volumes of RNA solutions containing the required quantity of RNA were 
freeze dried. These were then resuspended in 5|H de-ionised E^O and 
25[ii of sample buffer (0.38 ml formamide, 0.08ml 10 x MDPS, 0.12ml 
formaldehyde, 0.05ml de-ionised K p  0.05ml glycerol and 0.1% 
bromophenol blue) was then added. To this mixture 1(11 of ethidium 
bromide (l.Omg/ml) was added. These samples were then
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electrophoresed through a 1 % agarose gel which contained 2 % 
formaldehyde and 1 x MOPS (0.2M morpholinopropanesulfonic acid 
(ph7.0), 50rriM sodium acetate, 5mM EDTA, pH8.0) . Following 
electrophoresis the gel was soaked in 20 x SSC for 20 minutes. The 
electrophoresed RNA was transferred directly on to nitrocellulose 
membrane (Sartorius 0.10|Jm) by blotting in 20 x SSC (3M NaCl, 0.3M 
sodium citrate pH7.0) as described previously (339) . The blotting 
apparatus was set up as described by Southern (340) . The 
nitrocellulose was soaked in 10 x SSC for 30 minutes prior to 
blotting overnight. At the completion of transfer the nitrocellulose 
was air dried and then baked for 2 hours at 80°C to immobilise the 
RNA.
2.3.2. Synthesis of labelled DNA probe and hybridisation procedures.
To probe the nitrocellulose filters 20-50ng of DNA was labelled with 
32P using the random priming technique (341) . The fos probe used was 
the lkbp PstI fragment from pFos I (8 ) which contain v-fos sequences. 
The P2 _microglobulin probe was the 0.55kbp PstI fragment from a cDNA 
which contains human p2 -microglobulin sequences (342) . Both DNA 
fragments were isolated from 1% agarose gels (1 x T.A.E.) by the 
Geneclean method.
Prior to hybridisation the nitrocellulose filters were placed in a 
polythene bag and pre-hybridised with pre-hybridisation buffer (50% 
formamide, 500pg/ml sheared salmon sperm DNA, lOfll/ml poly A, 10|ig/ml 
poly C, 0.1% SDS, 5 x Denhardt's solution, 5 x SSC, 50mM sodium 
phosphate buffer pH7.0 and 1% glycine) at 42°C overnight in a shaking
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water bath. Following pre-hybridisation the filter was then
■ • 32
hybridised with the P-labelled DNA probes. This involved heating
appropriate amounts of the labelled DNA probe (106 d.p.m./ml 
hybridisation buffer) to 100°C for 10 minutes and then adding this to 
hybridisation buffer (50% formamaide, 10% dextran sulphate, lOOjlg/ml 
sheared salmon sperm DNA, lOjjg/ml poly A, 10|ig/ml poly C, 0.1% SDS, 5 
x SSC, 1 x Denhardt's solution and 20mM soldium phosphate buffer 
pH7.0) . This mixture was then incubated with the pre-hybridised 
nitrocellulose filter in a polythene bag overnight at 42°C in a 
shaking water bath.
Following the hybridisation the filter underwent a series of washes 
at 65°C in a shaking water bath: 2 x 30 minutes with 2 x SSC, 0.1%
SDS; 2x30 minutes with 0.5xSSC, 0.1% SDS; 2x30 minutes with O.lxSSC, 
0.1% SDS. At the completion of washing filters were placed in 
polythene bags and autoradiogrphed with Kodak "XAR" of "X-S" X-ray 
film using Cronex "lightning plus" intensifying screens in Harmer 
X-ray cassettes. After exposure at -70°C the films were developed in 
a Kodak ME-1A automatic X-ray processor.
2.4. Molecular Cloning.
2.4.1. Preparation of recombinant DNA molecules.
Vector DNA for the synthesis of recombinant DNA molecules was 
prepared in the following manner. The plasmid vector was linearised 
with the appropriate restriction endonuclease (in certain cases the 
vector was digested with two restriction endonucleases), run on an
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agarose gel and then purified. The linearised vector DNA was then 
treated with Klenow enzyme to form blunt-ends if necessary. In 
certain cases it was also necessary to phosphatase the linearised 
vector DNA and this was carried out with calf intestinal phosphatase.
Insert DNA was prepared by digesting the appropriate recombinant 
plasmid with restriction endonuclease (s) . The digestion mixture was 
then run on an agarose gel and the relevant DNA fragment purified 
from the agarose gel.
All restriction endonuclease digestions were carried out according to
the manufacturer's instructions. To phosphatase DNA the DNA was
treated with 0.1 units of calf intestinal phosphatase (CIP-BCL) in
phosphatase buffer (0.05M Tris HC1 pH9.0, ImM MgC^, O.lmM ZnC^ and
ImM spermidine) for 30 minutes at 37°C. Following this another 0.1
units of CIP was added to the reaction mix which was incubated at
37°C for a further 30 minutes. After phosphatase treatment the
reaction mix was incubated at 65°C for 15 minutes to destroy the CIP.
The reaction mix was then run on a 1% agarose gel and the vector DNA
isolated from the agarose gel. Klenow treatment was carried out
32using the random priming kit (345) that was used to P-label probe
DNA (see sub-Section 2.3.2.), with the exception that the 
32P-labelled nucleotide used in this reaction was replaced by the 
corresponding unlabelled nucleotide. Once more the reaction mix was
run on a 1% agarose gel and the vector DNA isolated from the agarose 
gel.
Following the preparation of the vector and insert DNA recombinant
108
DNA molecules were made by ligation reactions. In the ligation 
reactions approximately 20ng of the linearised vector plamid DNA was 
incubated with approximately lOOng of insert DNA with 1 unit of T4 
DNA ligase (BCL) in ligation reaction mix (0.07M Tris HC1 pH7.6 , 5rrM 
M 3 CI2 / 5mM DTT and ImM ATP) . This provided a high ratio of insert 
DNA ends to linearised vector plasmid DNA ends which favours the 
insertion of the insert DNA fragment into the linearised vector 
plasmid DNA. The ligation reaction was incubated overnight at room 
temperature.
2.4.2. Preparation of competent JM83 bacterial cells.
A glycerol stock of JM83 E.coli cells was used to inoculate 10ml of 
L-Broth. This was incubated at 37°C overnight in an orbital shaking 
incubator. The following morning 1ml was taken from this overnight 
culture and added to 100ml of L-Broth which was incubated at 37°C in 
an orbital shaking incubator. When the O . D . o f  the culture was 
approximately 0.6 it was split between two 50ml Falcon tubes. The 
bacterial cells were pelleted by centrifuging the culture at 2 , 0 0 0  
r.p.m. (560xg) for 5 minutes at 4°C in an IEC Centra-8 R centrifuge. 
The cells were resuspended in lOmM MgSO^ (lOmls in each 50ml Falcon 
tube) and incubated on ice for 20 to 30 minutes. Following this 
incubation the bacterial cells were pelleted once more by 
centrifuging the suspension at 2,000 r.p.m. (560xg) for 5 minutes at 
4°C in an IEC Centra-8 R centrifuge. The pelleted cells were then 
resuspended in 50mM CaCl2  (10ml total for both 50ml Falcon tubes) and 
incubated on ice for at least 30 minutes. Following this procedure 
the cells were competent; i.e. they were capable of being transformed
109
by circular plasmid DNA. molecules.
2.4.3. Transformation of competent JM83 bacterial cells.
One-half of the ligation reaction was placed in a fresh, sterile 
1.5ml test-tube and 100|il of the competent JM83 cells was added to 
this test-tube. This mixture was incubated on ice for 20 minutes. 
Following this the test-tube was incubated at 42°C for 2 to 3 minutes 
and then allowed to stand at room temperature for 10 minutes. The 
reaction mix was then mixed with 800|il of L-Broth and incubated at 
37°C for 45 to 60 minutes. Following this incubation an appropriate 
aliquot of each culture was spread onto L-Broth agar plates 
containing ampicillin (L-Broth, 1.5% agar, 200|ig/ml ampicillin) . The 
culture was allowed to dry onto the agar plate which was then 
incubated overnight at 37 °C.
2.4.4. Screening of bacterial colonies.
Any bacterial colonies that form after the overnight incubation at 
37°C contain circular plasmid DNA molecules that confer the 
ampicillin resistance to the bacterial cells. To determine which of 
the colonies contained plasmids with the desired DNA fragments 
inserted into them, small scale plasmid preparations were carried out 
to isolate sufficient plasmid DNA for restriction endonuclease 
analysis. Bacterial colonies were picked from the agar plates and 
used to inoculate 2ml of L-Broth containing 200fJg/ml penicillin. 
This was then incubated overnight at 37°C. The following morning a 
1.5ml test-tube was filled with this overnight culture and spun for
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30 seconds in a microcentrifuge to pellet the bacterial cells. The 
pellet was then resuspended in 100|ll of solution I (50mM glucose; 
25mM Tris HC1 pH8.0, lOmM EDTA pH8.0, 4mg/ml lysozyme) and incubated 
for 5 minutes at room temperature. After this 200|ll of solution II 
(0.2M NaOH and 1% SDS) was added and the mixture incubated on ice for 
5 minutes after gentle mixing. 150^1 of solution III (3M pottasium 
acetate) was then added and the mixture vortexed and placed on ice 
for 5 minutes. The mixture was then centrifuged for 5 minutes at 
room temperature in a microcentrifuge. The resultant supernatant was 
placed in a fresh test-tube and an equal volume of a 
phenol-chloroform mix (1 : 1 v/v, saturated with T.E.) was added and
the mixture vortexed. This solution was then centrifuged for 5 
minutes at room temperature in an eppendorf centrifuge 5415. The 
upper aqueous phase was then placed in a fresh 1.5ml test-tube and 
the plasmid DNA was precipitated with two volumes of 100% ethanol. 
This mixture was incubated at room temperature for 2 minutes and then 
centrifuged for 2 minutes at room temperature in an eppendorf 
centrifuge 5415. The resultant pellet was resuspended in 30(ll of 
sterile de-ionised H^O. For each restriction endonuclease reaction 
5|ll of the plasmid preparation was used and in the final 30 minutes 
of the digestion reaction l|il of lOmg/ml RNAse A was added to degrade 
the RNA present in the plasmid preparation.
2.4.5. Sequencing of plasmid DNA.
All plasmid DNA sequenced was prepared using the CsCl method 
described in 2.2.7. The DNA (3 to 5 fig) was denatured by treating 
with 0.2M NaOH for 5 minutes ( a total volume of 20|ll) . After this
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incubation 8|Jl of 5M ammonium acetate was added along with 100)11 of 
100% ethanol. This mixture was incubated at -70°C for 10 minutes and 
then centrifuged for 15 minutes at 4°C in an eppendorf centrifuge 
5415. The pellet was washed with 70% ethanol and freeze dried for 15 
minutes. The dried pellet was resuspended in 9(ll of 1 x Sequenase 
buffer (from the Sequenase kit (343)) and l|ll of sequencing primer 
was added to this solution (approximately 5 to lOng of DNA.) . This 
mixture was heated at 65°C and then allowed to cool very slowly to 
below 30°C. This solution was then ready for sequencing and the 
protocol and reagents used for this are described in the Sequenase 
kit (343) . The samples were electrophoresed through a 5% denaturing 
polyacrylamide gel which was then dried. The dried gel was 
autoradiographed with Kodak X-AR of X-S X-ray film using Cronex 
"lightning plus" intensifying screens in Harmer X-ray cassettes. 
After exposure at -70°C the films were developed in a Kodak ME-1A 
automatic X-ray processor.
2.5. Transfection of Cultured Animal Cells.
2.5.1. Cell lines and culture conditions.
All of the cell lines used throughout this project were monolayer 
cell lines: the mouse fibroblast cell line CT3 (a derivative of NIH
3T3 cells) (344), the human epithelial cell line HeLaS3 (345), the 
mouse fibroblast cell line LATK- $46) and the mouse embryonal 
carcinoma cell line F9 (77). These were all grown in Special Liquid 
Medium (SIM-Gibco), 10% foetal calf serum, 2mM glutamine and
37.5(jg/ml penicillin apart from F9 cells. F9 cells were grown in
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Dulbecco's Modification of Eagle's Medium (DMEM; NBL, Cramington), 
10% foetal calf serum, 2mM glutamine and 37.5jlg/ml penicillin. One 
additional step was required when culturing F9 cells and this 
involved gelatinising the tissue culture flasks. This was carried 
out by covering the plastic surface of the culture flasks with a 0 .1 % 
gelatin solution (in de-ionised t^ O) and leaving them for 5  to 1 0  
minutes. Following this the gelatin solution was removed and the 
flasks allowed to air dry (under sterile conditions).
To passage each cell line the medium was removed from the monolayers 
which were then washed with PBS. A volume of trypsin solution (2.5% 
trypsin, 0.2M NaCl, 0.01M trisodium citrate, 0.01M tricine 
(N-tris-hydroxymethyl) methylglycine and 0.005% phenol red) was then 
added to the washed monolayer and "waved" over the monolayer for 30 
seconds. The trypsin solution was removed and the monolayers left at 
room temperature for 5 to 10 minutes. The flask was tapped gently 
which dislodged the monolayer of cells from the plastic and these 
cells were taken 1 5 ) in 10ml of medium. An aliquot of the cells was 
counted in a Coulter Counter to estimate the concentration of the 
cells in the 10ml of medium. Cells were aliquoted into fresh tissue 
culture flasks along with fresh medium to the required cell density. 
The flask was incubated at 37°C in 5% CC^ .
2.5.2. Calcium phosphate co-precipitation of plasmid DNA.
Plasmid DNA was introduced into cultured cells by the calcium 
phosphate co-precipitation technique of Graham and van der Eb (347) 
as modified by Wigler et al (348) . The precipitates were made under
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sterile conditions in Bijoux bottles. For each precipitate, two
bijouxs were used. To one bijoux 2ml of 125mM CaCl2 were added 
followed by the plasmid DNA. To the second bijoux 2ml of 2 x HBS 
(hepes buffered saline: 2 x HBS; 140mM NaCl, 25mM HEPES
(N-2-hydroxyethylpiper-ozined-N-2-ethanesulphonic acid), 0.75mM
disodium hydrogen phosphate, pH7.1) were added. The DNA-CaCl2 
solution was added dropwise to the 2 x HBS solution (which was
agitated at the same time) . Following the addition the mixture was
returned to the first bijoux and allowed to stand at room temperature 
for 30 minutes. During this period the calcium phosphate precipitate 
forms which was divided between at least two flasks of cells.
2.5.3. Transient transfection procedure.
The cells to be transfected were set up at the required density the 
day before addition of the transfection cocktail. The following day 
(usually 20 to 24 hours later) the calcium phosphate precipitate was 
added to the cells. The following morning (12 to 16 hours later) the 
medium was removed from the cells which were then washed with PBS and 
refed with the desired medium.
The following afternoon (30 to 36 hours later) the cells were 
harvested. The medium was removed and the monolayer washed with PBS 
and then incubated at room temperature or 37°C with a covering 
(approximately 1ml) of TEN buffer (0.04M Tris HC1 pH7.4, ImM EDTA and 
0.15M NaCl) . This detaches the cells from the flask which were taken 
up in the TEN buffer and placed in a 1.5ml test-tube. The cells were 
pelleted by spinning in an eppendorf centrifuge 5415 for 2 minutes.
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2.5.4. Stable transfection procedure.
The cells to be transfected were set up at the required density the 
day before the addition of the transfection cocktail. The following 
day (usually 20 to 24 hours later) the calcium phosphate precipitate 
was added to the cells. The calcium phosphate precipitate used in 
the stable transfection experiments contained high molecular weight 
eukaryotic cellular DNA (as a carrier) and plasmid DNA containing the 
neomycin resistance gene which confers G418 resistance on the 
transfected cells. The following morning the medium was removed and 
the cells washed with PBS and refed with medium containing 10% foetal 
calf serum. Two days later the transfected cells were removed from
the plastic by treating them with trypsin (see sub-Section 2.5.1.) .
2The cells were then counted and replated into 10cm tissue culture 
petri dishes and fed with medium containing lOmg/ml G418. The cells 
were incubated in this medium for 10 to 14 days after which time 
colonies of resistant cells become visible. The medium was removed 
from the petri dishes and individual colonies were taken up in a 
small quantity of medium and placed into a flask containing medium 
with lmg/ml G418. The flask was incubated until the cells were 
confluent whereupon they were trypsinised and passaged as individual 
cell lines. These cell lines were grown in the presence of lmg/ml 
G418.
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2.6. Transcription Assays of Transfected Plasmid DNA.
2.6.1. Preparation of cell protein extracts.
Protein extracts were made from transfected cells in the following 
manner. The cell pellets obtained following harvest of transfected 
cells (see sub-Section 2.5.3.) were resuspended in 200|ll of 0.2M Tris 
HC1 pH7.8. The cells were then placed on dry ice for 5 minutes and 
then incubated at 37°C for 5 minutes. This cycle was repeated 
another two times and following this freeze thawing the ruptured cell 
suspension was spun for 10 minutes in a microcentrifuge. The 
resulting pellet was removed from the test-tube leaving behind the 
protein containing supernatant. When required the protein 
concentration of these extracts was determined using a Biorad Protein 
Assay kit (349) by following the manufacturer's instruction.
2.6.2. (3-galactosidase assay.
This assay was based on the assay described by Miller (350) . An 
aliquot of the protein extract was placed in a 1.5ml test-tube 
containing 500(11 of solution I (60mM disodium hydrogen 
orthophosphate, 40mM sodium dihydrogen orthophosphate, lOmM KC1, ImM 
MgCl^ and 50mM p2 -mercaptoethanol) . To this mixture 100(11 of 
solution II (2mg/ml ONPG (o-nitrophenyl galactoside), 60mM disodium 
hydrogen orthophosphate, 40mM sodium dihydrogen orthophosphate,) was 
added and the test-tube incubated at 37°C for 15 to 60 minutes. The 
samples were removed from the 37°C incubation and 250(il of 1M Na2 CC> 2  
was added to terminate the reaction. The final solution has a yellow 
colour and the optical density of this solution at 595mm was
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determined. Thus, (3-galactosidase activity was expressed in O.D.
59b
units.
2.6.3. Chloramphenicol acetyl transferase assay.
This assay was based on the assay described by Gorman et al (188) .
An aliquot of the protein extract (2.6.1) was placed in a 1.5ml
14test-tube and lfil of C-labelled chloranphenicol was added. Acetyl
coenzyme A was then added to a concentration of 5mM which starts the
reaction. The reaction was incubated at 37°C for 45 to 60 minutes
and then extracted with 500(11 of ethyl acetate. This mixture was
centrifuged for 30 seconds in an eppendorf centrifuge 5415 and the
ethyl acetate (which forms the upper phase) placed in a fresh 1.5ml
test-tube. The ethyl acetate was then evaporated using either a
14speedy-vac centrifuge or a freeze drier. The C-chloramphenicol and 
its acetylated derivatives were taken up in 20(ll of ethyl acetate and 
spotted on to a 20cm x 20cm thin layer chromatography 0.25mm silica 
gel plate. The sample was allowed to dry on to the plate before it 
was placed into a solvent tank containing 95% chloroform and 5% 
methanol. The plate was chromatographed for 30 to 45 minutes and 
then taken out of the solvent tank and air dried for 2 to 3 minutes. 
The plates were autoradiographed with Kodak "XAR" X-ray film using 
Cronex "lightning plus" intensifying screens in Harmer X-ray 
cassettes. After exposure at -70°C the films were developed in a 
Kodak ME-1A automatic X-ray processor. The radioactive spots 
indicating the position of the labelled and unlabelled 
14C-chlorairphenicol were cut out from the TLC plate and placed in a
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liquid scintillation vial along with 5ml of Ecoscint liquid 
scintillation fluid. These vials were counted in an LKB 1217 
Rackbeta liquid scintillation counter and the percentage conversion
14
of the C-chloramphenicol to its acetylated derivatives calculated.
2.6.4. SI analysis
A double-stranded DNA probe was used in the SI analyses (351) carried
out in this project. This probe was similar to the one used by Fisch
et al (252) . The plasmid containing the DNA fragment of interest was
linearised by restriction endonuclease digestion and treated with
calf intestinal phosphatase (50|ig of plasmid DNA was used for each
preparation. The linearised de-phosphorylated plasmid DNA was run on
a 1% agarose gel and isolated using the geneclean protocol
(sub-Section 2.2.3.b)). This plasmid was then end-labelled by
treating with polynucleotide kinase. The DNA was incubated with 1 x
kinase buffer (50mM Tris HC1 pH7.6, 10mM MgCl^r 5mM DTT, O.lmM
32spermidine and 0. ImM EDTA), 50jllCi of P-labelled ATP and ten 
units of polynucleotide kinase (BCL) at 37°C for 30 minutes. The DNA 
was extracted from this reaction mix using the Geneclean protocol and 
digested with another restriction endonuclease to generate the 
labelled DNA fragment. This mixture was electrophoresed through a 
neutral polyacrylamide gel and the gel exposed to a Kodak "X-AR" film 
for 1 to 3 minutes which was then developed in a Kodak ME-1A 
automatic X-ray processor. The labelled DNA fragment was extracted 
from the polyacrylamide gel and precipitated and resuspended in H^O 
to the desired concentration.
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RNA used in the SI analysis experiments was prepared using the RNAzol 
technique. The RNA and double-stranded labelled DNA. probe were mixed 
together and freeze dried. The freeze dried pellet was then 
dissolved in 10(11 of formamide hybridisation buffer (80% formamide, 
0.4M NaCl, 0.04M PIPES (piperazine-N^N^-bis [Z-ethanesulfonic acid] ; 
1,4-piperazine-diethanesulfonic acid) pH6.4 and ImM EDTA pH8.0) which 
was overlayed with 20|ll of light liquid paraffin. This tube was 
incubated at 90 to 100°C for 10 minutes and then transferred to a 
water bath set at 44°C where it was incubated overnight. The 
following day 235(11 of ice-cold SI buffer (0.25M NaCl, 0.03M sodium 
acetate pH4.6, ImM ZnSO^ and 200(lg/ml sheared salmon sperm DNA) was 
added to the tube which was then incubated on ice after mixing the 
solutions together. To this tube, 100 units of SI (BCL) were added 
and the tube incubated at 37°C for 30 minutes. Following this 
incubation the reaction mix was mixed with an equal volume of 
phenol-chloroform (1:1 ratio, saturated with 1 x T.E.) and then spun 
for 5 minutes in an eppendorf 5415 centrifuge. The aqueous phase was 
placed in a fresh 1.5ml test-tube and the nucleotides were 
precipitated with 2 volumes of 100% ethanol, 0.2M sodium acetate in 
the presence of 10|ig yeast RNA carrier. This tube was incubated at 
-80°C for 10 minutes and the nucleic acids pelleted by spinning for 
10 minutes at 4°C in an eppendorf centrifuge. The pellet was given a 
wash with 70% ethanol and freeze dried for 15 minutes and redissolved 
in a 4|Jl of 1 x T.E.. This was mixed with 4)Jl of formamide dye mix 
(95% (v/v) formamide, 0.1% (w/v) Xylene cyamol FF, 0.1% (w/v)
bromophenol blue) and the mixture heated at 90°C for 3 minutes. The 
samples were then electrophoresed through a denaturing polyacrylamide 
gel. Following electrophoresis the polyacrylamide gel was dried and
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autoradiographed with Kodak X-AR or X-S X-ray film using Cronex 
"lightning plus" intensifying screens in Harmex X-ray cassettes. 
After exposure at -70°C the films were developed in a Kodak Ms-IA
automatic X-ray processor.
2.6.5. Primer extension analysis.
The oligonucleotide used in the primer extension assays (352) was
32end-labelled with gamma- P-ATP using polynucleotide kinase in a 
similar fashion to that described in sub-Section 2.6.4. The labelled 
oligonucleotide was ethanol precipitated in the presence of yeast 
carrier tRNA and electrophoresed through a denaturing polyacrylamide
gel. Following electrophoresis the gel was exposed to a Kodak X-AR
film for 1 to 3 minutes which was then developed in a Kodak Ms-IA
automatic X-ray processor. The polyacrylamide gel fragment 
containing the labelled oligonucleotide was incubated in lxT.E. at 
37°C overnight which elutes the labelled oligonucleotide from the 
gel. The oligonucleotide containing T.E. was extracted with 
phenol-chloroform and the oligonucleotide ethanol precipiated in the 
presence of yeast tRNA.
The required amount of RNA was freeze dried and the pellet was
resuspended in 8(11 of lOirM Tris HC1 pH7.9, ImM EDTA PH8.0 containing 
the end-labelled oligonucleotide. To this solution 2|Ul of 1M Tris 
HC1 pH7.9/ 400mM EDTA pH8.0, 1.25m KC1 was added. This was incubated 
at 65°C for 60 minutes to bind the primer to the RNA. This was
brought to roan temperature and diluted with 25pl of 1 x reverse
transcriptase buffer (20mM Tris HC1 pH8.7, lOmM MgCl2, 5mM DTT,
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10pg/ml actinomycin D and 0.5mM dNTPs) and 10 units of reverse 
transcriptase (BCL) were added. This mxiture was incubated at 42°C 
for 60 minutes. Following this incubation the reaction mix was 
precipitated with 300|H of 100% ethanol and incubated at -20°C 
overnight. The following day the nucleic acids were pelleted by 
centrifugation for 10 minutes at 4°C in an eppendorf 5415 centrifuge 
and the pellet washed with 70% ethanol. The pellet was freeze dried 
and then dissolved in 4|ll of formamide dye mix (sub-Section 2.6.4.) . 
This mixture was electrophoresed through a denaturing polyacrylamide 
gel which was then dried. The dried gel was autoradiographed as 
previously described (sub-Section 2.6.4.).
2.7. Analysis of DNA-Protein Interactions.
2.7.1. Preparation of nuclear protein extracts from cultured animal 
cells.
This protocol was carried out with slight modification (353) to that
described by Emerson and Felsenfeld (354) . Prior to harvesting,
2cells for nuclear protein extract preparation were grown in 800cm 
plastic roller bottles (4 to 8 bottles were used for each 
preparation) . The cells were removed from the roller bottles by 
treatment with glass beads. The medium was poured off and several 
hundred glass beads (2-3mm in diameter) were added to the roller 
bottle which retained a small amount of medium and the bottle rotated 
gently. The rubbing of the glass beads detaches the cells from the 
plastic, and they were collected in a centrifugation bottle along 
with the remaining medium. The cells were then pelleted by
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centrifuging at 2,000 r.p.m. (560xg) for 15 minutes at 4°C in an IEC 
Centra-8R centrifuge. The cells were then resuspended in 200ml of 
PBS + protease inhibitors (0.5mM phenyl methylsulfonyl flouride, 
0.5mM benzamidine, l(jg/ml pepstatin A, lfig/ml aprotinin and lpg/ml 
leupeptin) and then pelleted as before. The cells were lysed by 
resuspending them in 200ml of TMS (0.13M sucrose, 2.5mM MgCl2 and 5mM 
Tris HC1 pH7.5) + 0.25% triton + protease inhibitors + O.lmM EGTA 
pH7.9. The nuclei were then pelleted by centrifuging as before and 
then washed twice with 200ml of TMS + protease inhibitors + O.lmM 
EGTA pH7.9. After pelleting the nuclei following the second wash 
they were resuspended in 100ml of TMS + protease inhibitors + O.lmM 
EGTA pH7.9. Aliquots of the resuspended nuclei were taken and 
sonicated in the presence of 1.0M NaOH. The DNA concentration of 
this solution was estimated and following pelleting of the intact 
nuclei, they were resuspended in TMS + protease inhibitors + O.lmM 
EGTA pH7.9 to an equivalent concentration of 5 to lOmg/ml DNA. To 
this suspension 4M NaCl was added dropwise to a concentration of 
0.35M while the suspension was sitting on ice. This solution was 
then centrifuged in a Sorvall RC-5B Superspeed centrifuge using an 
S5-34 rotor at 17,000 r.p.m. for 20 minutes at 4°C. The supernatant 
was removed and centrifuged in an IEC/860 Ultracentrifuge using an 
SB-405 rotor at 35,000 r.p.m. for 60 minutes at 4°C. The supernatant 
was removed and mixed with ammonium sulphate (3.4g per 7.5ml) and 
incubated for 60 minutes on ice. This mixture was then centrifuged 
in a Sorvall RC-5B Superspeed centrifuge using an S5-34 rotor at 
17,000 r.p.m. for 30 minutes at 4°C. The resulting pellet was then 
resuspended in E^q buffer (50mM ammonium sulphate, 20mM Hepes pH7.9, 
5mM MgCl2, O.lmM EDTA pH8.0, 0.1% Brij 35 (Sigma), O.lmM DTT,
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protease inhibitors and 20% glycerol (v/v)) to a concentration of 4 
to 5 ml to lOOmg DNA (previously calculated) . This solution was then 
dialysed overnight at 4°C against 1 litre of storage buffer (50mM 
NaCl 20mM Hepes pH7.9, 5mM MgCl2, O.lmM EDTA pH8.0, ImM DTT, protease 
inhibitors and 20% glycerol (v/v)) . The following morning the 
solution was centrifuged in an IEC/B60 Ultracentrifuge using an 
SB-405 rotor at 35,000 r.p.m. for 60 minutes at 4°C and the resulting 
supernatant aliquoted into 1.5ml test-tubes and stored at -70°C.
2.7.2. Gel mobility shift assay.
This assay was based on that carried out by Strauss and Varshavsky
(355) . Double-stranded oligonucleotides (200ng) containing putative
DNA binding sequences for nuclear proteins were labelled with 20uCi 
32of gamma- P-ATP using polynucleotide kinase (sub-Section 2.6.4.). 
Following incubation at 37°C for 30 minutes the labelled 
oligonucleotides were ethanol precipitated in the presence of yeast 
tRNA and then electrophoresed through an 8% neutral polyacrylamide 
gel. Following electrophoresis the gel was exposed to a Kodak X-AR 
film for 1 to 3 minutes which was then developed in a Kodak ME-1A 
automatic X-ray processor. The polyacrylamide gel fragment 
containing the labelled oligonucleotide was incubated in 1 x T.E. at 
37°C overnight which elutes the labelled oligonucleotide from the 
gel. The following morning the acrylamide was removed from the T.E. 
which then contained the labelled oligonucleotide in solution.
In the gel mobility shift assay itself lfll of the labelled 
oligonucleotide was incubated with 4-5|H of the nuclear protein
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extract (2.7.1.) along with 3fig of poly (dl-dC) (Pharmacia) and lOOng 
of any competitor oligonucleotide to be used. The reaction was made 
up to 25pl with retard buffer (lOmM Tris HC1 pH7.5, 50mM NaCl, 5mM 
MgC^A ImM DTT, ImM EDTA pH8.0 and 5% glycerol (v/v)) . The reaction 
mixture was incubated at room temperature for 15 to 20 minutes and 
then electrophoresed through a 4-5% neutral polyacrylamide gel. 
Following electrophoresis the gel was dried and autoradiographed with 
Kodak "X-AR" or "X-S" X-ray film using Crone "lightning plus" 
intensifying screens in Harmer X-ray cassettes. After exposure at 
-70°C the films were developed in a Kodak ME-1A automatic X-ray 
processor.
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3.1. Construction of c-fos-CAT Hybrid Plasmids.
To analyse the transcriptional activation of the human c-fos gene 
c-fos-CAT hybrid plasmids were made which contained the CAT gene with 
various c-fos upstream sequences inserted to drive the transcription 
of the CAT gene. These constructs were then used in transfection 
experiments to identify enhancer sequences and/or stimulus responsive 
sequences.
Figure 3 shows the CAT containing plasmid used for the construction 
of the c-fos-CAT hybrid plasmids, pB9, and also details sequences 
upstream from the c-fos promoter previously identified as having a 
role in the transcriptional control of this gene. pB9 contains a 
promoterless CAT gene which contains several unique restriction 
enzyme sites (shown in Figure 3) that were employed to make 
recombinant constructs.
3.1.1. Construction of pB9+fpl400, pB9+fp402 and pB9+fp!16.
Figure 4 shows the construction of these recombinants in a flow 
diagram. The blunt-ended Nael fragment from the c-fos gene (-1400 to 
+42 in Figure 1) was isolated following a Nael digestion of 
pc-fos(human)-1 (11), electrophoresis through a 1% agarose gel and
then phenol extraction of the fragment from the agarose. pB9 was 
digested with BamHI and the overhanging ends filled in by a Klenow 
enzyme reaction to give a linearised plasmid with blunt ends. This 
linearised pB9 DNA was then treated with calf intestinal phosphatase 
to prevent self-ligation in any ligation reactions. The c-fos Nael
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Figure 3. Sequences and recombinant used in the construction of
c-fos-CAT hybrid plasmid constructs.
A. This figure details the upstream sequences of the c-fos gene 
which have been previously identified or postulated as having 
roles in the transcriptional control of this gene (1.6.). The 
restriction enzyme sites shown are the ones used in the cloning of 
these sequences upstream of the CAT gene present in pB9, details 
of which are given in the text. The numbers represent the 
position of the sequences, in bp, relative to the CAP site (+1) . 
SCM RE : sis-conditioned medium response element. SRE : serum
response element. AP-l/ATF : activator protein 1/adenovirus
transcription factor binding site.
B. A representation of pB9 which contains a promoter less CAT gene. 
The restriction enzyme sites shown are those used in the synthesis 
of the various c-fos-CAT constructs described in the text. This 
plasmid was a gift from Dr. J. Lang and was derived by deletion of 
the promoter present in pLW2 (356).. airp : ampicillin resistance 
gene.
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Figure 4. Construction of the c-fos-CAT recombinants
pB9+fpl400,pB9+fp402 and pB9+fp!16.
The construction of these recombinants is described in detail in the 
text. All of the reactions mentioned (restriction enzyme digestion, 
Klenow treatment, phosphatase treatment, ligation) are described in 
Section 2.4.1. amp : ampicillin resistance gene. A : BHI digestion, 
Klenow filled in, treated with CIP. B : Deletion of the SII to SII
fragment. C : Digestion with XIII and HII, Klenow filled in, ligated 
together. SII i Sstll. XIII i Xroalll. XI z Xbal. BHI z Bam HI. 
HII : HincII. HI 11 : Hind III. These constructs are not drawn to
scale.
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fragment was then inserted into this construct in a ligation reaction 
to give pB9+fpl400 (fos promoter and 1400bp of upstream sequence) . 
The orientation of the inserted fragment was determined by 
restriction endonuclease analysis.
Two further c-fos-CAT recombinants were made by deleting fragments 
from pB9+fpl400. First, pB9+fp402, which retains all previously 
identified transcriptional control elements, was made by deleting the 
Sstll fragment from pB9+fpl400 (-1300 to -402 in Figure 3) . The DNA 
of pB9+fpl400 was digested with Sstll and the fragments separated on 
an agarose gel. The residual CAT-containing plasmid DNA was isolated 
from the agarose gel by the phenol extraction method. The ends of 
this DNA were then self-ligated to form pB9+fp402. Second, 
pB9+fpll6, in which all previously identified transcriptional control 
elements (apart from those involved in basal promoter activity) have 
been deleted, was made by deleting from the Xmalll site 116bp 
upstream from the c-fos CAP site to the HincII site 6bp 5' of the 
BamHI site in pB9. HincII generates blunt ends upon digestion of 
DNA, but Xmalll creates overhanging ends which were filled in by a 
Klenow enzyme reaction. This gives a blunt-ended linear recombinant 
and the ends were ligated together to form pB9+fpll6. This construct 
was sequenced using Sequenase enzyme and this sequence is shown in 
Figure 5. The c-fos and CAT sequence shown in this Figure agrees 
100% with previously published sequences (12, 361) .
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A C G T
A  TCATTCATAAAACGCTTATAAAAGCAGTGGCTGCGGCGCCTCGTACTCCAACCGCA T CT 
FOS TCATTCATAAAACGCTTATAAAAGCAGTGGCTGCGGCGCCTCGTACTCCAACCGCATCT
GCAGCGAGCAACTGAGAAGCCAAGACTGAGCC GATCCG TCGAGAATTTT B 
FOS GCAGCGAGCAACTGAGAAGCCAAGACTGAGCC
C A T  TCGAGAATTTT
Figure 5. Sequence of pB9+fp!16.
4(jg plasmid DNA. was denatured as described in Section 2.4.5. The 
denatured plasmid was then annealed with the reverse Universal primer 
and sequenced as instructed in the Sequenase kit (343). Following 
the termination of the sequencing reactions the reactions were then 
electrophoresed through a 5% denaturing polyacrylamide gel which was 
then dried and autoradiographed. The sequence from A to B is shown 
and compared with previously published c-fos and CAT sequences.
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3.1.2. Construction of c-fos-CAT recombinants with inserted
oligonucleotides.
A common method used to analyse the role of short DNA elements 
thought, or known to be involved in transcriptional control is to 
insert oligonucleotides containing the sequence of interest upstream 
from a promoter and a reporter gene and then analyse in transfection 
studies the influence the inserted oligonucleotide has upon the 
transcription of the reporter gene from the promoter. This method 
was used to study the effects of sequences upstream from the c-fos 
promoter. A schematic diagram of how these oligonucleotides were 
inserted upstream from the c-fos promoter is given in Figure 6. 
pB9+fp402 was digested with Xmalll and then Hindi 11 and the digestion 
mixture ran on an agarose gel. The linear recombinant with the 
Hindi 11 to Xmalll fragment deleted was isolated by the Geneclean 
method (2.2.3.b)). Pairs of complementary oligonucleotides 
representing the sequences to be investigated were synthesised with 
Hindi 11 and Xmalll compatible ends. These were then ligated into the 
pB9+fp402 Hindi 11 to Xmalll deleted linear recombinant to give a 
construct containing the c-fos promoter upstream of the CAT gene with 
the oligonucleotide inserted 116bp upstream from the c-fos CAP site. 
This mehtod of construction had two advantages over previously 
published experiments where oligonucleotides inserted had similar 
restriction enzyme compatible ends.
1) Only a single copy of the oligonucleotides will be inserted 
upstream from the c-fos promoter.
2) The oligonucleotide inserted will be in a known
orientation.
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Figure 6. A schematic diagram representing the insertion of 
oligonucleotides upstream from the c-fos promoter in c-fos-CAT hybrid 
recombinants.
This diagram represents the insertion of oligonucleotides containing 
transcriptional control sequences upstream of the c-fos promoter in 
c-fos-CAT recombinants. The sequences of the oligonucleotides and 
names of individual constructs are given in Figure 7. All of the 
reactions mentioned (restriction enzyme digestion, ligation) are 
described in sub-Section 2.4.1. amp : ampicillin resistance gene.
A : HIII to XIII deletion. HIII : Hindlll. XIII : Xmalll. XI :
Xbal. SII : Sstll. HII : HincII. These constructs are not drawn to 
scale.
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Several constructs were synthesised using this protocol with the 
oligonucleotides inserted containing different sequences. These 
sequences, representation of sequencing gels of the constructs, and 
names of the constructs are all given in Figure 7. Sequencing was 
carried out using the Sequenase enzyme.
3.1.3. Analysis of the transcriptional start site of the parental 
c-fos-CAT construct.
On synthesis of recombinant constructs for transcriptional analysis 
it is important to determine that the construct is initiating 
transcription from the correct position. For this purpose SI and 
primer extension analyses were carried out with RNA prepared from 
IATK cells stably transfected with pCN+fpl400. This construct, 
pCN+fpl400, is based on pB9+fpl400 except it also contains the 
neomycin resistance gene.
The synthesis of pCN+fpl400 is described diagrammatically in Figure 8 
pB9+fpl400 was digested with Hindi 11 and Xbal and the resulting 
fragment containing the c-fos and CAT sequences was isolated from an 
agarose gel using the phenol method. This sequence was then ligated 
into Hindi 11 and Xbal double digested pUN-1 which contains the 
neo-resistance gene inserted into a BamHI site, and the resultant 
recombinant was nameJpCN+fpl400. pUN-1 was synthesised by inserting 
the BamHI fragment containing the neo-resistance gene from p61-C-24 
(a kind gift from Dr. J. Lang) into the BamHI site of pUC18. The 
neo-resistance gene present in p61-C-24 is under the control of a 
thymidine kinase (TEC) promoter, and has a TK polyadenylation site
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Figure 7. The sequence of oligonucleotide containing c-fos-CAT 
constructs.
A:A schematic diagram indicating where the oliginucleotides have been 
inserted with respect to the c-fos promoter.
B:4|ig of the respective c-fos-CAT construct was denatured as 
described in sub-Section 2.4.5. The denatured plasmid was then 
annealed with a 35bp CAT oligonucleotide which anneals 24bp 3' to the 
start of the CAT gene sequence and sequenced as instructed in the
Sequenase kit (343) . Following the termination of the sequencing
reactions the reactions were heated at 65 C for 2 minutes in the
presence of formamide dye mix. The reactions were then
electrophoresed through a 5% denaturing polyacrylamide gel which was 
then dried and autoradiographed. The sequence of the inserted 
oligonucleotides are shown along with representative sequencing gels. 
A to B denotes the sequence from the Hindi 11 to the Xmalll site 
resepctively.
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Figure 8. Construction of pUN-1 and pCN+fpl400.
The construction of these recombinants is described in detail in the 
text. All of the reactions mentioned (restriction enzyme digestion, 
phosphatase treatment, ligation) arerdescribed in sub-Section 2.4.1. 
amp : ampicillin resistance gene neo : neomycin resistance gene. A 
: BHI digestion, CIP treatment. B. HIII, XI double digest. C:
Digestion with HIII, XI followed by isolation of the fragment 
containing the c-fos-CAT sequences. BI : BamHI. HIII : HindiII. XI 
: Xbal. HI I : HincII. SII : Sstll. XIII : Xmalll. These
constructs are not drawn to scale.
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inserted 3' of the gene, all of which is present in the BamHI 
fragment cloned into pUC18.
This construct, pCN+fpl400, was transfected into LATK~ mouse
fibroblasts (2.5.2.) as follows. The cells were plated out at 5x10^
cells 16 to 24 hours prior to transfections. 16 hours after the
addition of the Ca PC>4 precipitate which contained ljig of pCN+fpl400
and 20|ig of genomic carrier DNA per flask the cells were washed with
PBS and refed with medium containing 10% FCS. 36 hours later these
cells were trypsinised from the flask, counted, and replated into 
2
10cm petri dishes with medium containing 800jjg/ml G418 and 10% FCS. 
10 days later G418 resistant colonies were clearly visible and 6 were 
picked, grown up, and assayed for CAT activity (2.6.3.) . There was a 
great deal of variation in CAT activity obtained with the clones and 
RNA was prepared from that which gave the highest CAT activity so 
that analysis of the transcriptional start site of pCN+fpl400 could 
be carried out. This stable clone was called L-fpl400-4. Figure 9 
shows the results of a primer extension analysis experiment with BNA 
prepared from L-fpl400-4. The largest primer extension product 
obtained in this experiment was HObp (estimated by analysis of the 
sequencing reaction run on the same gel) . The size of this product 
is as e^cted if pCN+fpl400 is initiating transcription at the 
correct position. A nunber of other products can also be observed in 
this primer extension analysis experiment which are probably due to 
premature termination of the reverse transcriptase reaction.
To confirm that pCN+fpl400 can initiate transcription at the correct
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Figure 9. Printer extension analysis of RNA extracted from 
L-fpl400-4. "
The CAT sequence oligonucleotide used in the sequencing of 
oligonucleotide containing c-fos-CAT constructs was used in this 
gjsay (see Figure 7) . This oligonucleotide was end-labelled with 
P-ATP using polynucleotide kinase and annealed to 30|ig of RNA 
prepared from L-fpl400-4. This mixture was then treated with reverse 
transcriptase as described in sub-Section 2.6.5. The resulting 
nucleic acids were electrophoresed through a 5% denaturing 
polyacrylamide gel which was dried and autoradiographed. Lanes 1 and 
2 represent reverse transcriptase reactions carried out with 30|lg of 
L-fpl400-4 RNA and 30|ig of yeast tRNA respectively. Lanes 3 to 6 
represent a sequencing reaction (A, C, G, T respectively) carried out 
with Universal primer and control Ml3 DNA which was used as a size 
marker for the primer extension products.
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position SI analysis was carried out with RNA prepared from 
L-fpl400-4 (Figure 10) . The protected fragment obtained with the 
L-fpl400-4 RNA is 302bp in size and this is what is expected if 
pCN+:fpl400 is initiating transcription at the correct position.
In an attempt to characterise the transcriptional start site of other 
c-fos-CAT constructs RNA was prepared from transiently transfected 
CT3 cells. These transiently transfected cells were stimulated with 
serum or TPA after serum deprivation in an identical fashion to the 
experiments described in sub-Section 3.4.2. The cells were 
transfected with 20|Jg of the c-fos-CAT constructs and 10|ig of pLW2 
which was designed to act as a transfection efficiency control. 
Following preparation of the RNA (total cellular) 30|ig was taken and 
used in SI analysis experiments identical to those described in 
Figure 10. The same probe was used in the transient analysis as was 
used for analysis of the L-fpl400-4 RNA. Unfortunately these 
experiments failed to detect CAT transcripts presumably due to the 
instability of this mRNA.
So, the primer extension and SI analyses both show that the parental 
c-fos-CAT construct, pCN+fpl400, is capable of initiating 
transcription from the correct position. In all of the manipulations 
carried out with pB9+fpl400 (from which pCN+fpl400 was derived) to 
generate further c—fos—CAT constructs, the c—fos—CAT junction is not 
affected, so these other constructs should also initiate 
transcription from the correct position.
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Figure 10. SI analysis of L-fpl400-4 RNA..
The probe used in this assay was an end-labelled double-stranded DNA. 
probe. This probe was generated by digestion of pB9+fp402 with 
EcoRI. This?linearised plasmid was then phosphatased and labelled 
with gamma- P-ATP by treatment with polynucleotide kinase. The 
labelled, linearised plasmid was then digested with BssHII and the 
labelled fragment isolated from a neutral polyacrylamide gel. This 
double-stranded DNA probe was then used in SI reactions which are 
described in sub-Section 2.6.4. Following the SI reaction the 
nucleic acids were electrophoresed through a 5% denaturing 
polyacrylamide gel which was then dried and autoradiographed. Lanes 
3 and 4 represent SI reactions carried out with 30fig of yeast tRNA 
and 30|ig of L-fpl400-4 RNA respectively. 32 Lane 2 represents PhiX 
Haelll markers end-labelled with gamma- P-ATP by treatment with 
polynucleotide kinase. Lane 1 shows the undigested probe. Marker 
sizes in bp are given down the right hand side of the figure.
PROBE
302bpF0S-CAT
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3.2.1. Transcriptional activity of fos-CAT plasmid constructs in CT3 
cells.
The purpose of the experiments shown, described and quantified in 
this section was to identify sequences upstream from the c-fos 
promoter that contribute to the transcriptional activity of the c-fos 
promoter. In all of the experiments described in this section 
proliferating CT3 cells in medium containing 10% FCS were transfected 
as described in sub-Section 2.5.2., washed with PBS the following day 
and fed with fresh medium containing 10% FCS. These cells were
harvested 30-36 hours later and protein extracts prepared (2.6.1.) 
for (3-gal assays (2.6.2.) and CAT assays (2.6.3.).
The first experiment compared the degree of transcription obtained 
with several c-fos-CAT hybrid plasmid constructs and this experiment 
is shown in Figure 11 and quantified in Table 1. Comparing the 
results obtained with pB9+fpll6 and pB9+fp402 it can be seen that 
deleting the sequences containing the previously reported enhancer 
elements (190) of the c-fos gene between positions -116bp and -402bp 
reduced transcription between 13- and 24- fold. pB9+fpll6SRE, the 
construct containing the oligonucleotide insertion representing the 
SRE, give 7- to 16- fold greater transcription than pB9+fpll6 and 
this agrees with published results (190) suggesting that the SRE can 
behave as an enhancer of transcription when inserted upstream from 
the c-fos promoter. Interestingly, the construct that contains the 
previously unstudied ATF/AP-l-like sequence, pB9+fpll6ATF, gives a 4- 
to 5- fold greater transcription than pB9+fpll6. pB9+fpl 16SRE-ATF 
increases transcription to levels similar to those obtained with
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pB9*fp402 pB9*fp116
1 2  3 4 5 6 7 8 9 10 11 12
pB9*f p116SRE pB9+fp116ATF PB9+fpH6SRE-ATF
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Figure 11. Transcriptional activity of c-fos-CAT plasmid constructs 
in CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells
transfected with pB9+fp402 (lanes 1 to 6), pB9+fpll6 (lanes 7 to 12), 
pB9+fpll6SRE (lanes 13 to 18), pB9+fpll6ATF (lanes 19 to 24) and 
p B 9+fpl16SRE-ATF (lanes 25 to 30). The experiment shown above is 
quantified in Table 1 and is Experiment B. Experiments A, B and C 
all gave similar results and therefore only one of them is shown in 
this figure. In Experiment B the cells were plated out at 3
different densities prior to transfection. The firgt two lanes with 
each construct represent cells plated out at 5x10 cells per F7g 
flask, the second two 10 cells per F75 and the third part 1.5xl05 
per F75. In Experiment A  the CT3 cells were plated out at 5x10 
cells per F75 and in C at 1.5x10 per F75. 16 to 24 hours later the
transfection cocktail was added to each flask (2.5.2.) and 16 hours 
after the addition of the cocktail cells were washed with PBS and 
then refed with medium containing 10% FCS. 36 hours later the cells 
were harvested. In Experiments A  and B transfection cocktails were 
divided into 2 flasks to form duplicates, and each duplicate sample 
is beside the other in this figure (and also in Table 1) i.e. 1 and 2 
are duplicates, 3 and 4 are duplicates etc. In Experiment C all of 
the samples come from different cocktails. In Experiment A  and B 
7.5|ig of c-fos-CAT plasmid was added to each flask in the 
transfection cockctail along with 10pg of HSV-p-gal plasmid while in 
Experiment C 7.5|lg of each plasmid was added per flask. (3-gal assays 
were performed on aliquots from each extract and a volume from each
extract representing equivalent amounts of (3-gal activity was taken
and used in each CAT assay.
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Table 1. Transcriptional activity of c-fos-CAT plasmid constructs in 
CT3 cells.
This table quantifies the CAT activity obtained in the 
experiments shown and described in Figure 11. Numbers represent the 
percentage of C-chloramphenicol converted to mono-acetylated forms 
in each extract. The fold increase represents the ratio of the 
average percentage conversion (and standard deviation) obtained with 
the c-fos-CAT constructs to that obtained with pB9+fpll6. In 
Experiment B the numbers 1 to 36 correspond to lanes 1 to 36 of 
Figure 11.
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pB9+fpll6SRE. This is not surprising since the fosATF/AP-1 sequence 
increases transcription only 4 to 5 fold and therefore any 
contribution this sequence may make to the transcriptional activity 
of pB9+fpll6SRE-ATF may be masked by the much stronger 
transcriptional activitor, SRE.
So, the previously unstudied fosATF/AP-1 sequence gives a weak (4- to 
5- fold) increase in transcription in comparision to the 
promoter-only construct, pB9+fpll6. To confirm that the 
transcriptional activation is due to the inserted fosATF/AP-1 
sequence and not to the creation of a transcriptional activator due 
to oligonucleotide insertion an identical construct to pB9+fpll6ATF 
was made except for two mutations in the AP-l/ATF like sequence of 
the inserted oligonucleotide (see sub-Section 3.1.2.) . This 
construct, called pB9+fpll6MUT-ATF, was assayed along with pB9+fpll6 
and pB9+fpll6ATF in transfection experiments similar to those 
described previously. These experiments are shown in Figure 12 and 
quantified in Table 2. As predicted, pB9+fpl 16MUT-ATF shows no 
increase in transcription when compared to pB9+fpll6 showing that it 
is the fosAP-l/ATF sequence that is responsible for the 
transcriptional increase obtained with pB9+fpll6ATF.
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p B9«(p 116 pB9*fp116ATF pB9+fpfl6MJT-ATF
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Figure 12. Comparison of transcriptional activity obtained with 
pB9+fp!16, pB9+fp!16ATF and pB9+fpll6MUT-ATF.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fpll6 (lanes 1 to 6), pB9+fpll6ATF (lanes 7 to 
12) and pB9+fpll6MUT-ATF (lanes 13 to 18) . The experiment shown above 
is quantified in Table 2 and is Experiment A. Experiments A  and B 
gave similar results and therefore only one of them is shown in thig 
figure. In Experiments A  and B the CT3 cells were plated out at 10
cells per F75 flask; 16 to 24 hours later the transfection cocktail
was added to each flask (2.5.2.), and 16 hours after the addition of 
the cocktail cells were washed with PBS and then refed with medium 
containing 10% FCS. 36 hours later the cells were harvested. In
both of these experiments transfection cocktails were split into 2 
flasks to form duplicates, and each duplicate sanple is beside the
other in this figure (and also in Table 2) i.e. 1 and 2 are
duplicates, 3 and 4 are duplicates etc. In Experiment A  8fJg of 
c-fos-CAT plasmid was added to each flask in the transfection
cocktail along with 4pg of HSV-|3-gal plasmid while in Experiment B
10|ig and 5|lg respectively were used. (3-gal assays were performed on 
aliquots from each extract and a volume from each extract
representing equivalent amounts of (3-gal activity was taken and used 
in each CAT assay.
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PLASMID CONSTRUCT
pB9+fpll6 pB9+fpll6ATF pB9+fpll6MUT-ATF
1 4.4 7 9.7 13 4.0
2 5.0 8 19.0 14 2 2EXPERIMENT 3 3.9 9 12.6 15 3.0A 4 4.2 10 11.3 16 3.6
5 4.7 11 8.8 17 4.6
6 7.1 12 16.0 18 4.3
AVERAGE
CONVERSION 4.9 12.9 3.6
STANDARD
DEVIATION 1.1 3.9 1.0
FOLD
INCREASE 1.0+\-0.2 2.6+\-0.8 0.7+\-0.2
_ 17.9
4.2 8.2
EXPERIMENT 6.4 15.6 4.5
B 4.9 8.8 1.8
2.6 6.7 2.4
1.8 8.6 3.5
AVERAGE
CONVERSION 4.0 11.0 3.1
STANDARD
DEVIATION 1.8 4.5 1.0
FOLD
INCREASE 1.0+\-0.4 2.8+\-l.l 0.8+\—0.3
Table 2. Comparison of transcriptional activity obtained with 
pB9+fpll6, pB9+fp!16ATF and pB9+f^ll6MUT-ATF.
This table quantifies the CAT activity obtained in the 
experiments shown and descj^bed in Figure 12. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated forms in each extract. The fold-induction 
represents the ratio of the average percentage conversion (and 
standard deviation) obtained with the c-fos-CAT constructs to 
that obtained with pB9+fpll6. In experiment A the numbers 1 to 
24 correspond to lanes 1 to24 of Figure 12.
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In an attempt to determine whether the fosATF/AP-1 sequence complexes 
with AP-1 or ATF protein (s) a series of experiments was carried out 
comparing the fosATF/AP-1 sequence with previously characterised AP-1 
and ATF binding sites .
3.3. Comparison of the fosATF/AP-1 sequence with previously 
characterised AP-1 and ATF sequences.
Two approaches were adopted in an effort to identify the protein 
factor (s) responsible for stimulating transcription from the c-fos 
promoter through interaction with the fos ATF/AP-l-like sequence. 
The first of these approaches was the gel mobility shift (or gel 
retardation) assay which was used to identify protein(s) present in 
HeLaS3 nuclear protein extract able to bind to the fosATF/AP-1 
sequence. An alternative approach was to compare the expression of 
c-fos-CAT constructs containing previously characterised AP-1 and ATF 
sequences in cell lines vhich have widely different levels of AP-1 or 
ATF activity.
3.3.1. Protein binding studies on the fosATF/AP-1 sequence.
Oligonucleotides representing the fosATF/AP-1 sequence, an AP-1 
sequence and an ATF sequence (both taken from the adenovirus type 5 
E3 promoter which had been characterised previously (267) were 
synthesised for use in gel mobility shift assays. The AP-1 and ATF 
sequences, termed E3-AP-1 and E3-ATF, can be seen in 3.1.2. These 
sequences were end-labelled with polynucleotide kinase (2.6.4.) and 
incubated with HeLaS3 nuclear protein extracts, before resolving the
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resultant mixture by polyacrylamide gel electrophoresis. 
Cross-competition between the sequences was carried out by including 
1000-molar excess of cold competitor oligonucleotide in the 
incubation reaction. Figure 13 represents a gel mobility shift assay 
using the three mentioned oligonuceotides and the HeLaS3 nuclear 
protein extract. As can be seen from this figure the fosATF/AP-1 
sequence binds a protein (lane 1) that is specifically competed out 
by its own cold oligonucleotide (lane 2) . The mobility of this 
retarded complex is more similar to that seen with the E3-AP-1 
sequence (lane 5) than that seen with the E3-ATF sequence. However, 
when the E3-AP-1 sequence is used as a competitor for the protein 
binding to the fosATF/AP-1 sequence (lane 3) it seems to shift the 
complex from the mobility of an AP-1 complex to that seen with
E3-ATF. The fos ATF/AP-1 sequence is a poor competitor for the
proteins that bind to the E3-AP-1 sequence (lane 6) and the E3-ATF 
sequence (lane 10) suggesting that it is a weak binding site for one 
of the two proteins, or that it binds a relative of these proteins. 
The pattern of proteins binding to the E3-AP-1 and E3-ATF sequences 
are similar to those previously published (267) as are the
competition results obtained in this figure. In summary, the 
fosATF/AP-1 sequence seems to preferentially bind an AP-1 like 
protein but also seems to be able to bind an ATF like protein when 
the AP-1 proteins are "removed" from the nuclear protein extract by 
competitor AP-1 sequences.
To confirm that the protein forming the complex with the
oligonucleotide containing the fosATF/AP-1 sequence is actually 
binding to the sequence that is similar to AP-1 and ATF a gel
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Figure 13. A  gel mobility shift assay involving the incubation of 
fosATF/AP-1, E3-AP-1 and E3-ATF sequences with HeLaS3 nuclear protein 
extract.
Gel mobility shift assay using end-labelled oligonucleotides 
representing fosATF/AP-1 (lanes 1 to 4), E3-AP-1 (lanes 5 to 8) and 
E3-ATF (lanes 9 to 12) sequences. The oligonucleotides were 
incubated with equivalent amounts of HeLaS3 nuclear protein extract 
for 20 minutes at room temperature before the reaction mixture was 
electrophoresed through a 5%, 0.5xTBE, polyacrylamide gel (2.7.2.). 
Competitor oligonucleotides used are shown above each lane and are 
co-incubated with the labelled oligonucleotide-HeLaS3 nuclear protein 
extract mix. O.lng of probe used per reaction. lOOng competitor DNA 
used in each lane where indicated. No comp : no competitor.
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mobility shift assay was carried out using labelled fosATF/AP-1 
oligonucleotide. This oligonucleotide and one containing the 
fosATF/AP-1 sequence with two mutations in it were used as competitor 
oligonucleotides in increasing concentrations. The sequence of this 
mutated fosATF/AP-1 oligonucleotide is given in sub-Section 3.1.2. 
and is the same sequence that was inserted upstream from the c-fos 
promoter to form the construct pB9+fpll6 MJT-ATF. This experiment is 
shown in Figure 14. As can be seen, when fosATF/AP-1 sequences are 
used as a competitor for binding to the fosATF/AP-1 sequence 
reduction in binding occurs with a 50-fold molar excess and 
elimination of any band representing specific protein binding occurs 
when a 1000 molar excess of this competitor is used. However, the 
mutant fosATF/AP-1 sequence fails to compete even partially for the 
proteins that bind to the fosATF/AP-1 sequence and the complex 
persists even at 2000 molar excess of competitor. This demonstrates 
that the fosATF/AP-l-like motif contributes directly to complex 
formation.
Because the fosATF/AP-1 sequence is adjacent to and continuous with 
the previously described SRE in the endogenous c-fos upstream 
sequence it was important to determine whether complexes can form on 
both elements simultaneously or whether they are mutually exclusive. 
A gel mobility shift assay with labelled oligonucleotides containing 
sequences representing the SRE, fosATF/AP-1 and SRE-ATF (fosATF/AP-1) 
was carried out to answer this question. This experiment is shown in 
Figure 15. Unfortunately the quality of the SRE and SRE-ATF 
containing oligonucleotides was poor resulting in competition of the 
non-specific band (compare the uniformity of the non-specific band in
154
FOS-ATF MUT-FOS-ATF
Q. CL
o  o
°  o  O  °  O  o
2  o o ° 2 S o o °
-BOUND 
-NON-SPECIFIC
1 2 3 4 5 6 7 8  9 10
Figure 14. Competition for the HeLaS3 nuclear protein that binds to 
the fosATF/AP-1 sequence with fosATF/AP-1 and mutated fosATF/AP-1 
sequences.
Gel mobility shift assay using an end-labelled oligonucleotide 
containing the fosATF/AP-1 sequence (lanes 1 to 10) . The 
oligonucleotide was incubated with equivalent amounts of HeLaS3 
nuclear protein extract for 20 minutes at room temperature before the 
mixture was electrophoresed through a 5%, 0.5xTBE, polyacrylamide gel 
(2.7.2.). Competitor oligonucleotides are indicated at the top of 
the figure and the numbers above each lane represent the excess molar 
concentration of competitor used in:each reaction. O.lng of probe 
used per reaction. No coup : no coipetitor.
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Figure 15. A  gel mobility shift assay involving the incubation of 
fosATF/AP-1, SRE and SRE-ATF sequences with HeLaS3 nuclear protein 
extract.
Gel mobility shift assay using end-labelled oligonucleotides 
representing the SRE (lanes 1 to 4), fosATF/AP-1 (lanes 5 to 8) and 
SRE-ATF (lanes 9 to 12) sequences. The oligonucleotides were 
incubated with equivalent amounts of HeLaS3 nuclear protein extract 
for 20 minutes at room temperature before the reaction mixture was 
electrophoresed through a 5%, 0.5xTBE, polyacrylamide gel (2.7.2.). 
Competitor oligonucleotides used are shown above each lane and are 
co-incubated with the labelled oligonucleotide, HeLaS3 nuclear 
protein extract mix. O.lng of probe used per reaction. lOOng of 
competitor DNA used in each lane where indicated. No comp : no
competitor.
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Figure 13 and that seen in Figure 15) . However, several points may 
still be made from this experiment. The oligonucleotide containing 
the SRE sequence binds a protein in the HeLaS3 nuclear protein 
extract to form a complex with a greater mobility shift than that 
obtained with the fosATF/AP-1 containing oligonucleotide (compare 
lanes 1 and 5) . This is expected since the protein that binds the 
SRE sequence, the serum response factor (SRF) is 67kD (206, 207, 208) 
in size whereas the AP-1/ATF family of proteins range in size from 39 
to 47 kD (330). The oligonucleotide containing the SRE-ATF sequence 
forms two protein complexes (lane 9) . The upper one involves the 
binding of the SRF since it is competed out by the oligonucleotide 
containing the SRE sequence. The lower complex would appear to bind 
a portion of the Comdex that forms with the fosATF/AP-1 containing 
oligonucleotide (compare lanes 5 and 9) suggesting that the presence 
of the SRF has an influcence over the protein (s) that can bind to the 
fos-ATF/AP-1 sequence in this oligonucleotide. It might be expected 
that a complex representing both the SRF and the AP-1/ATF like 
protein binding together onto the oligonucleotide containing the 
SRE-ATF sequence would be observed. The failure to observe such a 
complex in Figure 15 may be due to the insensitivity of the gel 
mobility shift technique.
In all three of the gel mobility shift assays described so far 
(Figures 13, 14 and 15) there have been suggestions that the
fosATF/AP-1 sequence is capable of binding more than one protein. In 
Figure 13 it forms two complexes (lanes 1 and 3) similar in mobility 
to those observed with AP-1 and ATF containing oligonucleotides. In 
Figure 14, increasing concentrations of fosATF/AP-1 competitor DNA
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seems to enable the fosATF/AP-1 sequence to bind a number of proteins 
(lane 3) while in Figure 15 the presence of the SRE sequence in the 
SRE-ATF containing oligonucleotide seems to limit the width of the 
complex forming with the fosATF/AP-1 sequence (compare lanes 5 and 
9) . To determine whether, as is suggested by Figure 13, the 
fosATF/AP-1 sequence can form complexes with both AP-1 and ATF-like 
proteins a gel mobility shift assay was carried out in which the 
fosATF/AP-1 containing oligonucleotide was incubated with HeLaS3 
nuclear protein extract and a 1000 molar excess of E3-AP-1 containing 
oligonucleotide was co-incubated. Increasing amounts of either 
fosATF/AP-1 or E3-ATF containing oligonucleotides were also 
co-incubated in this experiment which is shown in Figure 16. As in 
Figure 13 the E3-AP-1 containing competitor oligonucleotide leads to 
the formation of a new complex (compare lanes 1 and 2) . When E3-ATF 
containing oligonucleotide is co-incubated in increasing 
concentrations with the E3-AP-1 containing oligonucleotide competitor 
it conpetes for the protein shifted down the gel by the E3-AP-1 
competitor sequences more efficiently then the fosATF/AP-1 sequence 
containing oligonucleotide. Both competitor DNAs (fosATF/AP-1 and 
E3-ATF) do evenutally compete for this complex although at these 
concentrations (500 molar excess) it would be expected that these 
competitors would abolish formation of the retarded conplex with or 
without the presence of a 1000 molar excess of E3-AP-1 
oligonucleotide. However, this experiment does suggest that the 
E3-AP-1 competitor DNA allows the fosATF/AP-1 sequence to bind a 
protein that is similar to that which forms a complex with the E3-ATF 
oligonucleotide.
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Figure 16. Competition for the HeLaS3 nuclear protein that binds to 
the fosATF/AP-1 sequence by co-incubation with E3-AP-1 and either 
fosATF/AP-1 or E3-ATF containing oligonucleotides .
Gel mobility shift assay using an end-labelled oligonucleotide 
containing the fosATF/AP-1 sequence (lanes 1 to 12) . The 
oligonucleotide was incubated with equivalent amount of HeLaS3 
nuclear protein extract for 20 minutes at room temperature before the 
mixture was electrophoresed through a 5%, 0.5xTBE polyacrylamide gel 
(2.7.2.). In lanes 2 to 12 1000 molar excess of E3-AP-1
oligonucleotide was co-incubated with the reaction mix. Other 
competitor oligonucleotides co-incubated are indicated at the top of 
the figure and the numbers above each lane represent the excess molar 
concentration of the competitor oligonucleotides used in each 
reaction. O.lng probe used per reaction. No comp : no competitor.
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In Figure 13 it can also be seen that the fosATF/AP-1 oligonucleotide 
competes very poorly for the protein that binds to and forms a 
complex with the E3-ATF oligonucleotide even at a 1000 molar excess, 
although the E3-ATF oligonucleotide can completely abolish any 
formation of a complex with the fosATF/AP-1 oligonucleotide. Because 
the competitor concentrations in this experiment were in 1000 molar 
excess it is impossible to determine whether the E3-ATF 
oligonucleotide can compete as efficiently (or identically) as the 
fosATF/AP-1 oligonucleotide for the protein-DNA complex formed with 
the fosATF/AP-1 oligonucleotide. To determine whether this is the 
case a gel mobility shift assay was carried out which used increasing 
concentration of fosATF/AP-1 and E3-ATF oligonucleotides as 
competitor DNAs with labelled fosATF/AP-1 oligonucleotide. This 
experiment is shown in Figure 17. The oligonucleotide containing the 
fosATF/AP-1 sequence competes slightly more efficienctly for the 
protein that forms the complex with the labelled fosATF/AP-1 
oligonucleotide than the E3-ATF oligonucleotide (compare lanes 6 and 
8) . It is also interesting to note that at certain concentrations of 
fosATF/AP-1 competitor oligonucleotide several proteins appear to 
form complexes with the fosATF/AP-1 sequence (lanes 4 and 5) . This 
is similar to the pattern observed in Figure 14, lane 3.
In summary, Figures 13 to 17 indicate that the fosATF/AP-1 sequence 
is capable of binding a protein from a HeLaS3 nuclear protein extract 
that is related to the AP-1/ATF family. Because it forms a complex 
similar in mobility to that formed with the E3-AP-1 oligonucleotide 
it would suggest that the fosATF/AP-1 sequence prefentially binds an 
AP-l-like protein (Figure 13), but can bind a protein and form a
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Figure 17. Competition for the HeLaS3 nuclear protein that binds to 
the fosATF/AP-1 sequence with fosATF/AP-1 and E3-ATF sequences.
Gel mobility shift assay using an end-labelled oligonucleotide 
containing the fosATF/AP-1 sequence (lanes 1 to 12) . The 
oligonucleotide was incubated with equivalent amounts of HeLaS3 
nuclear protein extract for 20 minutes at room temperature before the 
mixture was electrophoresed through a 5%, 0.5xTBE, polyacrylamide gel 
(2.7.2). Competitor oligonucleotides are indicated at the top of the 
figure and the numbers above each lane represent the excess molar 
concentration of competitor used in each reaction O.lng of probe was 
used in each reaction. No comp : no competitor.
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complex similar to that formed with the E3-ATF oligonucleotide when 
AP-1 protein (s) are effectively removed from the nuclear protein 
extract by an excess of E3-AP-1 competitor oligonucleotide. The 
fosATF/AP-1 sequence is a poor competitor for the proteins that form 
complexes with the E3-AP-1 and E3-ATF oligonucleotides, suggesting 
that it is perhaps a weak binding site for which ever protein binds 
to this sequence, or alternatively that it binds a particular member 
of the AP-l/ATF family. To compare the transcriptional activity of 
these sequences with the fosATF/AP-1 sequence the E3-AP1 and E3-ATF 
oligonucleotides were inserted upstream from the c-fos promoter 
(3.1.2.) and transfection experiments carried out to compare the 
contribution that these sequences make to transcription from the 
c-fos promoter.
3.3.2. Comparison of the transcriptional activation obtained with 
c-fos-CAT constructs containing fosATF/AP-1 E3-AP-1 and E3-ATF 
sequences inserted upstream from the c-fos promoter.
Transfection experiments similar to those carried out in Section 3.2. 
were carried out to compare the degree of transcriptional activation 
obtained with pB9+fpll6ATF, pB9+fpll6E3-AP-l and pB9+fpll6E3-ATF 
(3.1.2.). This experiment involved the transfection of these 
constructs into proliferating CT3 cells, washing the cells the 
following morning and growing them for a further 36 hours in medium 
containing 10% FCS before cell harvest. This experiment is shown in 
Figure 18. Once again, pB9+fpll6ATF give 3 to 4 fold greater CAT 
activity than that obtained with pB9+fpll6 which agrees with previous 
results (see Tables 1 and 2) . pB9+fpll6E3-ATF and pB9+fpll6E3-AP-l
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Figure 18. Comparison of the transcriptonal activation obtained with 
c-fos-CAT constructs containing fosATF/AP-1, E3-AP-1 and 
E3-ATFsequences inserted upstream from the c-fos promoter.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fpll6 (lanes 1 to 8), pB9+fpll6ATF (lanes 9 to 
16), pB9+fpll6E3-ATF (lanes 17 to 24) and pB9+fpll6E3-AP-l (lanes 25 
to 32) . The experiment shown here is quantified in Table 3. The 
cells were plated out at 10 per F75 flask. 16 to 24 hours later the 
transfection cocktail was added to each flask (2.5.2.) and 16 hours 
after the addition of the cocktail cells were washed with PBS and 
then refed with medium containing 10% FCS. 36 hours later the cells 
were harvested. In this experiment transfection cocktails were split 
into 2 flasks to form duplicates, and each duplicate sample is beside 
the other in this figure i.e. 1 and 2 are duplicates, 3 and 4 are 
duplicates etc. 10|Jg of c-fos-CAT plasmid was added to each flask in 
the transfection cocktail along with 10|lg of HSV-(3-gal plasmid. 
(3-gal assays were performed on aliquots from each extract and a 
volume from each extract representing equivalent amounts of (3-gal 
activity was taken and used in each CAT assay.
* These CAT assays had incorrect amounts of extract used and are 
therefore not included in Table 3.
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PLASMID CONSTRUCT
pB9+fpll6 pB9+fpll6ATF pB9+fpll6E3-ATF pB9+fpll6E3-AP-l
1 2.0
2 1.5
3 1.1
4 1.4
5 2.9
6 1.3
7 1.4
8 2.6
9 3.9
10 5.9
11 8.5
12 8.0
13 5.3
14 7.3
15 -
16 5.2
17 19.6
18 17.6
19 18.2
20 15.3
21 25.1
22
23 25.1
24
25 24.6
26
27
28
29 21.7
30 27.3
31 12.4
32 18.2
AVERAGE
CONVERSION 1.8 6.3 20.2 20.8
STANDARD
DEVIATION 0.6 1.7 3.8 6.0
FOLD
INDUCTION 1.0+V-0.3 3.5+\—0.9 11.2+V-2.1 11.6+\-3.3
Table 3. Comparison of the transcriptional activation obtained 
with c-fos CAT constructs containing fosATF/AP-1, E3-AP-1 and 
E3-ATF sequences inserted upstream from the c-fos promoter.
This table quantifies the CAT activity obtained in the 
experiment shown.and described in Figure 18. Numbers represent 
the percentage C-chloramphenicol converted to mono-acetylated 
forms in each extract. The fold increase represents the ratio of 
the average percentage conversion (and standard deviation) 
obtained with the c-fos-CAT constructs to that obtained with 
pB9+fpll6. The numbers 1 to 32 correspond to lanes 1 to 32 of 
Figure 18.
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both give 11-fold greater activity than that obtained with pB9+fpll6 
suggesting that the E3-ATF and E3-AP-1 sequences are stonger 
transcriptional activators than the fosATF/AP-1 sequence. This 
correlates with the gel mobility shift assay shown in Figure 3 where 
it can be seen that the fosATF/AP-1 oligonucleotide probably binds a 
member of the AP-l/ATF family of proteins weakly in comparison to the 
complexes formed with the E3-AP-1 and E3-ATF sequences.
So, all of the evidence obtained so far suggests that the fosATF/AP-1 
sequence binds a member of the AP-l/ATF family of proteins and that 
perhaps this protein is distinct from those which form complexes with 
the E3-AP-1 and E3-ATF sequences. In a further effort to indicate 
that the protein binding to the fosATF/AP-1 sequence in gel mobility 
shift assays and activating transcription via this sequence in 
transfection studies is a member of the ATF/AP-1 family of proteins 
transfection experiments were carried out with the murine 
teratocarcinoma cell line, F9. This cell line has previously been 
shown to contain no PEA-1 (the muringe homologue of AP-1) (310)
activity in footprinting studies. Upon differentiation of this cell 
line PEA-1 activity becomes detectable by footprinting experiments 
using the polyoma a-enhancer.
3.3.3. Transcriptional properties of f os-CAT constructs transfected 
into the murine embryonal carcinoma cell line, F9.
The transfection experiments described in this section were carried 
out with F9 cells that were grown in medium containing 10% FCS 
throughout the experiment, and were then harvested and protein
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extracts prepared for p-gal (2.6.2.) and CAT (2.6.3.) assays. Three 
to four times more plasmid than in the previous transfection studies 
was used per flask in these transfection studies because the 
transfection efficiency with F9 cells is lower than that obtained 
with CT3 cells. Figure 19 shows the results obtained with 
transfection experiments carried out with F9 cells, and Table 4 
quantifies these experiments. The striking feature of these 
experiments when cortpared to those carried out with CT3 cells is the 
absence of differential expression of c-fos-CAT constructs containing 
sequences that enhance transcription in CT3 cells when compared to 
the promoter-only c-fos-CAT construct, pB9+fpll6. The possible 
exception to this is pB9+fp402 which gives at best a 2-fold increase 
in CAT activity over that obtained with pB9+fpll6. This is compared 
to a 20-fold increase in CAT activity obtained with transfection 
experiments in CT3 cells. pB9+fpll6E3-AP-l gives no increase in 
transcription over pB9+fpll6 and this was expected since F9 cells had 
previously been shown to lack any AP-1 activity and it is not 
surprising that pB9+fpll6E3-ATF and pB9+fpll6ATF (the construct 
containing the fosATF/AP-1 sequence) did not give any increase in 
transcription since the proteins that bind to these sequences are 
probably members of the same family as the AP-1 proteins. However, 
it had not been previously established that the SRE fails to increase 
transcription in these cells, presumably due to a lack of the SRF. 
The increase in transcription obtained with pB9+fp402 (only 2-fold) 
could be due to another protein (s) contributing towards transcription 
from a previously unidentified cis-acting transcriptional control 
element (s), or it could be that there are low levels of SRF and the 
protein that binds to the fosATF/AP-1 sequence and that these operate
.-j -
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Figure 19. Transcriptional properties of c-fos-CAT constructs 
transfected into the murine teratocarcinoma cell line/ F 9 .
CAT assays carried out with cell extracts prepared from F9 cells 
transfected with pB9+fp402 (lanes 1 to 6), pB9+fpll6 (lanes 7 to 12), 
pB9+fpll6SRE (lanes 13 to 18), pB9+fpll6ATF (19 to 24), 
pB9+fpl16SRE-ATF (lanes 25 to 30), pB9+fpll6E3-ATF (lanes 31 to 36) 
and pB9+fpll6E3-AP-l (lanes 37 to 42). The experiment shown above is 
quantified in Table 1 and represents Experiment B. Experiments A  and 
B gave similar results and therefore only^one of them is represented 
in this figure. In both experiments 10 cells were plated out the 
day before transfection. 3 hours before transfection the cells were 
refed with medium containing 10% FCS. The cocktail was then added 
and 8 hours later removed and the cells were then given a 2 minute 
shock with 15% glycerol and then washed and refed with medium 
containing 10% FCS. The cells were harvested 24 hours later. In 
Experiment B the transfection cocktails were split into 2 flasks to 
form duplicates, and each duplicate sample is beside the other in 
this figure i.e. 1 and 2 are duplicates, 3 and 4 are duplicates, etc. 
In Experiment A  one transfection cocktail was split into 3 flasks to 
form triplicates and another was split into 2 flasks to form 
duplicates. In Experiments A  and B 30|Jg of c-fos-CAT plasmid was 
added to each flask in the transfection cocktail along with 20|jg of 
HSV—B-gal plasmid. (5—gal assays were performed on aliquots from each 
extract and a volume from each extract representing equivalent 
amounts of (5-gal activity was taken and used in each CAT assay.
* These CAT assays had incorrect - amounts of extract used and 
are therefore not included in Table 3.
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Table 4. Transcriptional properties of c-fos-CAT constructs 
transfected into the murine embryonalcarcinoma cell line F9.
This table represents the CAT activity obtained in the 
experintent shown and deserved in Figure 19. Figures represent 
the percentage of C-chl orainpheni col converted to
mono-acetylated forms in each extract. The fold-increase 
represents the ratio of the average percentage conversion (and 
standard deviation) obtained with the c-fos-CAT constructs to 
that obtained with pB9+fpll6. The numbers 1 to 42 correspond to 
lanes 1 to 42 of Figure 19.
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more efficiently when their cis-acting transcriptional control 
elements are the correct distance from the c-fos promoter.
It was of interest to determine whether there were any proteins 
present in the F9 cells that would bind to the AP-l/ATF sequences 
that were transcriptionally inactive in the F9 cells as it could be 
argued that their transcriptional inactivity is not due to the 
absence of an activator protein but due to the presence of a protein 
that binds to these sequences and prevents transcriptional 
activation. For this purpose F9 nuclear protein extracts were made 
and gel mobility shift assays carried out using end-labelled 
oligonucleotides containing the AP-l/ATF sequences. This experiment 
is shown in Figure 20. Surprisingly the fosATF/AP-1, E3-ATF and 
E3-AP-1 sequences all form complexes which can be competed out by the 
corresponding cold oligonucleotide. Unlike the gel mobility shift 
assay with the HeLaS3 nuclear protein extract shown in Figure 13 the 
fosATF/AP-1 sequence seems to bind a protein and form a complex that 
is more like that formed with the E3-ATF sequence than the E3-AP-1 
sequence. This suggests that the proteins in the F9 nuclear protein 
extracts that bind to these sequences may be different from those in 
the HeLaS3 nuclear protein extract. It is surprising that the 
AP-l/ATF sequences form complexes with proteins present in the F9 
nuclear protein sequences since these sequences do not increase 
transcription from the c-fos promoter in transfection experiments 
with c-fos-CAT constructs in these cells (Figure 19 and Table 4). 
There could be two explanations for this observation.
1) The proteins from the F9 nuclear protein extracts that form
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Figure 20. A  gel mobility shift assay involving the incubation of 
fosATF/AP-1, E3-AP-1 and E3-ATF sequences with F9 nuclear protein
extract.
Gel mobility shift assay using end-labelled oligonucleotides 
representing fosATF/AP-1 (lanes 1 and 2), E3-ATF (lanes 3 and 4) and 
E3-AP-1 (lanes 5 and 6) sequences. The oligonucleotides were 
incubated with equivalent amounts of F9 nuclear protein extract for 
20 minutes at room temperature before the reaction mixture was 
electrophoresed through a 5%, 0.5xTBE, polyacrylamide gel (2.7.2.). 
Competitor oligonucleotides used are shown above each lane and were 
co-incubated with the labelled oligonucleotide, F9 nuclear protein 
extract mix. O.lng of probe used per reaction. lOOng of competitor 
DNA used in each lane where indicated. No comp : no competitor.
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complexes with the AP-l/ATF sequences are different from those 
responsible for the transcriptional activation observed in CT3 cells 
transfected with c-fos-CAT constructs containing these sequences. 
These proteins could either prevent binding of transcriptional 
activators, or are themselves transcriptional repressors.
2) The F9 cells had undergone some form of differentiation prior 
to preparation of the nuclear protein extract, thus inducing the 
production of AP-1 like proteins.
The second explanation seems unlikely as the cells were cultured for 
only four days without passaging prior to harvesting and preparation 
of the nuclear protein extract, and the morphology of the cells did 
not change prior to harvesting as would be expected if the cells had 
"spontaneously" differentiated. This period of culture was similar 
to that used in the transfection ejqperiments. To try and establish 
whether the proteins from the F9 and HeLaS3 nuclear protein extracts 
that form complexes with the AP-l/ATF sequences are different gel 
mobility shift assays involving pre-inclubation of the nuclear 
protein extracts with Fos antibodies prior to the gel mobility shift 
reactions were carried out.
3.3.4. Gel mobility shift assays with nuclear proteins extracts 
pre-incubated with Fos antibody.
The proteins that form complexes with AP-1 sequences include Fos 
protein (s) (280, 281, 307 - 309) and it is possible to disrupt the
formation of the complex by pre-incubating the nuclear protein 
extract with a Fos antibody prior to carrying out the gel mobility
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shift reactions. Such an experiment with HeLaS3 nuclear protein 
extract and AP-l/ATF sequences is shown in Figure 21 where the 
protein extracts were pre-incubated with Fos antibody overnight prior 
to carrying out the gel mobility shift assay reactions. As can be 
seen the Fos antibody pre-incubation disrupts the formation of the 
complex with the E3-AP-1 oligonucleotide (lane 2) and this agrees 
with previously published results. However, the inclusion of the Fos 
peptide to which the Fos antibody was raised in the pre-incubation 
with the nuclear protein extract does not seem to reverse the 
disruption of this complex as it has done in previously published 
results (lane 3) . The reason for this is not clear but perhaps the 
Fos peptide has been "inactivated" in some way, perhaps due to 
degradation. The pre-incubation of the extract with the Fos antibody 
does not disrupt the formation of complexes with the E3-ATF or 
fosATF/AP-1 sequences. The lanes in this gel mobility shift assay 
show that the proteins are slightly more degraded than in the 
previous assays, and this is not surprising since the protein 
extracts were incubated overnight at 4°C.
Unfortunately, this experiment proved to be inconsistent when it was 
repeated, and when repeated with F9 and HeLaS3 nuclear protein 
extracts failed to produce a similar result, even with the HeLaS3 
extracts. So, it was impossible to differentiate between the 
proteins from the F9 and HeLaS3 nuclear protein extracts that form 
complexes with the AP-l/ATF sequences.
One further attempt was made to try and establish whether an AP-1 or
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Figure 21. Gel mobility shift assay with HeLaS3 nuclear protein 
extracts pre-incubated with Fos antibody.
Gel mobility shift assay using end-labelled oligonucleotides 
representing E3-AP-1 (lanes 1 to 4), E3-ATF (lanes 5 to 8 ) and 
fosATF/AP-1 (lanes 9 to 12) sequences. Equivalent amounts of HeLaS3 
nuclear protein extract were incubated overnight with or without Fos 
antibody or Fos antibody plus Fos peptide at 4°C. Fos antibody and 
Fos peptide treatment is indicated above the relevant lanes (FOSAB: 
Fos antibody; FOSAB+PEP: Fos antibody plus peptide) . The
oligonucleotides were then incubated with these mixtures at room 
temperature for 2 0  minutes before the reaction mixture was 
electrophoresed through a 4%, 0.5xTBE, polyacrylamide gel.
Competitor oligonucleotides used are indicated above the relevant 
lanes and are co-incubated with the labelled oligonucleotide-protein 
mix. O.lng of probe used per reaction. lOOng of competitor DNA used 
in each lane where indicated. No comp : no competitor.
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an ATF like protein binds to the fosATF/AP-1 sequence. So far the 
evidence has been conflicting with this sequence appearing to form a 
complex with a protein that shows a similar mobility to the complex 
formed with the E3-AP-1 oligonucleotide, but the Fos antibody 
experiment failed to disrupt the complex with the fos-ATF/AP-1 
sequence while disrupting that which formed with the E3-AP-1 
sequence. In order to try and establish whether this sequence binds 
an AP-1 or ATF like protein a gel mobility shift assay was carried 
out with in vitro-translated Fos and Jun proteins.
3.3.5. Gel mobility shift assay with in vitro translated Fos and Jun 
proteins.
The in vitro translated Fos and Jun proteins ( a kind gift from 
Dr. M. Frame) used in this experiment were co-translated in a rabbit 
reticulocyte lysate using RNA transcribed from human cDNAs of fos and 
jun (314) . A gel mobility shift assay using this in vitro translated 
protein is shown in Figure 22. As can be seen the two 
oligonucleotides which contain AP-1 sequences, E3-AP-1 and SRE-AP-1 
(3.1.2.) form complexes with the in vitro translated proteins that 
are stronger than those formed with the other oligonucleotides. The 
SRE-AP-1 sequence seems to form an additional complex to that formed 
with the E3-AP-1 sequence. Because the AP-1 sequence in the SRE-AP-1 
oligonucleotide is different from that in the E3-AP-1 oligonucleotide 
it is difficult to determine whether this additional complex is due 
to the presence of the SRE or the fact that the sequences are 
different. It should also be noted that the mobility of the complex 
formed between the in vitro translated proteins and the AP-1
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Figure 22. Gel mobility shift assay using in vitro translated Fos 
and Jun proteins.
Gel mobility shift assay using end-labelled oligonucleotides 
representing fosATF/AP-1 (lanes 1 and 2), E3-AP-1 (lanes 3 and 4,
lanes 11 and 12), E3-ATF (lanes 5 and 6 ), SRE-AP-1 (lanes 7 and 8 ) 
and SRE-ATF (lanes 9 and 10) sequences. In lanes 1 to 10 equivalent 
amount of in vitro translated Fos and Jun proteins were incubated 
with the oligonucleotides before the mixture was electrophoresed 
through a 5%, 0.5xTBE, polyacrylamide gel (2.7.2.). In lanes 11 and 
12 equivalent amounts of HeLaS3 nuclear protein extract were used in 
the reactions. Competitor oligonucleotides used are shown above each 
lane and are co-incubated with the labelled oligonucleotide-protein 
mix. O.lng of probe used per reaction lOOng of competitor DNA used 
in each lane where indicated. No comp : no competitor.
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sequences is (different from that formed between the HeLaS3 nuclear 
protein extract and these sequences (compare lanes 3 and 7 with lane
11) . The reason for this is not clear. The fosATF/AP-1 sequence 
forms a complex with the in vitro translated proteins although the 
mobility of this complex is much greater than that formed with HeLaS3 
nuclear protein extract. The E3-ATF sequence also forms a complex 
with the in vitro translated proteins that shows a mobility similar 
to that formed with the AP-1 sequences, although the binding is much 
weaker. Interestingly, the SRE-ATF sequence forms a complex with the 
in vitro translated protein that is similar in mobility to the 
complex formed with the AP-1 sequences suggesting that the SRE 
sequence has sane influence upon the formation of this complex since 
the fosATF/AP-1 sequence alone forms a complex that migrates much 
faster.
The experiments described so far have identified transcriptional 
control elements upstream from the human c-fos promoter and have 
attempted to characterise the proteins that bind to these sequences 
in gel mobility shift assays. It was decided to determine whether 
these sequences can activate transcription in response to 
extra-cellular stimuli such as serum or TPA, as has already been 
established for the SRE (185, 200, 201, 203, 204 216 - 218).
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3.4. Identification of transcriptional control elements upstream
from the c-fos promoter that are responsive to serum and TPA 
stimulation.
As described in Section 1.6., treatment of serum-deprived fibroblasts 
with mitogens results in transcriptional activation of the c-fos gene 
(104 - 107) . Transfection studies using plamid constructs containing 
upstream c-fos sequences linked to a reporter gene revealed the 
presence of the SRE 300bp upstream from the c-fos CAP site which can 
respond to various mitogens such as serum, growth factors and phorbol 
esters to activate transcription from the c-fos promoter (185, 200,
203, 216 - 218) . It was decided to further examine the role of the
SRE in the transcriptional activation of the c-fos gene in response 
to serum and TPA. Previous studies had characterised AP-1 sequences 
as being both TPA and serum response elements (see sub-Section
1.6.6.). For this reason the role of the fosATF/AP-1 sequence in the 
activation of transcription from the c-fos promoter in response to 
serum and TPA stimulation was also examined. The possibility of an 
interaction between the proteins binding to the continuous SRE and 
fosATF/AP-1 sequences was also examined.
Transfection studies with the c-fos-CAT constructs described 
previously (see sub-Sect ion 3.1.) were carried out to examine the 
role of various cis-acting DNA elements in the transcriptional 
activation of the c-fos promoter in response to stimulation of 
serum-deprived fibroblasts with mitogens. Once again the CT3 cell 
line was used in these transfection experiments as it is a derivative 
of NIH 3T3 cells which were used (along with BaIb/c-3T3 cells) in
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previous transfection experiments which identified DNA elements 
upstream from the c-fos promoter responsive to serum and TPA 
stimulation. In all of the transfection experiments carried out in 
this section the CT3 cells were plated out 16 to 24 hours prior to 
transfection and grown in medium containing 10% FCS. Sixteen hours 
after transfection the cells were washed with PBS and refed with 
medium containing 0.5% FCS. The cells were then maintained in 0.5% 
FCS for between 36 and 48 hours before stimulation (or not) with 
medium containing 15% FCS or medium containing lOOng/ml TPA with 0.5% 
serum. The cells were then harvested and protein extracts prepared 
for p-gal (2.6.2.) and CAT (2.6.3.) assays.
Before proceeding with transfection experiments Northern blot 
analyses were carried out with ENA prepared from serum deprived CT3 
and HeLaS3 cells stimulated with either serum or TPA to confirm that 
the transcription of the endogenous c-fos gene is increased in 
response to these treatment.
3.4.1. Northern blot analyses of ENA prepared from serum and TPA 
stimulated CT3 and HeLaS3 cells.
The serum stimulated ENA samples used in this section were extracted 
from cells that were serum-deprived by being grown in medium 
containing 0.5% serum for 30 hours (by which time they were 
considered quiescent) prior to stimulation with medium containing 15% 
FCS. The cells were then harvested for ENA preparation at the 
indicated time intervals after addition of this medium. TPA 
stimulation was carried out on both proliferating cells (ie those
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grown in medium containing 10% FCS prior to the TPA stimulation) and 
serum-deprived cells. The method of RNA extraction is detailed in 
each figure legend and described in sub-Section 2 .2 .1 .
Figure 23 shows Northern blots carried out with the serum stimulated 
samples from the CT3 and HeLaS3 cells and probed with a v-fos 
fragment from pFosl (2.3.2.) (A) . The induction of the c-fos mRNA in 
the two cell lines displays similar kinetics to previously published 
results with the induction being both rapid and transient, peaking 
between 30 and 45 minutes and decreasing by 60 minutes and becoming 
undetectable after 120 minutes. The sizes of the bands detected (2.5 
and 2.6kb in CT3 and HeLaS3 samples, respectively) are larger than 
previously reported c-fos mPNA (2.2kb and 2.3kb). The reason for 
this could be that the gels used in the electrophoresis of the ENA 
were small and could have led to inaccuracies in the measurement of 
the size of the bands. Figure 23B shows the same filters used in 23A 
re-probed with (^“inicroglobulin to check that the distribution of the 
ENA between the lanes was equal.
Figure 24A shows Northern blots of ENA sanples prepared from cells 
treated with lOOng/ml TPA. These cells were proliferating (ie were 
growing in medium containing 10% FCS) at the time of stimulation and 
no c-fos induction can be observed in these ENA sanples. This was
not entirely unexpected as previously reported TPA stimulations of 
c-fos expression had on some occasions been carried out on 
proliferating cells (as in Figure 24) and on other occasions on serum 
deprived cells. Presumably this variability is due to the different 
types of NIH 3T3 (or other 3T3 cell types) that were used in the labs
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CT3 HELA S3
A
1 2 3 4 5 6 7
'2.5
1 2 3 A 5 6 7 5
10/0 10 203060120 10/- 01020304560120
B
1 2 3 4 5 6 7
•3.0
12 3 4 5 6 7 6
1.4
10/0 10 203060120 10/-01020304560120
Figure 23. Induction of c-fos expression by serum stimulation of 
quiescent CT3 and HeLaS3 cells.
Northern blot analyses of RNA extracted from serum stimulated CT3 and 
HeLaS3 cells. In A the filters were probed with a lkbp PstI fragment 
from pFosl (v-fos) . The size of the bands are indicated to the right 
of each blot. Figures at the top of each blot represent the lane 
numbers and the figures at the bottom the time in minutes between 
serum stimulation and cell harvest. 10% : RNA extracted from
proliferating cells. In B the filters were re-probed with 
Pp-microglobulin to check the distribution of the RNA between the 
lanes. The RNA used in these blots was prepared using the phenol 
extraction method (2.2.1 a)) . 15|ig of RNA used per lane.
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CT3 HELA S3
1 2 3 4 5 6 7 12 3 4 5 6
10/102030 4560120 10/X) 304560120
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1 2 3 4 5 6 7
3.0
1 2 3 4 5 6
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10/ 1020304560120 10/10304560120
Figure 24. Failure of TPA to stimulate c-fos expression upon 
stimulation of proliferating CT3 and HeLaS3 cells.
Northern blot analyses of RNA extracted from proliferating CT3 and 
HeLaS3 cells stimulated with lOOng/ml TPA. In A the filters were 
probed with a lkbp Pstl fragment from pFosl (v-fos) . The figures at 
the top of each blot represent the lane number and the figures at the 
bottom the time in minutes between TPA stimulation and cell harvest. 
In B the filters were re-probed with f^-microglobulin to check the 
distribution of the RNA between the lanes. The RNA used in these 
blots was prepared using the pheonol extraction method (2.2.1.a)) . 
15|ig of RNA used per lane.
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reporting these conflicting results. Figure 24B shows the same 
filters used in 24A re-probed with [^“niicroglobulin to check that the 
distribution of the RNA. between the lanes was consistent. The next 
step taken was to stimulate serum-derprived cells with medium 
containing lOOng/ml TPA and 0.5% FCS. The cells were made quiescent 
in the same manner as that described for the serum-stimulation 
experiment (Figure 23) . The cells were then treated with the medium 
containing lOOng/ml of TPA (and 0.5% FCS) and RNA prepared from the 
cells at several intervals after the stimulation. The result of this 
experiment, shown in Figure 25A, shows that c-fos expression is 
induced in quiescent fibroblasts after stimulation with lOOng/ml TPA. 
This induction is very similar to previous studies as it peaks 
between 30 and 45 minutes and returns to basal levels after 60 
minutes. The size of the c-fos transcript detected in this 
experiment, 2.3kb, is also similar to previously published results. 
Figure 25B shows the same filter used in 25A re-probed with 
p2 ~microglobulin to check that the distribution of the RNA between 
the lanes was consistent.
Fran these Northern blot results it was established that in the 
transfection studies examining the induction of c-fos expression by 
TPA, the stimulations should be carried out with serum deprived 
fibroblasts.
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0 15 30^560120 0 15 30^560120
Figure 25. Induction of c-fos expression by TPA stimulation of 
quiescent CT3 cells.
Northern blot analysis of RNA extracted from serum deprived CT3 cells 
stimulated with lOOng/ml TPA. In A  the filter was probed with a lkbp 
Pstl fragment from pFosl (v-fos) . The size of the bands are 
indicated to the right of each blot. Figures at the top of the blot 
represent the lane numbers and the figures at the bottom the time in 
minutes between TPA stimulation and cell harvest. In B the filter 
was re-probed with -microglobulin to check the distribution of the 
RNA between the lanes. The RNA used in this blot was prepared using 
the RNAzol method (2.2.1.b)) . 15|ig of RNA used per lane.
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3.4.2. Short-term serum or TPA stimulation of serum-deprived CT3
cells transfected with c-fos-CAT constructs.
In all of the experiments detailed in this section proliferating CT3 
cells were transfected as described in 2.5.2., washed the following 
day and fed with medium containing 0.5% FCS. These cells were left 
for 36 hours and then stimulated with 15% FCS or lOOng/ml TPA as 
described, and harvested at various times thereafter.
A preliminary experiment with CT3 cells transfected with pB9+fp402, 
the c-fos-CAT construct that contains 400bp of intact upstream 
sequence which includes the SRE, is shown in Figure 26. 
Unfortunately this experiment (and others) was not quantified 
although it can clearly be seen that there is no increase in CAT 
activity with serum stimulated samples when compared to serum 
deprived samples. Indeed, the levels of CAT activities are about the 
same in serum-deprived and serum-stimulated cells and in those grown 
in 10% FCS up until cell harvest (+). This suggests that the serum 
deprivation of the CT3 cells has failed to shut down transcription 
from the c-fos promoter. Three reasons were thought of for this 
failure to observe the expected serum response: -
1) The c-fos-CAT construct is defective i.e. it does not 
initiate transcription from the correct position.
2) The cells were not quiescent prior to stimulation.
3) The density of the cells prior to stimulation plays a role
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— — + + + — — + + + — — +
TPA TPA 1 PA
Figure 26. Serum and TPA stimulation of CT3 cells transfected with 
increasing amounts of pB9+fp402.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfecteg with pB9+fp402. 16 to 24 hours after plating the cells
out at 10 per F75 flask the transfection cocktail was added to the 
flasks (2.5.2.). 16 hours after the addition of the cocktail cells
were washed with PBS and then refed with medium containing either 10% 
FCS or 0.5% FCS. All cells were harvested 48 hours later. A 
represents a set of 4 flasks transfected with aliquots from the same 
transfection cocktail, each flask being transfected with 6fig of 
pB9+fp402. Similarly, the flasks in B and C were transfected with 
15|ig and 30|ig of pB9+fp402 respectively. Lanes 1,5 and 9 represent 
extracts from cells grown in 10% FCS (+) whiles lanes 2, 6 and 10
represent extracts from cells grown in 0.5% serum (-). Lanes 3, 7
and 11 represent cells grown in 0.5% serum and treated with medium 
containing 15% FCS for one hour prior to harvest (- +). Lanes 4, 8
and 12 represent cells grown in 10% serum and treated with lOOng/ml 
of TPA one hour prior to cell harvest (+ TPA) . The protein 
concentration of each cell extract was estimated using the Biorad 
Assay (2.6.1.) and equivalent amounts of protein were used in each 
CAT assay.
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in the response of the c-fos-CAT constructs to serum.
Point 1 seems unlikely for two reasons. Firstly, primer extension 
and SI analyses of the parent c-fos-CAT construct, pCN+fpl400 (Figure 
7 and 8, 3.1.3.), demonstrated that the transcription initiation from 
this construct is occuring at the correct position. Secondly, 
transfection with constructs containing the SRE results in a clear 
increase in transcription as compared to constructs lacking this 
sequence (Figure 1, Table 1, 3.2.1.) which is in agreement with
previously published results. Point 2 also seems unlikely since 
serum deprivation for 36 hours has previously been described as 
sufficient to induce quiescence in these cells (104). Also, 
microscrcpic examination of the cells used in these experiments (an 
example of which is shown in Figure 26) showed the serum-deprived 
cells to be less dense than those grown in serum throughout the 
experiment, suggesting that they had stopped growing.
To test the third possibility, that cell density is important in the 
response of the c-fos-CAT constructs to serum stimulation, CT3 cells 
were plated out at three different densities, transfected with 
pB9+fp402 or pB9fpll6SRE, and then either serum-starved or 
serum-starved and then stimulated with medium containing 15% FCS for 
1 hour prior to being harvested. The result of this experiment is 
shown in Figure 27 and quantified in Table 5. In the CAT assays 
carried out with extracts prepared from CT3 cells transfected with 
pB9+fp402 it can be seen that there is no increase in CAT activity in 
serum-stimulated samples as compared to serum-deprived samples at the 
two lower cell densities. At the higher cell density a 2-fold
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pB9*fp1l GSRF
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Figure 27. The effect of cell density upon the serum stimulation of 
c-fos-CAT constructs in serum-deprived CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (1 to 12) or pB9+fpll6SRE (13 tg 24) . 
Cells were plated out at three different densities : A; 5x10 cells
per F75 flask : B; 10 cells per F75: C; 1.5x10 cells per F75. 16
to 24 hours after plating the cells out the transfection cocktail was 
added to each flask (2.5.2.). 16 hours after the addition of the
cocktail cells were washed with PBS and then refed with medium 
containing 0.5% serum. All cells were harvested 36 hours later. 
Transfection cocktails were made and divided between two flasks to 
form duplicates and one flask of cells from each pair remained serum 
deprived until cell harvest (-) while the other was stimulated with 
medium containing 15% FCS for 1 hour prior to cell harvest (-+) . 
7.5|ig of c-fos-CAT plasmid was added to each flask in the 
transfection cocktail along with 7.5|lg of HSV-(3-gal plasmid. P~gal 
assays were carried out on aliquots of the cell extract and 
equivalent amount of p-gal activity were used in each CAT assay.
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PLASMID CONSTRUCT
CELL
DENSITY
pB9+fp402 pB9+fpll6SRE
- -+ - -+
5 x 1 0 ^
1 8.3 
3 10.2
2 11.8 
4 8.9
13 3.5 
15 4.1
14 7.2 
16 11.0
AVERAGE
CONVERSION 9.3 10.4 3.8 9.1
STANDARD
DEVIATION 1.3 1.5 0.4 2.7
FOLD
INDUCTION 1.0+\-0.1 l.l+\-0.2 i.o+\-o.i 2.4+\-0.7
1 x 1 0 6
5 6.1 
7 9.6
6 8.8 
8 12.8
17 3.1 
19 2.2
18 12.3 
20 9.8
AVERAGE
CONVERSION 7.9 10.8 2.7 11.1
STANDARD
DEVIATION 2.1 2.8 0.6 1.8
FOLD
INDUCTION 1.0+\-0.3 1.4+\-0.4 1.0+\-0.2 4.1+\-0.7
1 . 5 x 1 0 6
9 11.0 
10 3.7
10 17.9 
12 11.8
21 1.7 
23 2.0
22 4.7 
24 13.6
AVERAGE
CONVERSION 7.4 14.9 1.9 9.2
STANDARD
DEVIATION 5.0 4:0 0.2 6.1
FOLD
INDUCTION 1.0+\-0.7 2.0+\-0.5 1.0+\-0.1 5.0+\-0.3
Table 5. The effect of cell density upon the serum stimulation 
of c-fos-CAT constructs in serum starved CT3 cells.
This table quantifies the CAT activity obtained in the 
experiment shown and descried in Figure 21. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated forms in each extract. The fold-induction 
represents the ratio of the average percentage conversion (and 
standard deviation) obtained with the serum stimulated samples 
(-+) to the average percentage conversion obtained with the 
corresponding serum deprived samples (-). The numbers 1 to 36 
correspond to lanes 1 to 36 of Figure 27.
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induction of CAT activity is observed with the serum stimulated 
samples, although the standard deviations of the results obtained 
with both the serum-starved and serum-stimulated samples are rather 
large making it difficult to interpret this result and to decide if 
it is significant. However, with pB9+fpll6SRE an increase in CAT 
activity can be observed in serum stimulated samples as compared to 
serum-deprived samples. The fold-increase in CAT activity is 
significant at all cell densities, although the fold-induction of CAT 
activity in the serum stimulated samples increases with increasing 
cell density (2.4 fold-induction at the lowest cell density compared 
to a 5-fold induction at the highest cell density) . So, both 
constructs give results which suggest that the density of the cells 
in the culture into which the c-fos-CAT constructs are transfected 
plays an inport ant role in the detection of a serum response in CAT 
assays carried out with extracts prepared from serum-deprived and 
serum-stimulated cells.
To determine whether other c-fos-CAT constructs were serum 
responsive, a transfection experiment similar to the one described in 
Figure 27 was carried out, the cells being plated out at the highest 
density used in the previous experiment, i.e. 1.5x10^ per F75 flask, 
the day before transfection. The result of this experiment is shown
in Figure 28 and quantified in Table 6. An experiment where the
5 . . . .cells were plated out at 7x10 cells per F25 is also quantified in
Table 6 and represents Experiment B. In Experiment A the results 
obtained with pB9+fp402 confirms that at a high cell density the 
transcription of this construct is induced following serum 
stimulation. However in Experiment B pB9+fp402 failed to show a
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Figure 28. Serum stimulation of c-fos-CAT constructs in high density 
serum deprived CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (1 to 9), pB9fp+116 (10 to 17),
pB9+fpll6SRE (18 to 26), pB9+fpll6ATF (27 to 35) or pB9+fpll6SRE-ATF 
(36 to 44) . The experiment shown above is quantified in Table 6 and 
represents Experiment A. Experiments A and B gave similar results and 
therefore only one of them is represented in ^this figure. In 
Experiment A the cells were plated out at 1.5x10 cells per F75 
tissue culture flask while in Experiment B they were plated out at 7 
10 cells per F25. 16 to 24 hours later the transfection cocktail was 
added to each flask (2.5.2.). 16 hours after the addition of the
cocktail cells were washed with PBS and then refed with medium 
containing either 0.5% FCS or 10% FCS. All cells were harvested 36 
hours later. Transfection cocktails were made and aliquoted into 3 
flasks to form triplicates. One flask from each triplicate was grown 
in serum (10%) throughout the experiment (+), one was serum deprived 
for 36 hours before harvest (-) and the other was serum starved but 
stimulated with medium containing 15% FCS for 1 hour prior to cell 
harvest (-+) . 7.5fig of c-fos-CAT plasmid was added to each flask in 
the transfection cocktail along with 7.5|ig of HSV-p-gal plasmid. 
(3-gal assays were performed on aliquots from each extract, and a 
volume from each extract representing equivalent amounts of (3-gal 
activity was taken and used in each CAT assay.
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Table 6. Serum stimulation of c-fos-CAT constructs in high 
density serum deprived CT3 cells.
This table quantifies the CAT activity obtained in the 
experiment shown and descr:jJ^ ed in Figure 28. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated forms in each extract. The fold-induction 
represents the ratio of the average percentage conversion (and 
standard deviation) obtained with the serum stimulated 
samples(-+) to the average percentage conversion obtained with 
the corresponding serum deprived samples (-) . The numbers 1 to44 
correspond to lanes 1 to 44 of Figure 28. In experiment B 
greater amounts of extract were used with the pB9+fpll6 samples 
leading to the comparatively elevated levels of activity.
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response following serum stimulation which contradicts the results 
obtained in Experiment A. The reason for this is not clear but
perhaps the density of the cells used in Experiment B was too low
preventing pB9+fp402 from showing a serum response. This would agree 
with the results obtained with the experiment shown in Figure 27 
which suggested that only at a high density of cells would pB9+fp402 
show a serum response. In Experiments A and B pB9+fpll6SRE fails to 
show a serum response and this is surprising as in the previous 
experiment (Figure 27) a serum response could be observed with this 
construct, even at a low cell density. The reason for this failure is 
unclear but could be related to the relatively high levels of
activity in the serum deprived samples. This contrasts with
pB9+fpll6SRE-ATF which gives a consistent serum response in both 
experiments. It should be noted that pB9+fpll6SRE-ATF gives a level 
of basal expression in the serum deprived samples that is 2- to 
3-fold lower than that obtained with pB9+fpll6SRE. pB9+fpll6 shows no 
increase in CAT activity in response to serum and this is as expected 
since no serum-responsive cis-acting DNA elements are present in this 
construct. Interestingly, pB9+fpll6ATF is sensitive to serum 
deprivation as in the serum starved samples the level of CAT activity 
is much reduced when compared to that obtained with samples taken 
from cells grown in 10% FCS throughout the experiment. The 
fosATF/AP-1 sequence is not responsive to serum as serum stimulation 
of cells transfected with pB9+fpll6ATF gives no increase in CAT 
activity.
A general feature observed with all the constructs was a reduction in 
transcriptional activity when the cells were serum deprived compared
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Figure 29. TPA stimulation of c-fos-CAT constructs in high density 
serum deprived CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (1 to 6), pB9+fpll6 (7 to 12),
pB9+fpll6SRE (13 to 18), pB9+fpll6ATF (19 to 24), pB9+fpll6SRE-ATF 
(25 to 30) agd pB9+fpll6E3-AP-l (31 to 36). The cells were plated 
out at 1.5x10 cells per F75 tissue culture flask and 16 to 24 hours 
later the transfection cocktail was added to each flask (2.5.2.) . 16
hours after the addition of the cocktail cells were washed with PBS 
and then refed with medium containing 0.5% FCS. All cells were 
harvested 36 hours later. Transfection cocktails were made and 
divided into 2 flasks to form duplicates and one flask of cells from 
each pair remained serum deprived until cell harvest (-) while the 
other was stimulated wiht medium containing lOOng/ml TPA, 0.5% FCS 
for 1 hour prior to cell harvest (- TPA) . 7.5|ig of c-fos-CAT
plasmid was added to each flask in the transfection cocktail along 
with 7.5|ig of HSV-|3-gal plasmid. (3-gal assays were carried out on 
aliquots from each cell extract and in this experiment differing 
amounts of (3-gal activity were taken for CAT assays. Aliquots 
representing 0.11 O.D. (3-gal units were taken from extracts 
representing cells transfected with pB9+fp402, pB9+fpll6SRE, 
pB9+fpl 16SRE-ATF and pB9+fpll6E3-AP-l, while 0.17 O.D.(3-gal units 
were taken from extracts representing cells transfected with 
pB9+fpl 16ATF and 0.25 O.D.(3-gal units were used from extracts 
representing cells transfectea with pB9+fpll6.
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Table 7. TPA stimulation of c-fos-CAT constructs in high density 
serum deprived CT3 cells.
This table quantifies the CAT activity obtained in the 
experiment shown and descried in Figure 29. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated forms in each extract. The fold induction 
represents the ratio of the average percentage conversion (and 
standard deviation) obtained with the TPA stimulated samples 
(-TPA) to the average percentage conversion obtained with the 
corresponding serum deprived samples (-) . The numbers 1 to 36 
correspond to lanes 1 to 36 of Figure 29.
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to the activity obtained with cells grown in 10% FCS throughout the 
experiment. This is not a general feature of all enhancer/upstream 
promoter elements as the HSV-p-gal construct (used an an internal 
control) gives equivalent levels of (1-gal activity in serum-deprived 
and serum-stimulated cells and cells grown in 10% FCS throughout the 
experiment. To determine whether any of the c-fos sequences increase 
transcription from the c-fos promoter in response to TPA stimulation 
of cells an experiment similar to that detailed in Figure 28 was 
carried out. It had been shown previously that with CT3 cells the 
cells must be serum deprived and then TPA stimulated (Figure 24 and
25) to induce the expression of the endogenous c-fos gene and 
therefore in the transfection experiment the cells were treated as 
described for Figure 28 only they were stimulated with medium 
containing lOOng/ml TPA (and 0.5% FCS) for one hour before cell 
harvest. This experiment is shown and described in Figure 29 and 
quantified in Table 7. The transfection efficiency in this 
experiment was poor leading to low levels of (1-gal activity obtained 
in (1-gal assays carried out with aliquots from the transfected cell 
extracts. This resulted in a variation between the c-fos-CAT 
constructs of the amount of (1-gal activity used in the CAT assasy, 
the details of which are given in Figure 29.
The SRE has been resported by other investigators to activate
transcription when cells are stimulated with TPA (185) and so it was
expected that constructs containing this element would give an
increase in CAT activity in response to TPA stimulation. As expected
pB9+fpll6 showed no increase in transcription in response to TPA 
<s
stimul^ion as it contains no putative TPA responsive elements; also
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as expected pB9+fp402, pB9+fpll6SRE and pB9+fpll6SRE-ATF gave a 2 to 
3-fold increase in CAT activity in response to TPA stimulation as 
these constructs all contain the SRE. The fosATF/AP-1 site had not 
been previously reported as being TPA responsive at the time of this 
experiment and here it can be seen that TPA stimulation leads to a 
2.5-fold increase in CAT activity with pB9+fpll6ATF. In this
experiment (Figure 29 and Table 7) the E3-AP-1 sequence, present in 
pB9+fpll6E3-AP-l, does not increase CAT activity upon TPA 
stimulation. Previous experiments identfying AP-1 as being a 
putative TPA responsive element involved the overnight stimulation of 
serum deprived fibroblast cells with TPA (248) and so perhaps it is 
not suprising that this sequence does not respond to TPA after 
stimulation of quiescent fibroblasts for 1 hour.
Several major points can be made from the short-term (1 hour) serum 
and TPA stimulation experiments described so far:
i) Cells must be plated out at a high density prior to
transfection in order to observe a serum response, at least with the 
construct containing the 400bps intact c-fos upstream sequence, 
pB9+fp402 (Figure 17 and Table 5).
ii) Constructs containing the SRE are both serum and TPA
responsive (Figure 28 and 29).
iii) Transcriptional activation of the c-fos promoter by the 
fosATF/AP-1 sequence (present in pB9+fpll6ATF) is shut down in serum 
deprived cells (Figure 28).
iv) In these short-term stimulation experiments the fosATF/AP-1
sequence does not increase transcription in response to serum
stimulation, but does in response to TPA stimulation (Figure 28 and
198
29) .
v) An AP-1 site (present in pB9+fpll6E3-AP-l) does not 
increase transcription from the c-fos promoter in response to a 
short-term stimulation with TPA (Figure 29) .
In Figure 29 the transfection efficiency in the experiment shown was
very low in comparison to other experiments. It was therefore decided
that this experiment should be repeated in order to better
characterise the fosATF/AP-1 sequence as being TPA responsive
folllowing a 1 hour TPA stimulation. For this purpose further
transfection experiments were carried out that were similar to those
carried out in Figures 27 to 29. Transfection cocktails were divided
into three flasks that allowed for a serum deprived sample, a serum
deprived and serum stimulated sample and a serum deprived and TPA
stimulated sample. This allows for a direct comparison between the
serum and TPA stimulated samples. In all of these experiments
pB9+fpll6SRE-ATF was included which acts as a positive control as in
the previous serum and TPA stimulation experiments this construct
gave the highest and most consistent inductions following serum or
TPA stimulation. Two such experiments are shown in Figure 30 in which
the cells were plated out at 2 different densities to determine
whether cell density influences the transcriptional properties of
other c-fos-CAT constructs. Unfortunately an error was made in
14cutting up the plates for counting the amount of C-chloramphenicol 
converted to mono-acetylated forms and so this experiment was not 
quantified. However by examining the CAT assay plates by eye several 
points may be made. The results clearly do not agree with the
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Figure 30. Serum and TPA stimulation of c-fos-CAT constructs in two
densities of serum deprived CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (lanes 1 to 6; A and B), pB9+fpATF (7 to 
14; A and B), pB9+fpll6SRE-ATF (15 to 20; A and B), pB9+f£116E3-ATF
(21 to 26; A and B) and pB9+fpll6E3-AP-l (27^to 32; A and B) . In 
Figure 30A the cells were plated out at 1.5x10 cells per F^5 tissue 
culture flask while in 30B the cells were plated out at 10 per F75 
and 16 to 24 hours later the transfection cocktail was added to each 
flask (2.5.2.) 16 hours after the addition of the cocktail cells were 
washed with PBS and then re fed with medium containing 0.5% FCS ( or
10% FCS in lanes 7 and 8; A and B) . All cells were harvested 36
hours later. Transfection cocktails were made and divided into 3 
flasks to form triplicates. One flask from each triplicate was grown 
in 0.5% FCS up until cell harvest (-), one was serum stimulated with 
medium containing 15% FCS for 1 hour prior to cell harvest (- +), and 
the other stimulated with medium containing lOOng/ml TPA; 0.5% FCS 
for an identical period prior to cell harvest (- TPA) . In lanes 7 
and 8 (A and B) the cells were transfected with aliquots from the 
same cocktail and grown in medium containing 10% FCS until cell 
harvest. lOjig of c-fos-CAT plasmid was added to each flask in the 
transfection cocktail along with 10|ig of HSV-p-gal plasmid. p-gal 
assays were performed on aliquots from each extract, and a volume 
from each extract representing equivalent amounts of f-gal activity 
was taken and used in each CAT assay.
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previous observation that at a high cell density (i.e. when cells are 
plated out at 1.5x10^ cell per F75 flask prior to transfection) a 
serum and/or TPA response can be observed with pB9+fp402 (Figures 27, 
28 and 29) . In this experiment clearly no such responses occur: the
CAT activity is high even in the serum-deprived samples resulting in 
a failure to observe any increase in CAT activity in response to the 
stimulations. This is similar to the results obtained with the 
experiment described in Figure 26. With pB9+fpll6ATF there is also an 
increase in the levels of CAT activity obtained in the serum deprived 
cells in comparison to previous experiments. This increase has 
resulted in a failure to observe any increase in CAT activity by this 
construct following TPA stimulation. The construct which contains the 
SRE and fosATF/AP-1 sequences inserted on an oligonucleotide upstream 
from the c-fos promoter, pB9+fpll6SRE-ATF, is the only construct to 
give an increase in CAT activity in reponse to serum or TPA 
stimulation. The serum response obtained with this construct was 
greater than that obtained with TPA (compare lanes 22 and 25 with 
lanes 23 and 26) and this agrees with studies of the transcriptional 
stimulation of the endogenous c-fos gene where the increase in 
transcription obtained with growth factor or serum stimulation is
greater than that obtained with TPA stimulation (106, 218) . The
A.t
results obtained when the cells were plated out a lower cell density 
prior to transfection were identical to those obtained with the 
higher density (compare Figure 30A with Figure 30B) with 
pB9+fpll6SRE-ATF again being the only construct to give an increase 
in CAT activity upon serum or TPA stimulation. The results obtained 
from the experiment described in Figure 30 are puzzling when Figures 
27, 28 and 29 are considered in which pB9+fp402 gave an increase in
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transcription in response to serum or TPA stimulation, whereas in 
Figure 30 no such response is observed. Also, the shut-down in 
transcription from pB9+fpll6ATF was not as marked as in previous 
experiments, again suggesting that there was a difference between the 
two sets of experiments. Several possibilities were thought of to 
explain these conflicting results.
i) The actual density of the cells upon stimulation with serum 
or TPA may have been markedly different in this experiment in 
comparison to the other. In the experiment shown in Figure 30 the
g
cells plated out at 1x10 per F75 prior to transfection were 30%
confluent prior to serum or TPA stimulation while the cells plated 
x io6
out at 1.5^per F75 were about 40% confluent. These estimations were 
made by eye and are therefore not particularly accurate although they 
may be used as a rough guideline. In the previous experiments (shown 
in figures 27, 28 and 29) no estimation of cell denisty was made
prior to stimulation and cell harvest. It is possible that the cells 
were at different densities prior to stimulation as CT3 cells 
demonstrated variable growth rates throughout this project, possibly 
due to different batches of serum. It is not known whether different 
batches of serum were used in the experiments described in Figures 27 
to 30. The toxicity of the transfection cocktails added to the cells 
may also have varied between experiments leading to varying degrees 
of cell death and hence varying densities of cells prior to 
stimulation.
ii) Perhaps the CT3 cells used in the transfection experiment 
described in Figure 30 were transformed leading to them becoming
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insensitive to serum deprivation. However this seems unlikely as the 
cells used failed to form foci, even when allowed to grow to 
confluence, and they also showed varying growth rates in 10% FCS and 
0.5% FCS with those growing in 10% FCS being more dense than those 
grown in 0.5% FCS suggesting that the cells were sensitive to serum 
deprivation.
iii) Perhaps the density of the cells prior to plating out for 
transfection is important, possibly because it dictates the growth of 
the cells after replating. However, this would seem unlikely as no 
particular attention was given to the density of the cells prior to 
setting up any of the transfection experiments described in Figures 
26 to 30. Basically, the cells were grown until they were 
sub-confluent and taken for re-plating when it was thought they would 
become confluent by the following day if they were not passaged. So, 
the density of the cells prior to plating out for transfection should 
not have been markedly different between experiments.
To determine whether the density of the cells prior to stimulation 
played a crucial role in obtaining an increase in transcription in 
response to serum or TPA with the pB9+fp402 and pB9+fpll6ATF 
constructs several transfection experiments were carried out in which 
the cells were plated out at different densities prior to 
transfection. By this time the CT3 cells were being grown in a 
different batch of serum from that used in any of the previous 
transfection experiments. In this serum the doubling time of the CT3 
cells was greatly reduced in comparison to those obtained with other 
batches of serum. Figure 31 shows an example of one of these
204
pB9>fp4Q2 pB9*f P116ATF
pB9»fo116E 3A P-1pB 9-fp1165R F -A TF
15 15 17 18 19 20 21 22 23 2A 25 26 27 28 29 30 31 32
TPA TPA TPA TPA TPA t p a
Figure 31. Serum and TPA stimulation of c-fos-CAT constructs in high 
density serum deprived CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (lanes 1 to 6), pB9+fpll6ATF (lanes 7 to 
14), p B 9+fpl 16SRE-ATF (lanes 15 to 20), pB9+fpll6E3-ATF (lanes 21 to
26) and pB9+fpll6E3-AP-l (lanes 27 to 32) . The experiment shown 
above is quantified in Table 8 and respresents Experiment B. 
Experiments A, B and C all gave similar results and therefore only 
one of them is represented jln this figure. In Experiment A  the CT3 
cells were plated out at 10 per F75 while in B they were plated out 
at 5x10 cells per F75 and in C at 1.2x10 per F75. 16 to 24 hours
later the transfection cocktail was added to each flask (2.5.2.) and 
16 hours after the addition of the cocktail cells were washed with 
PBS and then re fed with medium containing 0.5% FCS (or 10% FCS in 
lanes 7 and 8) . In Experiments A  and B the cells were harvested 36 
hours later while in C the cells were harvested 48 hours later. 
Transfection cocktails were made and divided into 3 flasks to form 
triplicates. One flask from each triplicate was grown in 0.5% FCS up 
until cell harvest (-), one was serum stimulated with medium 
containing 15% FCS for 1 hour prior to cell harvest (- +), and the 
other stimulated with medium containing lOOng/ml TPA; 0.5% serum for 
an identical period prior to cell harvest (- TPA) . In lanes 7 and 8 
the cells were transfected with aliquots from the same cocktail and 
grown in medium containing 10% FCS until cell harvest. In Experiment 
A  5|ig of c-fos-CAT plasmid was added to each flask in the 
transfection cocktail along with 5|ig of HSV-p-gal plasmid while in 
Experiments B and C 10|ig of each plasmid was added per flask. f^-gal 
assays were performed on aliquots from each extract, and a volume 
from each extract representing equivalent amounts of [1-gal activity 
was taken and used in each CAT assay.
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Table 8. Serum and TPA stimulation of c-fos-CAT constructs in 
high density serum-deprived CT3 cells.
This table quantifies the CAT activity obtained in the 
experiments shown and descjjbed in Figure 21. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated forms with each extract. The fold induction 
represents the division of the average percentage conversion 
(and standard deviation) obtained with the serum stimulated (-+) 
and the TPA stimulated (-TPA) samples by the average percentage 
conversion obtained with the corresponding serum deprived 
samples (-) . The numbers 1 to 38 correspond to the lane numbers 
in Figure 30.
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transfection experiments while three independent experiments are 
quantified in Table 8. It is clear that the results obtained with 
the experiment shown in Figure 31 and quantified in Table 8 are 
similar to those shown in Figure 30 i.e. the previously observed 
increase in CAT activity in response to serum or TPA stimulation of 
transfected cells (Figure 27 to 29) was not seen with pB9+fp402,nor 
was the transcriptional shut-down or TPA stimulation of pB9+fpll6ATF 
observed. Once more pB9+fpll6SRE-ATF gave an increase in CAT 
activity in response to both serum or TPA stimulation with serum 
providing the greater stimulation as predicted. In Experiment A and 
C described in Figure 31 the cells were confluent prior to 
stimulation and harvest while in Experiment B the cells were 
sub-confluent. This would suggest that the density of the 
transfected cells prior to stimulation was not a crucial factor in 
obtaining an increase in CAT activity with the c-fos-CAT constructs 
in response to serum or TPA stimulation. The failure to repeat the 
serum or TPA stimulation of pB9+fp402 or to observe the complete 
transcriptional shut-down with pB9+fpll6ATF contradicts previous 
experiments. The major difference between the earlier and later 
experiments was that a different batch of serum was used in both sets 
of experiments which may have resulted in the anomalous results. 
These results therefore failed to confirm the fos ATFEAP-1 sequence 
can activate transcription from the c-fos promoter following a 1 hour 
TPA stimulation. The failure to observe such an induction in the 
latter experiments could be explained by the comparitively high 
levels of CAT activity in the serum deprived cells masking any 
increase in CAT activity following a 1 hour stimulation with TPA.
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3.4.3. Overnight serum or TPA stimulation of CT3 cells transfected
with fos-CAT constructs.
As described in 3.4.2. it had become impossible to obtain an increase 
in CAT activity with the c-fos-CAT constructs (apart from 
pB9+fpll6SRE-ATF) in response to serum or TPA stimulation of 
transfected, serum deprived CT3 cells. The reason for this failure 
is unclear but stems from the base level CAT activity prior to 
stimulation being too great, thus apparently masking any increase in 
transcription that may be occuring due to serum or TPA stimulation. 
To get round this problem it was decided that the transfected, 
serum-deprived CT3 cells should be stimulated with serum or TPA for 
12 hours prior to cell harvest. This length of stimulation has been 
used previously to identify AP-1 sequences as being responsive to TPA 
stimulation (251) and these experiments also involved the 
transfection of CAT constructs into fibroblasts, and serum 
deprivation prior to stimulation.
The results of transfection experiments in which the length of 
stimulation of serum deprived, transfected CT3 cells was increased to 
12 hours are quantified in Table 9 and shown and described in Figure 
32. Essentially these experiments were identical to the previous 
short-term stimulation experiments, apart from the 12 hour 
stimulations prior to cell harvest. pB9+fp402, the construct with 
402bp of intact c-fos upstream sequence 5' of the CAT gene, 
consistently responded to TPA stimulation over this time period 
giving a 3- to 4-fold increase in CAT activity. However, the serum 
stimulation experiments carried out with cells transfected with this
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Figure 32. Overnight serum or TPA stimulation of serum deprived CT3
cells transfected with c-fos-CAT constructs.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (lanes 1 to 9), pB9+fpll6 (lanes 10 to 
18), pB9+fpll6ATF (lanes 19 to 27), pB9+fpll6SRE-ATF (lanes 28 to 
36), pB9+fpll6E3-AP-l (lanes 37 to 45) and pB9+fpll6E3-ATF (lanes 46 
to 54) . The experiment shown in this figure is quantified in Table 9 
and represents Experiment B. Experiment A, B and C all gave similar 
results and therefore only one of them is represented in thig figure. 
In all three experiments the CT3 cells were plated out at 10 per F75 
flask and 16 to 24 hours later the transfection cocktail was added to 
each flask (2.5.2.) and 16 hours after the addition of the cocktail 
the cells were washed with PBS and then refed with medium containing 
0.5% FCS. The cells remained in 0.5% FCS for 36 hours and any 
stimulations were then given and the cells harvested 12 hours later. 
Transfection cocktails were made and divided into 3 flasks to form 
triplicates. One flask from each triplicate was grown in 0.5% FCS up 
until cell harvest (-), one was serum stimulated with medium 
containing 15% FCS for 12 hours prior to cell harvest (- +), and the 
other stimulated with medium containing lOOng/ml TPA; 0.5% FCS for an 
identical time period prior to cell harvest (- TPA) . In Experiment A 
lOfig of c-fos-CAT plasmid was added to eqch flask in the transfection 
cocktail along with 10|ig of HSV-|3-gal plasmid while in Experiments B 
and C 5(ig of each plasmid was added per flask. |3-gal assays were 
performed with aliquots from each extract, and a volume from each 
extract representing equivalent amounts of p-gal activity was taken 
and used in each CAT assay.
* These CAT assays had incorrect amounts of extract used and are 
therefore not represented in Table 9.
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Table 9. Overnight serum or TPA stimulation of serum deprived
CT3 cells transfected with c-fos-CAT constructs.
This table quantifies the CAT activity obtained in the 
experiments shown and descyjbed in Figure 32. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated forms with each extract. The fold-induction 
represents the division of the average percentage conversion 
(and standard deviation) obtained with the serum stimulated (-+) 
and TPA stimulated (-TPA) samples by the average percentage
conversion obtained with the corresponding serum deprived
samples (-) . The numbers 1 to 54 correspond to the lane numbers 
in Figure 32.
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construct provided inconsistent results. In Experiment A (Table 9) a 
5-fold induction is observed but in the proceeding two experiments no 
such induction was detectable. An increase in CAT activity is also 
obtained in response to serum or TPA stimultion with pB9+fpll6ATF, 
with serum giving a 2- to 3-fold induction and TPA a 2- to 4-fold 
induction. It was expected that TPA stimulation might give an 
increase in CAT activity since short-term stimulation with TPA 
indicated an increase in CAT activity with this construct (Figure 29 
and Table 7) . However, it was not expected that serum would induce 
this construct since in a short-term stimulation experiment no 
increase in CAT activity is observed with pB9+fpll6ATF (Figure 28 and 
Table 6) . pB9+fpll6SRE-ATF once more, as with the short-term 
stimulations, consistently gives the greatest fold-inductions with a 
7-fold increase in CAT activity with serum and a 3- to 4-fold 
increase with TPA. The two "foreign" sequences from the adenovirus 
E3 promoter, E3-ATF and E3-AP-1, both give an increase in CAT 
activity in response to both serum and TPA stimulation when placed 
upstream from the c-fos promoter. These sequences are present in 
pB9+fpll6E3-ATF and pB9+fpll6E3AP-l, giving a 2- to 7- and 2- to 
3-fold increase respectively in CAT activity in response to TPA. 
These results are as expected for pB9+fpll6E3AP-l as the AP-1 
sequence has been previously shown to be responsive to both TPA and 
serum (251, 254) stimulation. However, the results obtained with
pB9+fpll6E3-ATF were rather surprising since it has been shown that 
ATF sequences (although not the one used here) do not respond to TPA 
stimulation, but to cAMP stimulation (256) . Indeed the protein that 
binds to the ATF sequence is very similar or identical to the cAMP 
response element binding protein, CREB (264) .
214
In Experiment B cells were transfected with pB9+fpll6, and stimulated 
with either serum or TPA (after serum deprivation) . As can be seen
from Figure 32 and Table 9, no increase in CAT activity is obtained
with this construct in response to serum or TPA stimulation. This 
shows that any of the effects observed in these experiments in 
response to serum or TPA stimulation are due to the sequences 
inserted upstream from the c-fos promoter.
The overnight stimulation experiments identified several sequences 
that were responsive to both serum and TPA stimulation. 
Interestingly, pB9+fpll6SRE-ATF gave the greatest and most consistent 
fold-inductions in both short-term and long-term stimulation 
experiments. Also in the short term stimulation assays described in 
Figure 28 pB9+fpl 16SRE-ATF gave lower levels of CAT activity than 
pB9+fpll6SRE in the serum deprived cells. These results suggested 
that that there may be an interaction occuring between the proteins 
complexing with the fosATFEAP-1 sequences to influence transcription 
from the c-fos promoter.
3.4.4. Short-term serum or TPA stimulations investigating a possible
interaction between the proteins complexing with the c-fos SRE and
ATF/AP-1 sequences.
The results obtained with the short-term and long-term stimulation 
assays suggested that there may be an interaction between the 
proteins complexing with the SRE and fosATF/AP-1 sequences. Two main 
pieces of evidence suggested that this may be the case:-
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1) As mentioned above, pB9+fpll6SRE-ATF gave lower levels of CAT 
activity in serum deprived cells than pB9+fpll6SRE. This led to a 
more consistent serum and TPA response
2) The two sequences are continuous with one another in the
endogenous c-fos gene sequences with not a ip separating them. This 
is also the case with two other immediate-early genes (192)
suggesting a function for this juxtaposition of transcriptional 
control elements.
Because of these observations transfection experiments were carried 
out to investigate the possibility on an interaction between the two 
(or more) proteins complexing with these sequences.
In order to determine whether the SRE and fosATF/AP-1 sequences
require to be continuous to exert their transcriptional control, two
further c-fos-CAT constructs were synthesised: pB9+fpll6SRE-5bp-ATF
and pB9+fpll6SRE-10bp-ATF. These constructs contain the SRE and 
fosATF/AP-1 sequences separated by the insertion of 5bp and lObp of 
random sequence. Another c-fos-CAT construct was made, 
pB9+fpll6SRE-AP-l, to determine whether the fos-ATF/AP-1 sequence is 
crucial for the transcriptional control exerted by the SRE and 
fosATF/AP-1 sequences. In pB9+fpll6SRE-AP-l the fosATF/AP-1 is 
replaced by a consensus AP-1 binding site. These three constructs, 
along with pB9+fpll6SRE-ATF, were used in transfection experiments 
where the cells were serum deprived as previously described and serum
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Figure 33. Short-term serum or TPA stimulations of cells transfected 
with c-fos-CAT constructs designed to investigate interactions 
between SRF and fosATF/AP-1.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fpll6SRE-ATF (lanes 1 to 9), 
pB9+fpll6SRE-10bp-ATF (lanes 10 to 18), pB9+fpll6SRE-5bp-ATF (lanes 
19 to 27) and pB9+fpll6SRE-AP-l (lanes 28 to 36) . The experiment 
shown in this Figure is quantified in Table 10 and represents 
Experiment B. Experiments A  and B gave similar results and therefore 
only one of them is represented in this Figure. In both of these 
experiments the CT3 cells were split 1 in 5 16 to 24 hours prior to 
transfection. 16 hours after the addtion of the transfection 
cocktail cells were washed with PBS and then refed with medium 
containing 0.5% FCS. The cells were serum starved for 36 hours 
before cell harvest. Transfection cocktails were made and divided 
into 3 flasks to form triplicates. One flask from each triplicate 
was grown in 0.5% FCS up until cell harvest (-), one was serum 
stimulated with medium containing 15% FCS for 12 hours prior to cell 
harvest (- +), and the other stimulated medium containing lOOng/ml 
TPA; 0.5% FCS for an identical time period prior to cell harvest 
(-TPA) . In Experiments A  and B 5fig of c-fos-CAT plasmid was added to 
each flask in the transfection cocktail along with 5fig of HSV-(3-gal 
plasmid. (3-gal assays were performed with aliquots from each 
extract, and a volume from each extract representing equivalent 
amounts of [3-gal activity was taken and used in each CAT assay.
217
PL
AS
MI
D 
CO
NS
TR
UC
T
pB
9+
f
pl
l6
SR
E-
5b
p-
AT
F
-T
PA m o m  
VO (— oo
83
.9
10
.4
m
o
i
H-
rH
CM
mcovo 
m  ^  vo
ON ON ON
rH 1 
CM CM CM
94
.9 1.
7
rH
O
1
+m
to
+
1
io^ r cm
CM ON CO 
o \ t o 76
.7
17
.3
o
1
-f-
ON
rH
ON CO tO
VOOON 
OO ON (—
<3 CO VO 
CM CM CM
85
.7 vo
^r
o
i
H-
co
M1
1
u ir ^ r -
CM lO rH 
to  CM 40
.0
17
.0
O
1
H-o
rH
M 'M T '
<300 
CM rH rH
ONCMlO 
rH CM CM
17
.8 3.
2
CM
<3
1
+
<3
rH
pB
9+
fp
ll
6S
RE
-1
0b
p-
AT
F
-T
PA on to m
rH CO to
to  to 51
.9
vo
vo
VO
O
1
H-
lO
tO^TCM
on m  vo 
r-O N r-
cm toco
rH rH rH
83
.0
vo
ON
oo
<3
1
H-m
VO
+
1
C>VOlO
OOON 
to  to 50
.0 3.
3
m
<3
1
-f-m
ON rH xi*
vo to  vo
r^ ONOO
H ^ r -  
H  rH rH
86
.1
9*6
OO
o
i
H-r-
vo
1
14
.3
 
10
.2
10
.3
11
.6
VO
CM
CM
<3
1
H*
<3
rH 10
 
12
.9
 
13 
12
.3
 
16
 
13
.2
12
.8 0.
5
<3
O1
H-<3
rH
u.
E-»
<
k
C/l
VO
H
H
(X<M
H-
ON
CQ
P«
-T
PA m  to  rH
r-t'^ r<y\ 
CM m  rH 25
.1 7.
7
OO
<31
H-vo
CM
3^* OO rH
r-m^r
mvooN
5.
1 O
CM
<31
H-O
rH
H-1
oo to
tooNm 
vo to  to 59
.6
on
to
VO
<31
H-
CM
VO
rHOOVO
lOCOM* 
m  CM CM
CM LOCO
29
.5 5.
3
rH
rH
1
H-
ON
to
1
to m o
CM (— On 
rH
vo
ON 2.
7
m
<3
1
H-o
rH
o^rr-
tO CM C"- 
rH
<3
to 2.
7
to
<3
1
H-
<3
rH
TR
EA
TM
EN
T 
OF 
CE
LL
S
EX
PE
RI
ME
NT
A
AV
ER
AG
E
CO
NV
ER
SI
ON
ST
AN
DA
RD
DE
VI
AT
IO
N
FO
LD
IN
DU
CT
IO
N
E
XP
ER
IM
EN
T
B
AV
E
RA
G
E
CO
NV
ER
SI
ON
ST
AN
DA
RD
DE
VI
AT
IO
N
FO
LD
IN
DU
CT
IO
N
218
CM
H r o r ^ o o
< <3 • • i
PU 1 vo covo r - H
EH
1
1
0
.1
1
0
.9
1
2
.3
I
’ll 1
.1 +
CM
CM
OCOVO
rococo
“t-
oo
H
Eh
y
H
r> Pu
pi H
Eh 1 t-H CO <7\ cm O
co
a
• « • • • • to
55 M*<OU) CO o 1
O co H- coco cm ■nr 1 M*lOVO to CM
CJ co 1 • • • • +
rH VO CO CO r - VO
Q tH 'q rn o o CO r - <7% CM tO «
EH (X CM CO CO CO
X MH r - rH
CO -E
a PQ
PU a.
1 o r ^ r - rH <j\
CM
o
i
-f-
to  to r ^  
cm ^ 3.
9
1
.2
CO
o
1
-f-
i o -m* to to <z> o
H
o o r- i^ r  
CM CO CO
o
H
Eh 55 tH
EH 55 O 55 o 55
^ c o M M Q O o
a
EH q o O
a d
22 w w M pa co ££ H M
M u o : J?tH tH EH c j  a 3  tH EH
Eh W
2 2
Q < CJ PSPQ
2 2
Q *< O
<  U W Z  M
3 t >
tH W
Q Q pa 55 M  
eh pa
Q  O
a  pu & 2 §
Q055 & 2 § Q  Q  O  55
Eh O pa < C J COQ Cm h pa COQ Pm H
Table 10. Short-term serum or TPA stimulation of cells 
transfected with c-fos-CAT constructs designed to investigate 
interactions between SRE and fosATF/AP-1.
This table quantifies the CAT activity obtained in the 
experiments shown and descj^bed in Figure 33. Figures represent 
the percentage of C-chloramphenicol converted to 
mono-acetylated and di-acetylated forms with each extract. The 
fold-induction represents the ratio of the average percentage 
conversion (and standard deviation) obtained with the serum 
stimulated (-+) and the TPA stimulated (-TPA) samples to the 
average percentage conversions obtained with the corresponding 
serum deprived samples (-) . In experiment B the numbers (1 to 36) 
correspond to the lane numbers in Figure 33.
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or TPA stimulated for 1 hour prior to cell harvest. The results of
such experiments are shown and described in Figure 33 and quantified
in Table 10. Unfortunately, in Experiment A all of the
pB9+fpl 16SRE-ATF samples and the first 2 sets of 3 from the
pB9+fpll6SRE-5bp-ATF samples had a different batch of 
14C-chloramphenicol used in the CAT assays. This batch was less 
active than the batch used for the rest of the experiment and led to 
higher percentage conversions than would have been obtained had the 
second batch been used throughout (for example, compare the results
obtained with the last set of 3 with the first 2 with
pB9+fpl 16SRE-5bp-ATF in Table 10) . However, many points can still be 
made from these experiments, particularly since the standard
deviations were relatively small throughout Experiment B. In the
cells that remained serum deprived throughout these experiments it
can be seen that the constructs which have the insertions between the
SRE and fosATF/AP-1 sequences show an increased level of CAT activity 
when compared to pB9+fpSRE-ATF. The lObp insert increases levels 
approximately 2-fold while the 5bp insert increases it around 3-fold. 
The CAT activity obtained with serum stimulated samples representing 
pB9+fpll6SRE-10bp-ATF and pB9+fpll6SRE-5bp-ATF is greater than that 
obtained with pB9+fpll6SRE-ATF but the inductions are similar because 
the basal levels obtained with pB9+fpll6SRE-10bp-ATF and
pB9+fpl 16SRE-5bp-ATF in the serum deprived samples are greater than 
those obtained with pB9+fpll6SRE-ATF. In response to TPA 
stimulation, pB9+fpll6SRE-10bp-ATF and pB9+fpll6SRE-5bp-ATF give 
fold-inductions of CAT activity that are similar to those obtained 
with serum stimulation. This is different from the results obtained 
with pB9+fpll6SRE-ATF where once again the response to TPA
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stimulation is significantly less than the response to serum 
stimulation. Interestingly pB9+fpll6SRE-AP-l, the c-fos-CAT 
construct which contains the SRE sequence directly beside an AP-1 
sequence, behaves in an almost identical fashion to pB9+fpll6SRE-ATF. 
The levels of CAT activity obtained with the serum deprived samples 
are equivalent and stimulations with serum or TPA gave very similar 
inductions. The results obtained with pB9+fpll6SRE-AP-l suggest that 
the SRF, the protein that binds to the SRE, influences or dictates 
the protein that binds to the AP-1/ATF site beside it.
To determine whether pB9+fpl 16SRE-1 Obp-ATF and pB9+fpl 16SRE-5bp-ATF 
give a greater level of CAT activity in proliferating cells in 
comparison to pB9+fpSRE-ATF a transfection experiment was carried out 
in which the cells were grown in medium containing 10% FCS up until 
cell harvest.
3.4.5. Comparison of the transcriptional activity obtained with
pB9+fpSRE-l Obp-ATF, pB9+fpll6SRE-5bp-ATF and other c-fos-CAT
constructs in proliferating CT3 cells.
A transfection experiment similar to those carried out in Section 
3.2. was carried out to compare the levels of CAT activity obtained 
with various c-fos-CAT constructs. This experiment involved the 
transfections of the constructs into proliferating CT3 cells and 
maintaining these cells in medium containing 10%FCS up until cell 
harvest. This experiment is shown and described in Figure 34 and 
quantified in Table 11. Unfortunately in this experiment the samples 
representing pB9+fpll6 and pB9+fpll6SRE were lost and so the
221
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Figure 34. Comparison of transcriptional activity obtained with 
pB9+fp!16 SRE-5bpATF and pB9+fpll6SRE-10bp-ATF and other c-fos-CAT 
constructs in proliferating CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fpll6ATF (lanes 1 to 6), pB9+fpll6SRE-ATF (lanes 
7 to 12), pB9+fpll6E3-ATF (lanes 13 to 18), pB9+fpll6E3-AP-l (lanes 
19 to 24), pB9+fpll6SRE-5bp-ATF (lanes 25 to 30), lanes 
pB9+fpll6SRE-lObp-ATF (lanes 31 to 36) and pB9+fpll6SRE-AP-l (lanes 
37 to 42). The experiment shown in this figure is quantified in 
Table 11. 16 to^24 hours prior to transfection the CT3 cells were
plated out at 7x10 per F75 tissue culture flask. 16 hours after the 
addition of the transfection cocktail the cells were washed with PBS 
and refed with medium containing 10% FCS. 36 hours later the cells 
were harvested. Transfection cocktails were split between two flasks 
to form duplicates and each duplicate sample is beside the other in 
this figure i.e. 1 and 2 are duplicates, 3 and 4 are duplicates etc. 
lOfig of c-fos-CAT plasmid was added to each flask in the transfection 
cocktail along with 10|ig of HSV— (3-gal plasmid. (3-gal assays were 
performed with aliquots from each extract, and a volume from each 
extract representing equivalent amounts of (3-gal activity was taken 
and used in each CAT assay.
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Table 11. Comparison of transcriptional activity obtained with 
pB9+fpll6SRE-5bp-ATF and pB 9+fp 116SRE-1 Obp-ATF and other 
c-fos-CAT constructs in proliferating CT3 cells.
This table quantifies the CAT activity obtained in the 
experiment shown and descried in Figure 34. The figures 
represent the percentage of C-chloramphenicol converted to 
mono- and di-acetylated forms with each extract. The 
fold-increase represents the ratio of the average conversion 
obtained with pB9+fpll6ATF to all the average conversions and 
standard deviations obtained with the other c-fos-CAT 
constructs. The numbers (1 to 42) correspond to the lane numbers 
in Figure 34.
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experimental results had to be standardised using pB9+fpll6ATF as the 
construct that is least active. This does not enable comparison with 
previous experiments carried out to examine promoter and/or enhancer 
elements upstream from the c-fos promoter (Table 1 and 2), but 
probably more importantly does allow for comparison within this 
experiment. The most striking feature of this experiment is the 
greatly elevated levels of CAT activity obtained with 
pB9+ fpl 16SRE-1 Obp-ATF and pB9+fpll6SRE-5bp-ATF compared to that 
obtained with pB9+fpll6SRE-ATF. These two constructs give 
approximately 3-fold greater CAT activity with the 5bp construct 
giving the slightly higher levels. Indeed, these differences are 
very similiar to those observed when these constructs are assayed for 
CAT activity in cells that have been serum deprived prior to cell 
harvest (see Table 10, particularly Experiment B). From Table 11 it 
can also be seen that pB9+fpll6SRE-AP-l gives a 2-fold greater level 
of CAT activity when compared to the level obtained with 
pB9+fpll6SRE-ATF. This increase is probably due to the AP-1 sequence 
present in the former which is a much stronger transcriptional 
activator than the fosATF/AP-1 sequence (see Table 3).
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3.5. Ela trans-activation of the c-fos gene via upstream sequences.
The Ela gene of adenoviruses codes for one RNA transcript which is 
then processed to form two, therefore producing two proteins called 
12s and 13s (for a review see 257) . The 13s protein contains a 
domain that is responsible for the trans-activation of viral and 
cellular genes, and this domain is deleted from the 12s protein (for 
a review see 258). Previous reports of co-transfection experiments 
with Ela encoding constructs and c-fos-CAT constructs provided 
conflicting results with one report suggesting that sequences around 
the SRE were responsible for the trans-activation of the c-fos gene 
by the Ela 13s protein, while another identified sequences in the 
promoter region as being responsible for the trans-activation (261, 
262) . In an effort determine which of these reports were correct 
transfection experiments were carried out in which c-fos-CAT 
constructs were co-transfected (or not) with plasmid constructs 
coding for the 12s and 13s Ela gene products (kind gifts from Dr. 
N.C. Jones, ICRE, London) (358) . It was also hoped that it would be 
possible to identify exact sequences which were responsive to Ela 13s 
trans-activation.
3.5.1. Co-transfection of Ela 12s and 13s plasmid constructs with 
c-fos-CAT constructs into CT3 cells.
To examine trans-activation by Ela 13s, a transfection experiment 
similar to those described in Section 3.2. was carried out, apart 
from the Ela 12s and 13s plasmid constructs being co-transfected with 
the c-fos-CAT constructs. This experiment is shown and described in
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3B9-*-fp116SRE
p B 9 -f g ‘1i)ATF
17 16 19
12s 12s 12s 
5 5 10
20 21 22 23 24
12s 13s 13s 13s 13s
10 5 5 10 10
pB9*fp116SRE-ATF
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Figure 35. Co-transfection of Ela 12s and 13s plasmid constructs
with c-fos-CAT constructs into CT3 cells.
CAT assays carried out with cell extracts prepared from CT3 cells 
transfected with pB9+fp402 (lanes 1 to 12), pB9+fpll6 (lanes 13 to 
24), pB9+fpll6 SRE (lanes 25 to 36), pB9+fpll6ATF (lanes 37 to 49)
and pB9+fpl 16SRE-ATF (lanes 59 to 60) . Ela plasmids were 
co-transfected with the c-fos-CAT constructs in some of the lanes and 
these are indicated by 12s and 13s written under the relevant lanes. 
The numbers under the 12s and 13s notations indicate the amounts (in 
Mgs) of the Ela plasmid co-transfected. This experiment. is 
quantified in Table 12. The CT3 cells were plated out at 5x10 per 
F75 flask and 16 to 24 hours later the transfection cocktail was 
added to each flask (2.5.2.) and 16 hours after the addition of the 
cocktail the cells were washed with PBS and then refed with medium 
containing 10% FCS. 36 hours later the cells were harvested.
Transfections cocktails were split between two flasks to form 
duplicates and each duplicates sample is beside the other in this
figure i.e. 1 and 2 are duplicates, 3 and 4 are duplicates, etc.
7.5pg of c-fos-CAT plasmid was added to each flask in the 
transfection cocktail along with 10pg of 116V-|3-gal plasmid (and the 
Ela plasmid where indicated) . (3-gal assays were performed with 
aliquots from each extract, and a volume from each extract 
representing equivalent amounts of (3-rgal activity was taken and used 
in each CAT assay.
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Table 12. Co-transfection of Ela 12s and 13s plasmid constructs
with c-fos-CAT constructs into CT3 cells.
This table quantifies the CAT activity obtained in the 
experiment shown and descried in Figure 35. The figures 
represent the percentage of C-chloramphenicol converted to 
mono- and di-acetylated forms with each extract. In this table 
the results obtained with the different amounts of 
co-transfected Ela plasmid constructs have been taken to 
represent equivalent samples as no appreciable difference can be 
detected between the two sets of results. The fold-increase 
represents the ratio of the average conversion obtained with the 
Ela minus samples (-) to the average conversions and standard 
deviations obtained with the samples that had Ela plasmid 
constructs co-transfected. The numbers 1 to 60 correspond to 
lanes 1 to 60 of Figure 35.
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Figure 35 and quantified in Table 12. In this experiment no increase 
in CAT activity is obtained when the Ela 13s construct is 
co-transfected with any of the c-fos-CAT constructs containing the 
SRE (pB9+fp402, pB9+fpll6SRE and pB9+fpll6SRE-ATF) . With the 
construct that has had the SRE and fosATF/AP-1 site removed, 
pB9+fpll6, a 3-fold increase in CAT activity is obtained with the 
samples that were co-transfected with the plasmid coding for the Ela 
13s product. It can be seen that when pB9+fpll6ATF is co-transfected 
with the Ela 13s construct that there is a 2-fold increase in CAT 
activity. It is perhaps not surprising that the Ela 13s protein 
trans-activates the c-fos promoter through the fosATF/AP-1 sequence 
since it can trans-activate through AP-1 and ATF sequences (270), 
which this fos sequence is certainly related to.
The inductions obtained in the experiment shown in Figure 35 are 
rather low in comparison to these previously reported (262) using 
similar c-fos-CAT constructs where pB9+fpll6 would have been expected 
to give a 12-fold increase in CAT activity when co-transfected with 
the Ela 13s plasmid. The reason for this discrepancy soon became 
clear. In a further transfection experiment repeating the 
co-transfection of pB9+fpll6 and pB9+116ATF with Ela plasmid 
constructs it was observed that the HSV-ji-gal plasmid was being 
trans-activated by the Ela 13s gene product. On examination of the 
results obtained the p-gal assays carried out with aliquots from the 
extracts used in Figure 35 it became clear that the HSV-(3-gal plasmid 
was also trans-activated in this experiment.
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3.5.2. Trans-activation of control plasmids by the Ela 13s gene 
product.
Any trans-activation of the transfection efficiency control plasmid 
(such as HSV-(3-gal) is obviously going to lead to inappropriate 
aliquots being taken from the cell extract for use in the CAT assays. 
By the time the trans-activation of the HSV-(3-gal plasmid construct 
was detected several transfection experiments had been carried out 
and the results of the (3-gal assays performed with aliquots of the 
cell extracts from these transfection experiments are shown in Table 
13. After this phenomenon had been identified an identical 
experiment to that described in Figure 35 was carried out using a 
P-gal construct with an SV40 promoter as an internal control (359) 
(HSV-|3-gal was derived from this construct by the insertion of the 
HSV promoter present in pLW2 (356)) . The (3-gal assay results 
obtained with this construct are also given in Table 13 and it can be 
seen that this construct is also trans-activated by the Ela 13s gene 
product. It is difficult to determine whether the trans-activation 
of this construct is less than that observed with HSV-(3-gal since 
only one experiment was carried out with the SV40-(3-gal construct, 
and as can be seen with the results obtained with HSV-(3-gal the 
levels of induction are variable.
In an attempt to obtain a suitable internal control plasmid 
co-transfection experiments were carried out with a further three 
plasmid constructs. These three constructs all contained the human 
growth hormone (HGH) gene with its transcription driven by three 
different promoter. These were the TK (364) (X-globin and PBG
231
PLASMID
CONSTRUCT EXPERIMENT n NO Ela n 12s n 13s
HSV-B-GAL A 20 0.418 20 0.505 20 1.165
FOLD
INDUCTION 1.00 1.24 2.86
HSV-B-GAL B 8 0.137 16 0.078 14 0.211
FOLD
INDUCTION 1.00 0.57 1.50
SV40-B-GAL C 20 0.082 19 0.081 20 0.153
FOLD
INDUCTION 1.00 0.99 1.87
HSV-B-GAL D 18 1.037 20 0.730 20 1.713
FOLD
INDUCTION 1.00 0.70 1.65
HSV-B-GAL E 6 0.076 12 0.070 12 0.187
FOLD
INDUCTION 1.00 0.92 2.46
HSV-B-GAL F 19 0.097 20 0.117 20 0.539
FOLD
INDUCTION 1.00 1.21 5.56
Table 13. Trans-activation of ft-gal plasmid constructs by the Ela 13s 
gene product
The results shown in this table all involve co-transfection 
experiments in which the p-gal constructs and the Ela constructs were 
added to the cells in the same transfection cocktails. One such 
typical experiment is described in Figure 35. The figures represent 
the average O.D.^g obtained with p-gal assays (2.6.2.) carried out 
with similar cell extracts, n is the number of similar cell extracts 
used in each experiment. No Ela; P~gal constructs added to the cells 
in the absence of Ela constructs: 12s and 13s; p-gal constructs added 
to the cells in the presence of constructs coding for the Ela 
products 12s and 13s respectively. The fold-increase represents the 
ratio of the average O.D..^ obtained with the no Ela samples to the 
average O.D.^g obtained with the samples that had Ela plasmid 
constructs co-transfected i.e. 12s and 13s.
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deaminase gene promoters (both kind gifts from Dr. J. Frampton) . The 
constructs containing the first two promoters gave results in 
preliminary co-transfection experiments which suggested that both 
promoters were trans-activated by the Ela 13s gene product (data not 
shown) while the third construct, which contained the PBG-deaminase 
promoter, did not show any expression. This is not surprising since 
PBG-deaminase is a red blood cell specific gene. This inability to 
obtain a suitable internal control plasmid for Ela co-transfection 
experiments led to the adoption of a strategy in which the results 
obtained with the internal control constructs were adjusted to 
correct for the trans-activation by Ela 13s.
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3.5.3. Co-transfection of c-fos-CAT and Ela plasmids into CT3 cells
and correction for the trans-activation of the internal control
plasmid by Ela 13s.
In Table 13 Experiment A represent p-gal assays carried out with 
aliquots from the cell extracts used for the CAT assays carried out 
in the experiment shown in Figure 35. It can be seen that the Ela 
13s product gives a 3-fold increase in p-gal activity when compared 
to assays carried out with extracts that had no Ela plasmid 
co-transfected. However, the average °-D *4 2 o ^  these p-gal assays 
is rather high and so they were repeated with less extract to ensure 
that there was no possibility of the p-gal assays going off the 
linear scale. The results of these repeat P~gal assays are given in 
Table 13 Experiment F where it can be seen that the Ela 13s gene 
product gives a 6-fold increase in p-gal activity. The CAT assays 
carried out in the experiment shown in Figure 35 were repeated, only 
the amount of extract used in each assay was adjusted to compensate 
for the 6-fold trans-activation of the HSV~p-gal control plasmid.
This experiment is shown and described in Figure 36 and quantified in 
Table 14. As can be seen from Table 14 the correction for the 
trans-activation of the control plasmid increases the induction with 
pB9+fpll6 and pB9+fpll6ATF to around 7-fold. This induction is more 
like that observed in previous publications (262) . However, 
pB9+fp402 also gives around a 7-fold induction in this experiment. 
This is probably due to the rather low lev^ of CAT activity obtained
with the samples that had no Ela plasmid contructs co-transfected as
with 12s co-transfected (which is not trans-activating protein) a 3 
to 4-fold induction is observed. So, the trans-activation of
234
nB<Wo402
nB9*fo116
3 4 5 6 7 8 9  10 11
-  12s 12s 12s 12s 13s 13s 13s 13s
5 5 10 10 5 5 10 10
DB9*fpH6SRE
12 13 14
oB9+fDl16ATF
12s 12s 12s 12s 13s 13s 13s 13s
5 5 10 10 b b 10 10
24 25 26 27 28 29 30 31 32 33 34 35
-  -  -  -  12s 12s 12s 12s 13s 13s 13s 13s
5 5 10 10 5 5 10 10
DB9*fo116SRE-ATF
36 37 38 39 40 41 42 43 44 45 46 47
- ~ - -  12s 12s 12s 12s 13s 13s 13s 13s
5 5 10 10 5 5 10 10
48 49 50 51 52 53 54 55 56 57
"  '  " 12s 12s 12s 12s 13s 13s 13s
5 5 10 10 5 10 10
Figure 36. Co-transfection of c-fos-CAT and Ela plasmids into CT3 
cells and correction for the trans-activation of the internal control 
plasmid by Ela 13s.
This figure is essentially identical to Figure 25 apart from one 
significant difference i.e. the amount of extract used in each CAT 
assay is corrected to compensate for the trans-activation of the 
HSV-p-gal internal control plasmid by the Ela 13s gene product (see 
test in details) . It should also be noted that lanes 1, 50 and 58
from Figure 35 are missing in this figure because of a lack of cell 
extract. This experiment is quantified in Table 14.
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Table 14. Co-transfection of c-fos-CAT and Ela plasmids into CT3
cells and correction for the trans-activation of the internal control 
plasmid by Ela.
This table quantifies the CAT activity obtained in the experiment
shown and dejgribed in Figure 36. The figures represent the
percentage of C-chloramphenicol converted to mono-acetylated forms 
with each extract. In this table the results obtained with the
different amounts of co-transfected Ela plasmid constructs have been 
taken to represent equivalent samples as no appreciable difference 
can be detected between the two sets of results. The fold-increase 
represents the ratio of the average conversion obtained with the Ela 
minus samples (-) to the average conversions and standard deviations 
obtained with the samples that had Ela plasmid constructs 
co-transfected. The numbers 1 to 57 correspond to lanes 1 to 57 of 
Figure 36.
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pB9+fp402 by 13s is probably only around 2-fold, the same levels of 
trans-activation of pB9+fpll6SRE and pB9+fpll6SRE-ATF by Ela 13s 
co-transfection were also observed.
In a subsequent experiment involving the co-transfection of HSV-p-gal 
plasmid with Ela plasmids, the 13s producing construct 
trans-activated HSV-|J-gal 35-fold (data not shown) . Because of this 
wide variability in the degree of trans-activation by Ela 13s of the 
HSV-p-gal construct it was decided that the adoption of the 
correction strategy should be stopped. Bio-rad protein estimations 
(2.6.1) were carried out on some extracts and equivalent amounts of 
protein used in each CAT assay. However, the variability in CAT 
activity between equivalent samples was large using this technique, 
presumably due to the variation in transfection efficiencies (data 
not shown) . It was therefore decided that this technique was also of 
no use. So, because of the difficulties of obtaining an internal 
transfection efficiency control and because no other methods yielded 
satisfactory results it was decided to stop further experimental work 
involving the trans-activation of the c-fos-CAT constructs by Ela 
gene containing plasmids. However, preliminary results did indicate 
that the Ela 13s protein trans-activates c-fos expression through 
sequences within 116bp upstream of the mRNA CAP site (which contains 
the basal promoter elements) and not through the SRE or fosATF/AP-1 
sequences (which are 300bp upstream from the mRNA CAP site) .
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4.1. Identification of cis-acting Transcriptional Control Elements.
It is possible that gene expression may be regulated at a variety of 
steps that lead to the production of the protein encoded by a 
particular gene. The control may come at the transcriptional, 
post-transcriptional, translational or post-translational levels, or 
it may involve a combination of these steps. In recent years great 
efforts have been made to characterise the transcriptional control of 
eukaryotic genes as the initiation of transcription is probably the 
most important step in the regulation of gene expression.
A combination of in vivo and in vitro techniques have been employed 
to identify cis-acting DNA sequences involved in the transcriptional 
control of eukaryotic gene expression. DNA sequences to which
nuclear proteins bind have been identified by in vivo and in vitro
methods (sub-Section 4.1.1.), whereas in vivo studies employing
transfection techniques (sub-Section 4.1.2.) have been used as 
functional tests of the interaction of specific DNA sequences with 
putative transcription regulatory factors.
4.1.1. Identification of cis-acting transcriptional control elements 
by protein binding studies.
It was originally thought that eukaryotic gene transcription was
controlled by the interaction of protein factors with DNA sequences 
in or around the genes. This idea was supported by the observation 
that DNAse 1 hypersensitivity in chromatin is most frequently 
confined to discrete domains in the 3'- or 5'-flanking regions of
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genes (361), and is usually correlated with the expression of those 
genes (362, 363). These DNAsel hypersensitive sites are formed due
to the presence of protein factors that bind to the relevant DNA. 
sequences resulting in an increased accessibility for the nuclease. 
This observation was exploited to characterise further the precise 
DNA sequences involved in DNA-protein interactions. The DNasel 
footprinting assay was developed which involved the digestion of a 
labelled-DNA fragment that had been incubated in vitro with cellular 
protein extracts (364). This digestion results in a "ladder" when 
the recovered DNA is fractionated by electrophoresis through a 
denaturing gel, but any region protected from DNasel digestion (by 
protein binding) results in gaps appearing in the "ladder". These 
gaps were called footprints and represent DNA sequences involved in 
DNA-protein interactions. This technique has been used extensively 
to analyse many transcriptional control regions (for example see 365) 
and has proved an extremely useful tool in the identification of 
precise DNA sequences that are involved in the control of 
transcription. A modification of this technique employs the enzyme 
exonuclease III (366) . This enzyme, a 3' to 5' exonuclease, degrades 
a double-stranded DNA fragment progressively from both 3' termini 
until the substrate becomes single-stranded and resistant to further 
digestion. Specific protein binding blocks the passage of exoIII and 
generates fragments that remain resistant under limiting digestion 
conditions. This technique is more sensitive than DNasel 
footprinting as exonuclease resistant fragments can be positively 
identified even if they occur as a small fraction of the total DNA 
population. In summary both of these footprinting techniques are 
useful in delineating regions of DNA that bind protein factors and
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are therefore putatively involved in transcriptional control.
The identification of specific, relatively short DNA sequences 
putatively involved in transcriptional control led to a more 
extensive use of the gel mobility shift (or gel retardation) assay 
(355) . Gel mobility shift assays involve the incubation of labelled 
DNA fragments or oligonucleotides with protein extracts followed by 
electrophoresis through a neutral gel. If a protein-DNA complex is 
formed its mobility will be slower than that of the labelled DNA 
which allows for detection of the complex. This assay is quicker and 
easier to perform than either of the two previously mentioned assays 
and is useful in determining the affinity a particular protein has 
for its DNA recognition sequence and also for cross-competition 
experiments with other DNA sequences. As with the footprinting 
assays, this technique identifies DNA sequences that bind protein 
factors and are therefore putatively involved in transcriptional 
control.
The protein-DNA interaction assays described so far have involved in 
vitro techniques which involve the incubation of specific DNA 
elements/fragments with prepared protein extracts. The in vivo 
genomic sequencing technique (367) can be modified for in vivo 
footprinting. This technique involves the addition of 
dimethylsulphate (DMS) to the cells of interest before harvest, 
isolating the DNA, digesting it with a restriction enzyme and 
cleaving it with piperidine at the methylated residues. 
Electrophoresis of this DNA through a denaturing gel and 
hybridisation with a specific probe identifies sequences that were
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protected from methylyation and therefore presumably had bound nuclear 
protein at the time of the addition of DMS to the cells. This 
technique has been used in the analysis of protein-DNA. interactions 
occurring in the region of several genes (368, 369). DMS methylates 
guanine residues and this chemical also has been employed in in vitro 
DNA-protein interaction studies to characterise the points of contact 
a particular protein has with its recognition sequence (for example 
see 370) . Recently, this technique was used to analyse the c-fos SRE 
and showed that two cellular proteins can recognise this sequence and 
that each protein has different points of contact with the SRE (371) .
All of the techniques detailed so far have led to the identification 
of short DNA elements that interact with putative transcriptional 
control protein factors. This observation resulted in the 
purification of many of these transcription factors by DNA affinity 
chromatography (372). A technique that was helpful in characterising 
these proteins was the in vitro transcription assay (373), although 
this technique has also been used to characterise particular protein 
extracts. This assay analyses the effect of a purified protein (or 
protein extract) on the transcription in vitro of a DNA template and 
can therefore be used to characterise the specific effects of 
purified protein (or protein extracts) on transcription.
Following characterisation of DNA sequences that complex with protein 
factors it is necessary to determine the effects these sequences have 
upon transcription in vivo, and for this purpose transfection 
experiments have proved informative.
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4.1.2. Functional analysis of transcriptional control elements.
To define transcriptional control elements by functional tests, 
plasmid constructs can be transfected into eukaryotic cells. These 
plasmids contain the promoter and upstream sequences of interest 
(sequences 3' of transcription initiation can also be assayed using 
this technique) linked to a reporter gene whose product can be 
assayed following the harvesting of the transfected cells. The 
transcription assays determine the influence that the promoter and 
upstream sequences exert over the transcription of the reporter gene.
An alternative method for inserting exogenous DNA into eukaryotic 
cells is to infect the cells with retroviruses (374) containing the 
exogenous DNA sequences of interest. However, this technique has 
limited uses for the analysis of transcriptional control for several 
reasons. Firstly, when a cell is infected by a retrovirus low copy 
numbers of the foreign DNA sequences are incorporated into the cell 
which makes it difficult to assay for any reporter protein (or RNA) . 
Secondly, many retroviruses have a limited cellular host range which 
often makes it impossible to compare results between species. 
Thirdly, the retroviral genome is larger than that of a plasmid 
making cloning into, and manipulation of, the retroviral DNA 
extremely difficult. Fourthly, upon infection by a retrovirus the 
cells containing the retrovirus must be selected for making it 
difficult to carry out transient transfection studies to analyse 
transcriptional control. When all of these facts are considered it 
is clear that the transfection technique has many advantages over 
retroviral infection as a method for analysing the control of
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eukaryotic gene transcription.
There are two types of transfection studies that can be employed in 
the analysis of transcriptional control : stable and transient.
Stable transfections involve the transfection of the transcription 
assay plasmid along with a plasmid containing a drug resistance gene, 
the most commonly used of which is the neomycin resistance gene 
(which confers resistance to the drug G418) . Following transfection, 
cells that have taken up the DNA can be selected for by incubating 
the cells in medium containing the drug to which the co-transfected 
gene confers resistance. The cells are then incubated for 10 to 14 
days whereupon colonies are formed representing individual cells that 
have been transfected with the plasmid DNA. These colonies can then 
be grown up and the cloned cells analysed or, more frequently, the 
colonies are pooled and then grown up. In this way variations due to 
differences in the sites at which the exogenous DNA has been 
incorporated are averaged. In transient transfection studies a 
population of cells is transfected with the transcription assay 
plasmid and harvested 48 hours later and then prepared for 
transcription assays.
The transient and stable transfection techniques have certain 
advantages and disadvantages which must be considered before adopting 
a particular strategy. The major disadvantage of the transient 
transfection technique is the requirement for an internal control of 
transfection efficiency. Each population of cells transfected with 
an identical amount of plasmid shows a different degree of DNA 
uptake. To correct for this variation in transfection efficiency a
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plasmid must be co-transfected with the transcription assay plasmid, 
this co-transfected plasmid also encoding a gene whose product can be 
assayed. It is also important that the transcription of the internal 
control gene is not sensitive to the experimental conditions e.g. if 
the cells are stimulated in some manner it is important that, the 
transcription of the internal control gene is not affected by such 
stimulations. Following the internal control assay which corrects 
the variation in transfection efficiency, equivalent amounts of cell 
extract are used in the transcription assay. This technique operates 
well in checking for variations in transfection efficiency but there 
is still a degree of variation in the data produced. Thus it is 
still necessary to have a number of "identical" independent samples 
within each transfection experiment and to repeat these experiments 
at least once to confirm any results obtained. Another drawback of 
the transient technique is that only a sub-population of the cells to 
which the transfection cocktail is added will take up DNA and it is 
possible that this sub-population represents a sub-set of cells, e.g. 
at a certain point in their growth cycle. It is also possible that 
each of these cells will take up several hundred copies of the 
transcription assay plasmid (not all of which will be nuclear) which 
could titrate out particular nuclear protein factors that may act on 
the transfected plasmid DNA. However, the transient transfection 
technique does enable a large variety of plasmid constructs to be 
studied in a reasonably short time, and is thus amendable to detailed 
studies of the effects of differences in transcriptional control 
elements.
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Stable transfections obviate the requriement for an internal control 
plasmid used for correcting variations in transfection efficiency as 
once the population of stably transfected cells is established this 
really represents a "new" cell line. Populations of the stably 
transfected cells can therefore be plated out and harvested for 
transcription assays without further transfection which saves time if 
these cells are going to be used in many different experiments. If a 
pool of transfected cells are taken together to form the stable cell 
line this should average out the variation in copy number and/or 
insertion sites that would be present in each individual clone and 
would lend to a continuity between experiments carried out with the 
stable cell line. However, these stable transfection experiments are 
time consuming (transfected cells must be selected for between 10 and 
14 days) particularly when many different plasmid constructs are to 
be analysed.
So, when selecting a model for in vivo analysis of transcriptional 
control it is necessary to balance the advantages of the stable and 
transient transfection techniques. Most investigations employ the 
transient transfection technique simply because it quickly produces 
results that are rapidly repeatable. Both of these techniques have 
been used in recent years to analyse the control of transcription and 
they have identified many cis-acting DNA. transcriptional control 
elements (for reviews see 170 - 173) .
Upon harvesting of the transfected cells there are many transcription 
assays that can be employed to determine the transcriptional control 
exerted by the sequences under study upon the reporter gene. These
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assays can be divided into two different categories : the protein
assays and the RNA assays. Belonging to the former group is the CAT 
assay (188), the p-galatosidase assay (350) and the human growth 
hormone assay (360); and to the latter group SI analysis (351), 
RNAase protection analysis (375) and primer extension analysis (352). 
Although the advantages and disadvantages of each independent 
technique will not be discussed here, a comparison between protein 
and RNA assays will be made.
Protein assays; are generally rapid and simple but do contain certain 
features that are open to criticism:
1) Protein assays cannot determine whether the construct under 
examination initiates transcription from the correct position.
2) If the protein being assayed is particularly stable in 
comparison to its mRNA, small amounts of mRNA may lead to the 
accummulation of an unrepresentative quantity of the protein. 
Although this would not significantly alter gross differences between 
constructs, it may mask more subtle effects upon transcription.
3) Enhancer elements have been discovered previously in intron 
sequences (376) but it is impossible to assay the effect upon 
transcription of sequences 3' of the transcription initiation site of 
a gene in their endogenous positions using protein assays.
The best way to circumvent these problems is to employ RNA assays. 
These lead to the determination of the site of transcription 
initiation, obviate the problem relating to protein-mRNA stability 
and can allow for the assay of the effects of sequences 3' of the
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site of transcription initiation. This last point can be overcome 
using intact genes in the transfection assays (using a different 
species of eukaryotic cells from that of the gene under analysis to 
permit the endogenous and exogenous sequences to be differentiated), 
or by using deletions of the gene under examination. These assays 
also have the advantage that they are one step closer to the level of 
transcription and circumvent any possibility of post-transcriptional 
or translational control leading to artefactual results. RNA 
analysis can employ, as well as intact and deleted genes as 
mentioned, fusion plasmids similar to those used in the protein 
assays. This has the advantage of comparing the results obtained 
with protein assays with those obtained with RNA analysis assays, but 
has the disadvantage of not permitting the assay of sequences 3' to 
the site of transcription initiation in their endogenous positions. 
The major disadvantage of the RNA assays is that they are more time 
consuming and technically more difficult than their protein 
counterparts. Also, the RNA under analysis may be relatively 
unstable making it difficult to detect in the RNA assays.
As with the transient and stable transfection techniques described 
earlier it is a matter of choosing the correct transcription assay 
for the particular study being undertaken. It is often beneficial to 
employ both a protein assay and an RNA analysis assay when assaying 
for transcriptional control elements in vivo. Protein assays can be 
employed for obtaining preliminary results which can then be 
confirmed with an RNA assay.
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4.1.3. Transfection technique and transcription assays adopted in 
this project.
The previous two sub-Sections (4.1.1. and 4.1.2.) have detailed a 
variety of in vivo and in vitro techniques that can be used for the 
analysis of the control of eukaryotic gene transcription. This 
sub-Section will describe a selection of these techniques that were 
employed in this project for the analysis of c-fos transcriptional 
control.
Previous studies on the control of the c-fos gene transcription have 
employed a combination of in vivo and in vitro techniques and have 
identified several DNA elements involved in the transcriptional 
control of this gene (see Section 1.6.). All of these elements are 
present in the promoter and upstream region of the c-fos gene. These 
investigations used footprinting studies and gel mobility shift 
assays to identify DNA elements that bind nuclear proteins, and 
transfection studies using various transcription assays were employed 
to analyse the influence these sequences exert upon c-fos 
transcription in vivo. RNA analysis assays have been carried out 
using RNA prepared from mouse cells transfected with the entire human 
c-fos gene (including upstream sequences) (151) or with c-fos 
upstream sequences fused to the CAT gene (232) . CAT assays were also 
used in these studies (190) and in certain cases the CAT assays were 
complemented with RNA analysis assays (220). These studies 
identified a serum inducible protein binding enhancer element 
centered 308bp upstream from the transcription initiation site of 
c-fos and the results obtained with the CAT assays reflected those
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obtained with the RNA analysis assays.
The majority of these studies employed the transient transfection 
technique using calcium phosphate precipitates added to mouse 
fibroblast cells. In this project a similar system was adopted and 
the cell line used, CT3, was a derivative of NIH 3T3 cells which were 
used extensively in the previous analyses. The advantageous aspects 
of the transient transfection technique, compared to the stable 
transfection technique, also influenced the choice. This was 
important in this project as several of the c-fos-CAT constructs were 
made only after obtaining results in preliminary experiments that 
suggested the need for the production and assay of such constructs.
As mentioned earlier, previous reports with c-fos-CAT constructs 
showed that results obtained with CAT assays mirrored those obtained 
with RNA analysis of the same construct (220) . Since the CAT assay 
is quicker and easier to do than any of the RNA analysis assays it 
was decided that this would be the major transcription assay employed 
throughout this project. For this purpose, many c-fos-CAT hybrid 
plasmid constructs were made (see Section 3.1.) . To check for the 
variation in transfection efficiencies in these transient 
transfection assays a plasmid encoding the p-galactosidase gene was 
co-transfected with the c-fos-CAT constructs. The protein produced 
by this plasmid can be assayed for using the p-galactosidase assay 
and equivalent amounts of p-galactosidase activity were used in the 
CAT assays. Because CAT assays cannot determine whether the 
c-fos-CAT constructs initiate transcription from the correct position 
attempts were made to carry out SI analysis on RNA prepared from
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cells transfected with these constructs. Although such analysis 
failed on RNA prepared from cells transiently transfected with the 
c-fos-CAT constructs, such analysis using RNA prepared from on LATK 
cell line stably transfected with pCN+fpl400 was successful. The SI 
analysis carried out with the RNA prepared from the stably 
transfected LATK cells showed that pCN+fpl400 initiates 
transcription from the correct position. Since all of the other 
c-fos-CAT constructs were directly related to this construct it seems 
reasonable to assume that all of the c-fos-CAT constructs initiate 
transcription from the correct position.
Upon identification of a region in DNA that is involved in the 
control of the transcription of a gene it is usual to attempt to 
characterise the precise DNA sequence that is responsible for this 
control. In vivo protein binding studies on the DNA region identify 
sequences involved in DNA-protein interaction and are therefore 
putatively responsible for the control of transcription. To analyse 
these sequences in vivo an oligonucleotide containing the sequence of 
interest is synthesised and inserted upstream from the relevant 
promoter that has had its corresponding endogenous sequence deleted. 
These constructs are then analysed in transfection and transcription 
assay experiments to determine the effect the inserted 
oligonucleotide has upon transcription from the relevant promoter. 
This technique has been used extensively in characterising relatively 
short DNA sequences (10 to 20bp) that are involved in basal and 
inducible transcriptional activation. The data obtained in such 
experiments must be interpreted with caution particularly if the DNA 
sequence under analysis has been moved from its endogenous position
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(usually it is moved closer to its promoter). This may result in a 
failure of the protein binding to the sequence to interact with other 
DNA-binding proteins that have had their recognition sequences 
deleted in the synthesis of the oligonucleotide containing construct, 
or in a failure to interact with DNA binding proteins present in the 
promoter region of the gene under analysis due to an inability of the 
truncated DNA. to form the correct secondary structure. It is also 
important to check that the insertion of the oligonucleotide does not 
create a new transcriptional control element in the oligonucleotide 
plasmid overlap region. The best way of checking that this is not 
the case is to carry out mutation analysis to determine that it is 
the protein binding site present in the oligonucleotide that is 
responsible for exerting the transcriptional control. Such studies 
have been used in characterising DNA sequences involved in the 
control of c-fos transcription. The major element characterised by 
these studies is the SRE (see sub-Section 1.6.2.) which was shown to 
be a serum inducible enhancer element capable of conferring serum 
inducibility upon the c-fos promoter when a single copy was inserted 
upstream from the promoter. In a study of the element downstream 
from the SRE that bears close homology to the DNA sequeces which bind 
the transcription factors AP-1 and ATF (which I have termed 
fosATF/AP-1), a single copy of this element was capable of conferring 
TPA and EGF responsiveness on the c-fos promoter (252) . Previous 
studies of other AP-1 and ATF sequences (see sub-Sections 1.6.5. and 
1.6.6.) also showed that a single copy of such sequences is capable 
of exerting transcriptional control. Because of these observations 
it was decided that in this project single copies of oligonucleotides 
containing putative transcriptional control elements would be
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inserted upstream from the c-fos promoter in c-fos-CAT constructs. 
The effects of these sequences upon transcription from the c-fos 
promoter were assayed for in transient transfections followed by CAT 
assays. As a single copy of the relevant sequences were considered 
to be sufficient to control transcription from the c-fos promoter, 
the oligonucleotides containing these sequences were inserted 
■upstream from the c-fos promoter in an orientation dependent manner. 
This was done by giving the oligonucleotides different restriction 
enzyme sites at their 5' and 3' termini and inserting them into a 
c-fos-CAT construct that had been digested with the relevant 
restriction enzymes.
So, the transfection/transcription assay techniques employed 
throughout this project seemed reasonable when compared to those used 
in previous studies that have investigated the control of c-fos 
transcription. However, all data obtained using these techniques 
must be interpreted with caution as they occasionally produce results 
that are difficult to explain. For example, in a previous study on 
the fosATF/AP-1 sequence (252) this sequence was shown to confer TPA 
and EGF responsiveness on the c-fos promoter only in stably 
transfected cells while transient transfection studies failed to 
identify this element as a transcriptional control element. This 
observation suggested caution in interpretation of 
transfection/transcription assay data. Two independent reports 
produced conflicting reports on the serum inducibility of c-fos-CAT 
constructs transfected into mouse fibroblast cells (189,220) . In 
both cases the CAT assay was used as the transcription assay and the 
c-fos-CAT constructs were similar in structure. In stably
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transfected NIH 3T3 cells these constructs failed to show a
significant increase in CAT activity following serum stimulation of
serum deprived transfected cells (189), while a similar treatment of 
transiently transfected NIH 3T3 cells resulted in a significant
increase in CAT activity following serum stimulation (220) . The only 
major difference between these studies was the transfection technique 
and it is not known why this should contribute towards the anomalous 
results obtained. Some conflicting results were also obtained in 
this project using the transfection/transcription assay technique 
(see sub-Section 3.4.2.). Initial transfection experiments in CT3 
cells failed to identify the SRE containing c-fos-CAT construct 
pB9+fp402 as being serum responsive. The reason for this failure was 
not clear as Northern blot analysis showed that the endogenous gene 
is induced following serum stimulation of these cells. Three
possible explanations were thought of for the failure to observe a 
serum response with the c-fos-CAT construct :-
1) The c-fos-CAT construct was defective.
2) The CT3 cells were not quiescent prior to stimulation.
3) The density of the cells prior to stimulation is crucial.
It seems unlikely that the c-fos-CAT construct are defective as they 
do show variations in transcriptional activity similar to those 
reported previously, and the parent c-fos-CAT construct does initiate 
transcription from the correct position in stably transfected cells. 
It also seen* unlikely that the cells were not quiescent prior to 
serum stimulation as they were serum deprived for at least 30 hours 
prior to stimulation and harvest. This length of time has been used
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previously in rendering mouse fibroblasts into a quiescent state. 
The density of the cells prior to stimulation and harvesting for 
Northern blot analysis, and prior to stimulation and harvesting for 
transcription assays, was not noted. It was therefore possible that 
cell density played a crucial role in the serum stimulation of c-fos 
expression. Results obtained with transfection experiments with the 
cells at different densities prior to stimulation and harvest showed 
that the cell density did play a crucial role in obtaining a serum 
response with the c-fos-CAT constructs. The higher the density of 
the cells the greater the response of the c-fos-CAT constructs to 
serum stimulation. This observation provided an explanation for the 
failure to observe a serum response with the pB9+fp402 in the 
preliminary transfection experiments, i.e. the cells may not have 
been at a high enough density prior to serum stimulation. It could 
also explain the anomaly mentioned earlier in the previously 
published reports of serum stimulation of NIH 3T3 cells transfected 
with c-fos-CAT constructs i.e. the cells may have been at different 
densities in the two sets of experiments prior to serum stimulation. 
The results obtained with the high density of cells was repeated
another twice. However, following these two subsequent experiments 
it became inpossible to obtain a serum stimulation of pB9+fp402 even 
though the transfected cells were at a high density prior to serum 
stimulation. The results were similar to those obtained in the 
earliest experiments : there was a failure to shut down transcription 
upon serum deprivation of the cells. Several batches of frozen cells
were grown up and used in subsequent experiments, but still no serum
response could be detected with the transfected c-fos-CAT constructs. 
The major difference between the previous experiments that gave a
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serum response with pB9+fp402 and the subsequent ones that failed to 
do so was that a different batch of serum was used in the growth of 
the cells used in the different sets of transfection experiments. 
The precise effect these different batches of serum have upon the 
growth of the cells cannot be determined but it is possible that this 
difference may be responsible for the anomalous results obtained in 
the transfection experiments.
So, no matter the care taken in the choice of transfection technique 
and transcription assay, it is important to remember that data 
obtained in these studies must be interpreted with caution. However, 
these techniques have been used extensively in the characterisation 
of cis-acting transcriptional control elements and may be considered 
crucial in the analysis of the control of eukaryotic gene 
transcription.
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4.2. The c-fos Gene has Several cis-acting Transcriptional Control 
Elements.
The techniques discussed in Section 4.1. have resulted in the 
identification of many transcriptional control elements (for reviews 
see 170 - 173) . These elements can be separted into two categories: 
the upstream promoter elements (UPEs) and the enhancer elements. The 
UPEs contribute towards the basal levels of transcription from 
promoters and are located close to the transcription initiation site 
(usually within lOObp upstream) . The enhancer elements have 
different properties which include the ability to activate 
transcription in an orientation and distance independent manner and 
to exert transcriptional control over heterologous promoters 
(sub-Section 1.6.1.).
Previous studies on the control of c-fos transcription identified an 
element 300bp upstream from the transcription initiation site that 
can behave as an enhancer element and also activate transcription in 
response to serum stimulation of quiescent cells (see sub-Section
1.6.2.) . Two UPEs have also been characterised in the human c-fos 
promoter region which contribute to basal levels of transcription and 
form complexes with nuclear proteins. The experiments carried out in 
this project further investigated the role of the SRE in c-fos 
transcription, and also characterised a sequence that is continuous 
with the SRE that bears homology to previously identified 
transcription factor binding sites. This element was identified by a 
computer-aided search of the human c-fos sequence. It bears close 
homology to the previously characterised AP-1 and ATF proteins
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binding sites (see sub-Section 1.6.5. and 1.6.6.). These two binding 
sites differ by only lbp in their consensus sequences and it is 
therefore difficult to determine whether a similar sequence binds 
AP-1 or ATF simply by analysing its base composition. AP-1 binding 
sites are capable of conferring TPA or serum responsiveness upon 
heterologous promoters (see sub-Section 1.6.6.). As the c-fos gene 
is transcriptionally activated following treament of cells with serum 
or TPA, it was of interest to try and identify the protein that 
complexes with the fosATF/AP-1 sequence, and to establish whether 
this element plays a role in activating transcription from the c-fos 
promoter following serum or TPA stimulation.
4.2.1. Identification of cis-acting elements regulating c-fos 
transcription.
Transient transfection experiments carried out in this project with 
c-fos-CAT constructs detected the presence of an enhancer of 
transcription upstream from position -116bp (relative to the c-fos 
transcription initiation site) . Downstream from position -116bp 
retains the previously characterised UPEs (185) which contribute to a 
basal level of c-fos transcription. Both of these observations, and 
the degree of enhancement (approximately 20-fold), agree with a 
previously published report using similar c-fos-CAT constructs (190) . 
This report identified an enhancer element present between 200bp and 
400bp upstream from the c-fos transcription initiation site. The SRE 
and fosATF/AP-1 sequences are both within this region and are 100% 
conserved between the human, mouse and chicken c-fos genes. Previous 
reports have characterised the SRE as an enhancer element (see
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sub-Section 1.6.2.) . When the c-fos SRE is placed upstream from the 
X.laevis promoter that has had its SRE deleted, it enhances
transcription when placed in either orientation. This element also 
activates transcription from the c-fos promoter upon serum
stimulation of quiescent cells when placed in either orientation
upstream or downstream from the c-fos promoter (151) . At the
beginning of this project the fosATF/AP-1 element had not been
previously studied, but has subsequently been shown to induce
transcription from the c-fos promoter in response to stimulation with 
EGF or TPA (252).
In this project the effect of the SRE and fosATF/AP-1 sequences on 
transcription from the c-fos promoter were assayed in growing cells. 
When the SRE was placed 116bp upstream from the c-fos promoter it 
increased transcription approximately 10-fold in growing cells. This 
is in agreement with the previous report identifying the SRE as an 
enhancer element in growing cells (190) . When the fosATF/AP-1
sequence was inserted in an identical position to the SRE upstream
from the c-fos promoter it increases transcription approximately 
4-fold, which is a relatively low increase in comparison to other 
AP-l/ATF binding sites (see sub-Section 1.6.5. and 1.6.6.). Mutation 
of the fosATF/AP-1 element abolished the observed increase in 
transcription showing that this increase was specific for the 
fosATF/AP-1 sequence and not because of the synthesis of a 
transcriptional control element due to the insertion of the 
oligonucleotide containing the fosATF/AP-1 sequence. When the SRE 
and fosATF/AP-1 sequences are inserted together upsteam of the c-fos 
promoter it is difficult to determine whether these sequences act in
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an additive fashion to activate transcription as the fosATF/AP-1 
sequence contributes to the activation of transcription at a 
relatively low level. One fact that is clear from the transfection 
studies using the c-fos-CAT constructs with the inserted 
oligonucleotides is that they fail to activate transcription to the 
same degree as the full 400bp c-fos upstream region. This 
observation suggests one of two things :
1) The 400bp of c-fos upstream sequence contains further cis-acting 
DNA elements that contribute towards the transcriptional activation 
from the c-fos promoter.
2) The SRE and fosATF/AP-1 sequences activate transcription better 
when situated in their endogenous positions.
It is not clear which of these possibilities applies to this
discrepancy. However, footprinting analyses of the c-fos promoter 
region have not revealed any protein binding sites in this region 
that are not present in the construct containing the oligonucleotide 
with the SRE and fosATF/AP-1 sequences. This suggests that the 
latter possibility may be the one that applies in this situation. A 
similar result was obtained when the c-fos SRE was placed upstream 
from the X.laevis act in gene promoter (193) - this construct does not
restore endogenous levels of transcription when compared to the
activity obtained with the intact promoter region containing the SRE
in its correct position. This again suggests that the SRE and
fosATF/AP-1 sequences may activate transcription better when situated 
in their endogenous positions. The reason for this reduction in 
transcriptional activating properties of cis-acting DNA elements when
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they are moved from their endogenous position may be due to a failure 
of the proteins binding to these sequences to co-operate fully with
other proteins bound in the promoter region. Such interactions have
previously been proposed for the SRE (185) . When one of the UPEs 
present in the promoter region of the c-fos gene is deleted, the 
induction of c-fos transcription by the SRE in response to external 
stimuli is reduced in comparison to that obtained with an intact 
c-fos promoter. In vitro binding studies have also shown that the 
transcription factor ATF co-operates in the formation of the proteins 
binding to the TATA box of an adenovirus gene promoter (377) . This
co-operation leads to quicker formation of such complexes which
allows access for polymerase II. Obviously, if such binding 
sequences are moved from their endogenous positions this may affect 
the rate of formation of the complex at the TATA box and thus affect 
the rate of binding of polymerase II and therefore affect the rate of 
transcription from the relevant promoter.
4.2.2. The fosATF/AP-1 element binds a member of the AP-1/ATF 
protein family.
Although the fosATF/AP-1 element activated transcription when placed 
upstream of the c-fos promoter, this did not prove that a member of 
the AP-1/ATF protein family was responsible for this activation. To 
try and determine whether a member of this family was responsible for 
the transcriptional activation due to the fosATF/AP-1 element a 
combination of in vitro and in vivo studies were carried out.
Two previous reports had suggested that the fosATF/AP-1 sequence
264
could bind an AP-l-like protein. Footprinting studies of the c-fos 
upstream region showed that the protein binding to the fosATF/AP-1 
sequence could be competed out by an a-enhancer sequence from the 
polyoma virus which contains an AP-1 binding site (250) . In vitro 
translated AP-1 protein (from a c-jun clone) was also shown to be 
capable of complexing with the fosATF/AP-1 sequence (238) . However, 
neither of these studies determined the precise nature of the protein 
that would bind to this sequence if it were incubated with a nuclear 
protein preparation, nor did they determine the strength of the 
protein binding in comparison to other AP-1/ATF elements. Gel 
mobility shift assays were employed in this project to investigate 
the protein(s) binding to the fosATF/AP-1 sequence.
An initial mobility shift assay using HeLaS3 nuclear protein extract 
demonstrated that the fosATF/AP-1 sequence formed a specific complex 
with a nuclear protein. The mutant fosATF/AP-1 sequence that was 
used in the transfection studies failed to compete for this protein 
forming the complex, agreeing with the observation that the 
fosATF/AP-1 sequence is responsible for the transcriptional 
activation observed in the in vivo studies. To determine whether 
this protein was a member of the AP-l/ATF protein family a gel 
mobility shift assay was carried out using previously characterised 
AP-1 and ATF sequences as competitors. These sequences were taken 
from the adenovirus 5 E3 gene promoter region and were characterised 
as AP-1 and ATF sites using gel mobility shift assays with other AP-1 
and ATF sequeces as competitors (267) . In a gel mobility shift assay 
using these sequences and the fosATF/AP-1 sequence, the complex 
formed with the fosATF/AP-1 sequence shows a similar mobility to that
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formed with the E3-AP-1 sequence (the E3-ATF complex has a slightly 
quicker mobility). However, both the E3-AP-1 and E3-ATF sequences 
can compete for the protein that forms the complex with the 
fosATF/AP-1 sequence which in turn fails to compete for the proteins 
that form the complexes with the E3-AP-1 and E3-ATF sequences. Since 
the E3-AP-1 and E3-ATF sequences can partially compete for each 
others' binding protein (267), these results suggest that the 
fosATF/AP-1 sequence forms a weak complex with an AP-1 like protein. 
One interesting aspect of this particular study was the observation 
that, in the presence of excess E3-AP-1 competitor, the fosATF/AP-1 
sequence forms a new complex that has a mobility shift similar to 
that observed with the E3-ATF sequence. This observation suggests 
that the fosATF/AP-1 sequence may be capable of forming a complex 
with more than one particular nuclear protein. This phenomenon is 
not unique as it has been shown previously that the octamer sequence 
is capable of binding at least two different nuclear proteins : 
octl (378) and oct2 (379) . Like the ATF and AP-1 protein these 
two proteins have shared motifs that are involved in DNA binding and 
transcriptional activation (380) . More recently it has also been 
shown that the c-fos SRE can form complexes with at least two nuclear 
proteins (371) . Only one of the genes encoding these proteins has as 
yet been isolated, so it is not possible to determine whether they 
also represent a family of DNA-binding proteins which have shared 
motifs. So, these mobility shift assays showed that the fosATF/AP-1 
sequence can bind a member of the AP-1/ATF protein family. They did 
not make clear which of these two proteins complex with the sequence, 
and indeed it is possible that the fosATF/AP-1 sequence may complex 
with a previously unidentified member of this family.
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In a bid to characterise further the fosATF/AP-1 element the 
transcriptional activation properties of this sequence was compared 
with those of the E3-AP-1 and E3-ATF sequences. This study involved 
the transient transfection study of c-fos-CAT constructs with 
oligonucleotides containing the AP-1/ATF sequences inserted in an 
identical position upstream from the c-fos promoter. The results of 
this experiment showed that the E3-AP-1 and E3-ATF sequences are 
more potent transcriptonal activators than the fosATF/AP-1 sequence 
when all three are placed individually upstream from the c-fos 
promoter. This agreed with the gel mobility shift assays which 
showed that the fosATF/AP-1 sequence weakly binds a member of the 
AP-1/ATF protein family.
So, these in vivo and in vitro studies together suggested that the 
fosATF/AP-1 sequence forms a weak complex with a nuclear protein that 
is a member of the AP-1/ATF protein family. Because the gel mobility 
shift assays showed that the complex formed with the fosATF/AP-1 
sequence was similar in mobility to that formed with the E3-AP-1 
sequence, a gel mobility shift assay was carried out with nuclear 
protein extract pre-incubated with Fos antibody. Previous studies 
have shown that such a pre-incubation interferes with, or abolishes, 
the AP-1 complex formation (276, 277) which contains Fos protein. 
Such an assay carried out in this project showed that the 
pre-incubation with the Fos antibody did indeed interfere with the 
formation of the E3-AP-1-protein complex, but failed to do so with 
the fosATF/AP-1 complex or the E3-ATF-protein complex. This again 
suggests that the fosATF/AP-1 does not bind previously characterised 
AP-1 protein, and the pattern of the mobility shift had already
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suggested that it does not bind a previously characterised ATF 
protein. It is possible that the fosATF/AP-1 sequence complexes with 
c-Jun protein homodimers rather than with c-Jun-c-Fos heterodimers 
(see Section 1.7.) . If this were the case the Fos antibody 
pre-incubation would fail to interfere with such binding. c-Jun 
homodimers complex weakly with AP-1 sites (in comparison to 
c-Fos-c-Jun heterodimers), which also fits in with the observations 
made with the fosATF/AP-1 sequence. However, it is impossible to 
determine whether this is the case without similar pre-incubation 
experiments using a c-Jun antibody which was not available in this 
project. A gel mobility shift assay with in vitro co-translated Fos 
and Jun proteins also showed that the fosATF/AP-1 sequence formed a 
complex that was different in mobility to those formed with either 
the E3-AP-1 or E3-ATF sequences.
In a bid to characterise further the fosATF/AP-1 element as 
complexing with a member of the AP-l/ATF family of proteins 
transfection experiments were carried out with F9 embryonal carcinoma 
cells. Previous studies examined the role that PEA-1 (the murine 
homologue of AP-1) plays in the transcriptional control of the 
polyoma a-enhancer in this cell line (250, 310, 381) . This enhancer 
element contains a PEA-1 (AP-1) protein binding sequence and is 
transcriptionally inactive in F9 cells.
Protein binding studes on the polyoma a-enhancer revealed that there 
were very low levels of PEA-1 /AP-1 present in undifferentiated F9 
cells, but following differentiation (when the a-enhancer becomes 
active) protein binding to this sequence can be easily detected. The
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polyoma a-enhancer also contains a further protein binding site for a 
factor called PEA-2. This site overlaps with that of the PEA-1 /AP-1 
site and functions as a transcriptional (378) repressor. Following 
differentiation of F9 cells this factor becomes undetectable. This 
observation suggested that the polyoma a-enhancer may be inactive in 
F9 cells because of the repressor activity of PEA-2 rather than any 
lack of PEA-1 factor. It seems likely that there is a balance 
between the expression of these two factors that controls the 
transcriptional activity of the polyoma a-enhancer on the 
differentiated and undifferentiated F9 cells.
Studies of other AP-1 binding sites (such as that of the collagenase 
gene) have also shown that AP-1 elements are transcriptionally 
inactive in F9 cells. These sites do not contain overlapping PEA-2 
binding sites. In the studies carried out in this project the 
E3-AP-1, E3-ATF, fosATF/AP-1 and SRE elements were all 
transcriptionally inactive in F9 cells. Not all transcriptional 
control elements tested were inactive in these cells as the HSV-(3-gal 
plasmid gives a relatively high level of activity. The results 
obtained with the AP-l/ATF elements were not surprising as previous 
reports showed these to be inactive in F9 cells, but it has not been 
previously reported that the SRE is transcriptionally inactive in 
these cells. It is perhaps not surprising that this is the case as 
experiments examining the interaction between Fos and Jun proteins 
showed that co-transfection of Fos expressing constructs greatly 
enhanced the trans-activation properties of the Jun protein on 
constructs containing the AP-1 recognition sequence (305, 306). This 
suggested that in the F9 cells there was little or no Fos protein
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present prior to these co-transfection experiments. Although the 
enhancer elements were transcriptionally inactive in the F9 cells 
there is a basal level of expression from the c-fos promoter. Only 
the c-fos-CAT construct containing the intact 400bp of c-fos upstream 
sequence showed an elevated level of expression in comparison to the 
c-fos promoter only construct. This increase was much smaller than 
that observed in CT3 cells (2-fold in comparison to 20-fold) which is 
not surprising considering the SRE and fosATF/AP-1 sequences are 
transcriptionally inactive in the F9 cells. The small increase in 
the level expression could be due to further transcriptional control 
elements present in the intact c-fos upstream sequence that has been 
deleted from the oligonucleotide containing constructs. 
Alternatively it could be because any residual transcription factors 
present in the F9 cells (such as the SRF) operate better when their 
target sequences are situated in the correct position with respect to 
the c-fos promoter. This observation is similar to the results 
obtained with transfected CT3 cells. In these cells the intact 400bp 
of upstream activates transcription to a greater degree than any of 
the oliognucleotide containing c-fos-CAT constructs and a discussion 
of the possible explanations for this phenomenon is given in 
sub-Section 4.2.1.
To show that the transcriptional inactivity of the AP-l/ATF elements 
in the F9 cells was due to a lack of trans-activating proteins a gel 
mobility shift assay was carried out. Surprisingly, this assay 
revealed that in F9 nuclear protein extracts there were proteins 
present that were capable of forming complexes with the E3-AP-1, 
E3-ATF and fosATF/AP-1 sequences. This observation contrasted
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sharply with the transcription analysis and contradicted previously 
published work which showed that in a gel mobility shift assay no 
AP-1 binding activity could be detected (310) . Several reasons can 
be thought of to explain this anomaly. It is possible that in 
preparation of the nuclear protein extracts from the F9 cells a 
certain step caused pre-existing inactive AP-1 proteins to be 
modified resulting in an activation of their binding properties. It 
should also be noted that the oligonucleotide sequences used in the 
mobility shift assay shown here were different from those used in 
previously published studies. It is therefore possible that the 
proteins forming complexes with the AP-l/ATF elements may not 
necessarily be classical AP-l/ATF-like proteins , but could be 
proteins that are either incapable of activating transcription or 
perhaps act as transcriptional repressors. Evidence to support the 
idea that these proteins are not classical AP-l/ATF proteins comes 
from comparing the pattern of mobility shifts obtained between F9 
nuclear protein extracts and HeLaS3 nuclear protein extracts. The 
patterns are slightly different suggesting that it is different 
proteins forming complexes with the AP-l/ATF elements in the F9 and 
HeLaS3 nuclear protein extracts. However, it must be remembered that 
F9 and HeLa cells were established from different species which may 
also contribute to any differences observed in the proteins 
complexing with the AP-l/ATF sequences.
The original idea of studying the transcriptional control elements in 
F9 cells was to further characterise the fosATF/AP-1 sequences as a 
member of the AP-l/ATF family. Although this element does indeed 
behave in a similar fashion to the E3-AP-1 and E3-ATF sequences, the
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SRE is also transcriptionally inactive in these cells. This suggest 
that there are many transcriptional control elements that are 
inactive in F9 cells and that this property is not exclusive to 
AP-l/ATF like elements. So, although this series of experiments 
failed to add substantial weight to the idea that the fosATF/AP-1 
sequences complexes with a member of the AP-l/ATF family of proteins, 
they did not argue against this idea.
In a further bid to show that the fosATF/AP-1 sequence binds a member 
of the AP-l/ATF protein family in vivo, co-transfection experiments 
were carried out with a plasmid construct encoding the adenovirus 5 
Ela 13s trans-activating protein (358) . This protein can 
transcriptionally activate adenovirus early genes through AP-1 and 
ATF binding sequences (267) . Unfortunately, in this project the Ela 
13s protein trans-activated several transfection efficiency control 
plasmids and the inability to obtain a suitable internal control 
plasmid made it impossible to obtain conclusive results from these 
studies. However, the preliminary results that were obtained 
suggested that the Ela 13s protein activates c-fos transcription 
through sequences in the c-fos gene promoter region which agrees with 
a previous publication which suggested that the c-fos TATA box 
sequence is Ela 13s responsive (259) . The results obtained here also 
contradict a previous publication (258) which suggested that the 
region including the SRE was Ela 13s responsive. The study 
identifying the c-fos TATA box as an Ela 13s responsive element also 
showed that the sequence including the SRE was not Ela 13s 
responsive. These variations may be due to the different cells and 
plasmid contructs used in the different labs. The limited results
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obtained in this project also suggested that the fosATF/AP-1 sequence
was Ela 13s responsive. However, this sequence was not compared with
the E3-AP-1 or E3-ATF sequences and therefore no conclusions
concerning the nature of the protein binding to the fosATF/AP-1
sequence in vivo can be made from these experiments.
In conclusion, the experiments carried out in this project confirmed 
that the SRE acts as an enhancer of c-fos transcription in growing 
cells. They also identified a further cis-acting transcriptional 
control element upstream from the c-fos promoter, the fosATF/AP-1
sequence. This sequence binds a member of the AP-l/ATF protein
family and behaves as an AP-l/ATF sequence in the embryonal carcinoma 
cell line F9. However, it is a relatively weak transcriptional
activator when compared with previously identifed AP-1 and ATF 
sequences.
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4.3. Serum and TPA Response Elements Upstream from the Human c-fos 
Promoter.
The pleiotropic effects of different extra-cellular stimuli upon 
cells comes about through the expression of unique sets of genes. In 
recent years great efforts have been made to isolate these genes and 
to then analyse their transcriptional control. It was of great 
interest to determine whether genes activated in a co-ordinated 
fashion following a specific extra-cellular stimuli were 
transcriptionally activated by a similar mechanism. Such studies 
have resulted in the characterisation of the transcriptional control 
mechansisms of many genes in response to steroid hormones (for a 
review see 382), phorbol esters (see sub-Section 1.6.6.), cAMP (see 
sub-Section 1.6.5.), certain viral proteins (see sub-Section 1.6.7.), 
interferon (383, 384) and serum or serum growth factors (see
sub-Section 1.6.2.) . In all of these cases sets of genes that are 
transcriptionally activated in a co-ordinated fashion share a common 
mechanism of transcriptional activation. This involves cis-acting 
DNA elements upstream from the gene promoters that confer 
responsiveness and are common to all of the co-ordinately regulated 
genes. These elements bind proteins (trans-acting factors) that are 
responsible for the transcriptional activation. There seems to be 
three basic mechanisms for protein-DNA interaction that leads to the 
co-ordinated transcriptional activation of unique sets of genes:
1) In the case of steroid hormones (and retinoic acid (385)) the 
hormone binds to its receptor which then moves into the nucleus to 
complex with the relevant DNA response element (382) .
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2) Viral proteins activate transcription through pre-existing 
cellular factors. The mechanism involves the modification of 
cellular transcription factors, but the exact mechanism has not yet 
been characterised for any viral trans-activating protein.
3) Activation of intra-cellular pathways leading to the 
transcriptional activation of sets of genes. This mechanism applies 
to TPA, cAMP and serum or serum growth factors. A description of 
these pathways is given in sub-Section 1.4.3.
Studies of the transcriptional control of the c-fos gene have shown 
that all of the extra-cellular stimuli mentioned so far are capable 
of, or have been implicated in, activation of c-fos transcription 
(see Section 1.6.) . The cis-acting DNA elements and nuclear proteins 
involved in these transcriptional activations have been characterised 
in many cases. The majority of the analyses investigating the 
control of c-fos transcription have been carried out with transfected 
murine fibroblast cells that were made quiescent and then stimulated 
with the relevant extra-cellular stimuli which, results in the 
activation of endogenous c-fos transcription. The major cis-acting 
DNA transcriptional control elements identifed by such studies is the 
SRE positioned 300bp upstream from the c-fos transcriptional 
initiation site, which can activate transcription in response to a 
variety of extra-cellular stimuli including serum or serum growth 
factors, TPA and cAMP (see Section 1.6.) . The fosATF/AP-1 element 
can confer EGF and TPA responsiveness upon the c-fos promoter and can 
also function as a cAMP response element (232) . In this project the 
role of the SRE in the activation of c-fos transcription was 
investigated further, as was the fosATF/AP-1 element which was also
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compared with the E3-AP-1 and E3-ATF sequences.
4.3.1. The fosATF/AP-1 sequence acts as a serum and TPA response 
element.
The previous study on the fosATF/AP-1 sequence characterising this 
element as being EGF and TPA responsive involved 1 hour stimulations 
of quiescent cells transfected with a c-fos CAT construct containing 
this element (252) . As described in sub-Section 4.1.2. such 
short-term stimulations proved variable in this project. To overcome 
the inability to observe consistent serum or TPA responses in such 
stimulations, overnight stimulations were carried out on quiescent 
cells transfected with c-fos-CAT constructs containing the 
fosATF/AP-1, E3-AP-1 and E3-ATF elements. Overnight stimulations had 
been used previously in characterising AP-1 sequences as being TPA 
response elements (248) . The implications of the limited results 
obtained with the 1 hour stimulations are discussed later.
The data discussed in the previous Section (4.2.) characterised the 
fosATF/AP-1 element as an activator of c-fos transcription which 
could complex with a member of the AP-l/ATF family of proteins in 
vitro. However, these studies failed to determine whether an AP-1 or 
ATF protein complexed with this element, or whether a previously 
uncharacterised member of the ATF/AP-1 protein family was involved in 
this complex formation. Previous reports showed that AP-1 sites 
could confer both serum or TPA responsiveness upon heterologous 
promoters (251), while ATF sites failed to do so (253) . It was 
reasoned that the characterisation of the fosATF/AP-1 element as
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being a serum or TPA response element would therefore help in 
determining which protein (either AP-1 or ATF) could complex with 
this sequence in vivo. The overnight stimulation assays carried out 
in this project characterised the fosATF/AP-1 element as being both 
serum and TPA responsive; both inductions activated c-fos 
transcription through this element to a similar degree. The E3-AP-1
element also acted as a serum or TPA response element when placed 
upstream from the c-fos promoter. Again, the degree of induction of 
c-fos transcription was similar for each treatment and these results 
agreed with previously published results showing AP-1 sites as being 
able to confer both serum and TPA responsiveness upon heterologous 
promoters. Surprisingly, the E3-ATF sequence could also confer serum 
or TPA responsiveness upon the c-fos promoter. The protein that 
complexes with this sequence, ATF, is indistinguishable from the cAMP 
response element binding protein (187) which binds to CREs and 
activates transcription in response to cAMP. It has been previously 
reported that the CREs were incapable of conferring TPA 
responsiveness upon promoters (253) . Two reasons may be thought of 
to explain this discrepancy:
1) The E3-ATF sequence has not been characterised in vivo as being a 
CRE. So, although in vitro competition experiments with previously 
characterised CREs suggested that both elements complex with an 
identical protein (267), this may not be the case. They both may 
complex with different proteins that have equal affinities for both 
sites.
2) The sequences in the c-fos promoter may influence the response of 
the E3-ATF sequence to the serum and TPA stimulations. A previous
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study showed that sequences flanking AP-1 or CRE sites influence the 
degree of transcriptional activation these elements confer in 
response to extra-cellular stimuli. In this case these sequences may 
also contribute to the specificity of the response. It is also 
possible that proteins that are bound to the c-fos promoter region 
also contribute towards the specificity of the response of the 
inserted oligonucleotide.
These results once again suggest that the fosATF/AP-1 sequence 
complexes with a member of the AP-l/ATF family of proteins in vivo, 
but also once again fail to differentiate between which protein is 
involved in this complex. In the previous Section (4.2.) it was 
suggested that the fosATF/AP-1 element may complex with a previously 
uncharacterised member of the AP-l/ATF protein family as it complexes 
with a nuclear protein in vitro and does not behave as either a 
classical AP-1 or ATF element. Also the fosATF/AP-1 sequence is a 
poorer transcriptional activator than either the E3-AP-1 or E3-ATF 
sequences. The limited results obtained with the short-term (1 hour) 
stimulations in this project also indicate that the fosATF/AP-1 
element behaves in a different fashion from the E3-AP-1 element. The 
previously reported study on the fosATF/AP-1 element (252) showed 
that it could confer TPA responsiveness upon the c-fos promoter after 
a 1 hour stimulation. Classical AP-1 sites were characterised as 
being TPA response elements following 12 hours stimulations (248) . 
In this project it was shown that the fosATF/AP-1 element could 
confer TPA responsiveness on the c-fos promoter following a 1 hour 
stimulation, but that the E3-AP-1 sequences failed to do so. This 
result once again suggests that the fosATF/AP-1 does not behave as a
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classical AP-1 element, although it must be interpreted with some 
caution as subsequent experiments failed to repeat this observation. 
This was possibly because the basal level of transcription due to the 
fosATF/AP-1 sequence became relatively high in the subsequent
experiments and thus possibly masked any increase in activity
following the 1 hour TPA stimulation. It would be of obvious interest 
to determine whether the fosATF/AP-1 sequence could confer TPA 
responsiveness upon a heterologus promoter as other AP-1 elements 
are capable of doing so (see sub-Section 1.6.6.) .
$ One other interesting feature obtained from the limited number of 
short-term stimulation experiments was the inability of the
fosATF/AP-1 sequence to confer serum responsiveness upon the c-fos
promoter following a 1 hour stimulation. The enhanced transcription 
from the c-fos promoter due to the fosATF/AP-1 element was completely 
abolished in quiescent cells, but transcription failed to increase 
following the 1 hour stimulation. So, the protein complexing with 
the fosATF/AP-1 sequence in vivo can only activate transcription in 
short-term stimulation assays following TPA treatment. The
significance of this result is unclear.
Whatever the complexity of the situation, it is clear that the 
fosATF/AP-1 sequence can confer serum and TPA responsiveness upon the 
c-fos promoter, and that this responsiveness does not follow an 
identical pattern to that obtained with the E3-AP-1 sequence. These 
observations, taken together with those made in the previous Section 
(4.2.), suggest that it is possible that the fosATF/AP-1 sequence 
does not behave as a classical AP-1 element.
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4.3.2. A possible interaction between the proteins binding to the
SRE and fosATF/AP-1 sequences.
Previous reports have characterised the SRE as being able to confer 
both serum and TPA responsiveness upon the c-fos promoter following 
short-term stimulations (see sub-Section 1.6.2.). A preliminary 
experiment carried out in this project confirmed that the SRE could 
confer serum responsiveness upon the c-fos promoter, and this reponse 
increased with increasing cell density. In subsequent experiments 
where the SRE and SRE, fosATF/AP-1 sequences were assayed in the same 
experiments it was observed that the SRE, fosATF/AP-1 sequence showed 
a more consistent serum response. The reason for this seemed to be 
the low levels of CAT activity obtained with the SRE, fosATF/AP-1 
construct in the quiescent cells in comparison to those obtained with 
the construct containing the SRE alone. This observation suggested a 
possible interaction between the proteins complexing with the SRE and 
fosATF/AP-1 sequences. This was perhaps not surprising as two other 
immediate early genes also contain the juxtaposed SRE and fosATF/AP-1 
sequences in their putative transcriptional control regions (192). So 
in this project the possibility of such an interaction between the 
SRE and fosATF/AP-1 elements was analysed.
Before moving on to discuss the co-operation between the two elements 
in controlling transcription from the c-fos promoter it is worthwhile 
mentioning the results obtained with the c-fos-CAT construct 
containing an intact 402bp of c-fos upstream sequence. In overnight 
or short-term stimulations of cells transfected with this construct 
there was a failure to obtain a consistently reproducible serum or
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TPA induction of CAT activity. This seemed anomalous as this 
construct contains the SRE and fosATF/AP-1 sequences which together 
in oligonucleotide-containing constructs gave consistent and 
reproducible inductions of CAT activity following serum or TPA 
stimulation. Several explanations were thought of for this failure:
1) The intact 402bp contains a transcriptional activation sequence 
that has been deleted from the oligonucleotide containing c-fos-CAT 
constructs.
2) Sequence overlapping the SRE-fosATF/Ap-1 element infl u ences the 
way these elements behave in their endogenous positions.
3) The SRE-fosATF/AP-1 sequences behave in a different fashion in the 
oligonucleotide containing construct, pehaps due to different 
interactions with proteins bound to the c-fos promoter region due to 
different spacing.
A detailed discussion of these possibilities is given in sub-Section
4.2.1. with relation to the results obtained in growing cells. This 
discussion is also applicable to the results obtained in the serum 
and TPA stimulation assays and it is impossible to determine which of 
these possibilities may be responsible for the anomalous results 
obtained with the intact c-fos upstream region and the 
oligonucleotide containing c-fos-CAT construct.
In vitro protein binding studies carried out in this project and in 
other work (215) suggest that the SRE and fosATF/AP-1 elements bind 
their respective proteins in a mutually exclusive manner. A recent 
publication (386) has also detailed in vitro footprinting studies on
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these two sequences which also suggested a mutually exclusive pattern 
of protein binding to these sequences. However the same authors have 
also recently published a report of an in vivo genomic footprinting 
study showing that proteins bind to these sequences simultaneously 
(387) . Although the mutually exclusive binding would suggest that the
proteins complexing with the SRE and fosATF/AP-1 elements do not
co-operate in controlling c-fos transcription it is perhaps 
misleading to extrapolate results with on vitro protein binding 
studies to the in vivo situation. Indeed, the results obtained with 
the transfection experiments in this project do suggest an 
interaction between the proteins complexing with these two sequences, 
and the in vivo genomic footprinting result supports this hypothesis.
To investigate the possible interaction between the proteins 
complexing with the SRE and fosATF/AP-1 sequences oligonucleotides 
that contained the two sequences separated by 5bp and lObp inserts 
were inserted into c-fos-CAT constructs. These two inserts represent 
a half-helical and a full-helical turn of DNA respectively. The idea 
behind these insertions was to attempt to disrupt any interactions 
occurring between the proteins that complex with the SRE and
fosATEEAP-1 sequences. Obviously, the insertion of a half-helical 
turn of DNA between the sequences will place the protein recognition 
sites on opposite sides of the DNA helix in comparison to the
endogenous sequence, while the insertion of a full-helical turn 
should restore both sites to their endogenous sides. It was 
anticipated that the 5bp insertion would severely disrupt any 
interactions taking place between the proteins complexing with the 
SRE and fosATF/AP-1 sequences, while the lObp sequence may restore
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the interaction phenomenon. A similar study had been carried out 
previously with two elements involved in the synergistic 
transcriptional activation of the preproenkephalin gene promoter in 
response to cAMP stimulation (238). One of these elements contained 
a sequence identical to the fosATF/AP-1 sequence. In their 
endogenous positions these two sequences were separated by llbp, 
representing a full-helical turn. Increasing this spacing to 21bp 
decreased the synergistic response to cAMP stimulation 2-fold, while 
reduction of the spacing to 6bp reduced the response a further 
2-fold. The most dramatic decrease was obtained with insertion of 
14bp between the two elements which severely reduces both basal and 
cAMP regulated expression by these two elements. This showed that 
increasing the spacing by a half-helical turn severely interfered 
with the transcriptional control properties exerted by these two 
elements.
Separating the SRE and fosATF/AP-1 elements had three major effects 
that were observed in transfection studies. Firstly, the basal levels 
of transcription from the c-fos promoter in the serum deprived cells 
increased approximately 3-fold with the 5bp insertion construct and 
2-fold with the lObp insertion construct in comparison to the levels 
obtained with the contiguous sequences. This level of increase is 
similar to that observed between the constructs containing the SRE, 
fosATF/AP-1 and the SRE alone. This suggested that the fosATF/AP-1 
sequence must lie directly beside the SRE in order that the two 
sequences exert their control over transcription that leads to low 
levels of basal activity. Secondly, upon serum stimulation the level 
of transcription with the insert elements is approximately 3-fold
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greater than that observed with the two contiguous sequences. 
Thirdly, the level of transcription obtained with the separated 
elements following TPA stimulation is similar to the levels obtained 
following serum stimulation. This is clearly different from the 
results obtained with the contiguous sequences where the serum 
response was always significantly greater than the TPA response. Two 
recent reports, published after the completion of these experiments, 
corroborate the results obtained (386,388) . In one of the 
publications (388) it was observed that removal of the fosATF/AP-1 
sequence from the SRE resulted in a 3-fold increase in basal levels 
of transcription. This report suggested that Fos-Jun heterodimers 
were responsible for this transcriptional shut-down by the 
fosATF/AP-1 sequence as anti-sense fos sequences increased the levels 
of transcription from a construct containing the SRE-fosATF/AP-1 
sequences to levels similar to those obtained with the SRE alone. In 
the other publication (386) it was reported that separating the SRE 
and fosATF/AP-1 sequences resulted in an increased basal level of 
transcription in quiescent cells and an increase in transcription 
following serum stimulation when compared to the continuous 
sequences. Neither of these reports examined the transcriptional 
control exerted by the separated sequences following TPA stimulation. 
Another interesting result was obtained in this project when a 
consensus AP-1 binding site was juxtaposed with the SRE replacing the 
fosATF/AP-1 sequence. This construct behaved in an identical fashion 
to that containing the contiguous SRE and fosATF/AP-1 sequences. This 
again strongly suggests an interaction between the proteins 
complexing with these sequences as an AP-1 element on its own shows a 
relatively elevated level of transcription in quiescent cells in
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comparison to the SRE-fosATF/AP-1 containing c-fos-CAT construct.
I would like to propose a hypothesis to explain the complex 
phenomenon observed in this project and by others (386,388) . In the 
quiescent cells basal levels of transcription from the c-fos promoter 
are increased upon removal of the fosATF/AP-1 sequence from beside 
the SRE or by increasing the spacing between these two sequences by 
5bp or lObp. Also, mutations of the SRE which prevent proteins 
binding to this sequence lead to an increase in transcription from 
the c-fos promoter, probably due to the fosATF/AP-1 sequence (386) . 
All of these results suggest an interaction between the two proteins 
binding to these sequences, although it could be argued that a 
further protein binds to these adjacent sequences in quiescent cells 
and blocks binding of the SRF and/or AP-l/ATF elements. There are two 
possible ways in which these proteins may interact to repress c-fos 
transcription : either by a direct protein-protein interaction or by
the involvement of a third protein that recognises the proteins bound 
to these sequences and interacts with them to repress transcription. 
It is proposed here that a combination of a third protein and the 
influence of the protein (s) complexing with the SRE are responsible 
for the low basal levels of transcription observed with the 
continuous SRE and fosATF/AP-1 sequences. The construct containing 
the SRE juxtaposed with the consensus AP-1 site behaves in a similar 
fashion to the construct containing the continuous SRE and 
fosATF/AP-1 sequences. This suggests that the protein(s) corrplexed 
with the SRE must influence the protein (s) complexing with the 
consensus AP-1 site as an AP-1 site on its own leads to comparatively 
elevated levels of transcription from the c-fos promoter in quiescent
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cells. It is possible that bound SRF prevents complexing of Fos-Jun 
heterodimers with the AP-1 sequence. It is also possible that the 
same proteins complex with the AP-1 site as with the fosATF/AP-1 site 
due to the influence of the bound SRF. Although it is not known what 
these proteins may be it seems reasonable to suppose that they are 
members of the AP-l/ATF family of proteins. The third protein 
postulated to be involved in the SRF-AP-1/ATF complex, and therefore 
regulation of transcription from the c-fos promoter, may be the Fos 
protein itself. Two pieces of evidence support this hypothesis.
Firstly it has been reported that anti-sense fos sequences have a
similar effect upon transcription from the c-fos promoter as removal 
of the fosATF/AP-1 sequence (388) . Secondly, in this project Fos 
antibody did not disrupt the protein complex with the fosATF/AP-1 
sequence (while it did with an AP-1 sequence) which contradicted a 
previous publication (2 to ) . The gel mobility shift experiments
detailed in this paper used a DNA fragment that contained the SRE and 
fosATF/AP-1 sequences. So, if the Fos protein does not make a direct 
contact with the DNA of the fosATF/AP-1 sequence but depends upon 
recognition of the proteins binding to the SRE and fosATF/AP-1 
sequence this would explain the discrepancy between these two
results. Obviously, separation of the two sequences, which results in 
an increase in basal levels of transcription, may be due to the 
failure of the third protein, putatively Fos, to recognise the 
separated proteins.
When the SRE and fosATF/AP-1 sequences are separated not only is 
there an increase in the basal levels of transcription but there is 
also an increase in the levels of transcription following serum
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stimulation. The reason for this phenomenon is not clear but could 
again be due to the presence of a third protein that can interact 
with the proteins complexing with the SRE and fosATF/AP-1 sequences, 
or to a modified interaction between the bound proteins. In this 
project the separation of the SRE and fosATF/AP-1 sequences also 
resulted in an increase in transcription following TPA stimulation to 
levels similar to those obtained following serum stimulation. This is 
different to the results obtained with the contiguous sequences where 
the serum stimulation was always greater than the TPA stimulation. As 
well as postulating a role for a third protein in this stimulation 
andeor a modification of the interaction between the proteins 
complexing with the SRE and fosATF/AP-1 sequences it is also possible 
that the protein bound to the fosATF/AP-1 sequence contributes 
towards the TPA stimulation. This would agree with results obtained 
in this project which indicated that the fosATF/AP-1 sequence on its 
own can activate transcription from the c-fos promoter following TPA 
stimulation.
Interesting results were also obtained when the SRE, consensus AP-1 
and SRE-insert-fosATF/AP-1 containing constructs were assayed for 
their transcriptional properties in growing cells. In these cells the 
SRE and consensus AP-1 elements seem to act in an additive fashion to 
activate c-fos transcription. This suggests that the proteins 
complexing with these two sequences in growing cells are different 
(or modified) when compared to the proteins complexing with these 
sequences in quiescent cells where it was postulated that the 
proteins bound to the SRE influenced the protein (s) complexing with 
the AP-1 site. It was also of interest to note that the constructs
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containing the separated SRE and fosATF/AP-1 sequences gave a 3-fold 
higher transcriptional activity than did the construct containing the 
two contiguous sequences. Again it may be postulated that this is due 
to the involvement of a third protein or because of a modification in 
the interaction between the proteins recognising these sequences.
4.3.3. The c-fos gene has a complex mechanism of transcriptional 
control.
The results obtained in this project and published by others 
demonstrate that the c-fos gene has a complex mechanism of
transcriptional control. This project has detailed two cis-acting 
transcriptional control elements that activate transcription from the 
c-fos promoter in growing cells and following serum or TPA
stimulation of serum-deprived cells. Other studies have also 
identified further transcriptional control sequences which activate 
c-fos transcription in response to a host of extra-cellular stimuli.
Results obtained in this project also suggest a novel form of
interaction between two cis-acting transcriptional control elements 
(the SRE and fosATF/AP-1 sequences) . When these two sequences are 
placed together they maintain a low level of transcription from the 
c-fos promoter in quiescent cells. However, separation by as little 
as 5bp, or removal of the fosATF/AP-1 sequence leads to an increase 
in transcription from the c-fos promoter in quiescent cells. This 
suggests that these two sequences may be regarded as enhansons which 
co-operate to repress transcription from the c-fos promoter in 
quiescent cells. Enhansons were first identified in the SV40 enhancer 
where they were shown to co-operate with other enhansons to activate
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transcription from an adjacent promoter. As with the SRE and 
fosATF/AP-1 sequences the SV40 enhansons lose their co-operative 
control over transcription when they are separated by as little as 
5bp.
Further studies would be required to establish the precise mechanism 
of transcriptional control exerted by the contiguous SRE and 
fosATF/AP-1 sequences and to determine whether there is any 
interaction between the proteins that recognise these sequences. 
These would involve the delineation of the precise sequences required 
for the transcriptional control exerted by these two elements i.e. 
are the entire SRE and fosATF/AP-1 sequences required? Can the 
fosATF/AP-1 sequence be replaced by sequences other than the 
consensus AP-1 sequence analysed in this project? The spacing 
between the two elements may also be crucial : in this project
insertion of 5bp and lObp between the elements interfered with their 
transcriptional control but the effects of smaller or larger 
insertions were not examined.
The results presented here also suggest that the protein (s) bound to 
the SRE influence the protein (s) binding to the contiguous AP-l/ATF 
element in quiescent cells. For example, an AP-1 binding site when 
placed beside the SRE behaves in a different fashion to an 
independent AP-1 binding site. To establish whether this is the case 
it is possible that the use of antibodies in in vitro DNA-protein 
interaction studies would be capable of determining whether different 
proteins recognise the AP-1 site when it is with or without the SRE. 
A long-term goal following the studies on the proteins recognising
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these sequences would be to determine whether there is any physical 
interaction between the proteins. Previous studies have shown that 
the Fos and Jun proteins interact via a leucine zipper domain and it 
would be of interest to identify similar interactions occurring 
between the proteins complexing with the SRE and fosATF/AP-1 
sequences, and if possible to identify the domains involved in such 
interactions.
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